Page last updated: 2024-12-05

ranitidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Ranitidine is a histamine H2 receptor antagonist that was first synthesized in 1976. It is used to treat ulcers, heartburn, and other conditions related to excess stomach acid. It works by blocking the action of histamine, a chemical that stimulates the production of stomach acid. Ranitidine is well-absorbed from the gastrointestinal tract and reaches peak plasma concentrations within 1-3 hours. It is primarily metabolized by the liver and excreted in the urine. Ranitidine is generally safe and well-tolerated, but it can cause side effects such as headache, constipation, and diarrhea. In 2019, ranitidine was recalled from the market due to the presence of N-nitrosodimethylamine (NDMA), a probable human carcinogen. The drug remains under investigation, and its long-term safety is still under debate. Research on ranitidine continues to focus on understanding its mechanism of action, its potential therapeutic uses, and its long-term safety.'

Ranitidine: A non-imidazole blocker of those histamine receptors that mediate gastric secretion (H2 receptors). It is used to treat gastrointestinal ulcers. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ranitidine : A member of the class of furans used to treat peptic ulcer disease (PUD) and gastroesophageal reflux disease. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5039
CHEMBL ID1790041
SCHEMBL ID825
MeSH IDM0018469
PubMed CID3001055
CHEMBL ID512
CHEBI ID8776
CHEBI ID92246
MeSH IDM0018469

Synonyms (220)

Synonym
DIVK1C_000440
KBIO1_000440
SPECTRUM_001141
ul-pep
n-(2-((5-((dimethylamino)methyl)furfuryl)thio)ethyl)-n'-methyl-2-nitro-1,1-ethenediamine
ranidine
raniogas
zantab
sampep
randin
raniter
urantac
gastrosedol
achedos
radinat
einecs 266-332-5
quicran
ulceranin
ranitidinum [inn-latin]
istomar
acidex
ranitidina [inn-spanish]
n (2-(((5-((dimethylamino)methyl)-2-furanyl)methyl)thio)ethyl)-n'-methyl-2-nitro-1,1-ethenediamine
ezopta
weichilin
atural
ptinolin
verlost
weidos
vizerul
ranin
duractin
axoban
hsdb 3925
logast
zantadin
xanidine
vesyca
microtid
ranitiget
rantacid
DB00863
KBIO2_004189
KBIO2_006757
KBIO3_001858
KBIOSS_001621
KBIO2_001621
KBIOGR_001475
SPBIO_002102
PRESTWICK1_000201
NINDS_000440
SPECTRUM2_001425
PRESTWICK0_000201
SPECTRUM3_000909
SPECTRUM4_001008
SPBIO_001530
FT-0653261
nsc-757851
CHEMBL1790041
dtxsid8045191 ,
ec 266-332-5
unii-884kt10yb7
major ranitidine
nsc 757851
ranitidine [usan:inn:ban]
topcare jeartburn relief
884kt10yb7 ,
up and up acod redicer
FT-0630765
ranitidine [usan]
ranitidine [orange book]
ranitidine [mart.]
ranitidine [who-dd]
ranitidine [hsdb]
ranitidine [mi]
ranitidine [inn]
ranitidine [vandf]
n-[2-[[5-[(dimethylamino)methyl]-2-furanylmethyl]thio]ethyl]-n'-methyl-2-nitro-1,1-ethenediamine
n-[2-[[[5-(dimethylamino)methyl-2-furanyl]methyl]thio]ethyl]-n'-methyl-2-nitro-1,1-ethenediamine
n-[2-[[5-[(dimethylamino)methyl]-2-furanylmethyl]-thio]ethyl]-n'-methyl-2-nitro-1,1-ethenediamine
n-[2-[[[5-(dimethylamino)methyl-2-furanyl]methyl]thio]ethyl]- n'-methyl-2-nitro-1,1-ethenediamine
VMXUWOKSQNHOCA-UHFFFAOYSA-N
n-[2-[[[5-(dimethylamino)methyl-2-furanyl] methyl]thio]ethyl]-n'-methyl-2-nitro-1,1-ethenediamine
SCHEMBL825
bdbm50103506
AKOS030228563
n-(2-[(5-[(dimethylamino)methyl]furan-2-yl)methylthio]ethyl)-n'-methyl-2-nitroethene-1,1-diamine
Q423037
a02ba02
ranitidine (mart.)
n-(2-(((-5-((dimethylamino)methyl)-2-furanyl)methyl)thio)ethyl)-n'-methyl-2 -nitro-1,1-ethenediamine
n-(2-(((5-((dimethylamino)methyl)-2-furanyl)methyl)thio)ethyl)-n'-methyl-2-nitro-1,1-ethenediamine
(e)-n-(2-(((5-((dimethylamino)methyl)-2-furyl)methyl)sulfanyl)ethyl)-n'-methyl-2-nitroethene-1,1-diamine
ranitidina (inn-spanish)
1,1-ethenediamine, n-(2-(((5-((dimethylamino)methyl)-2-furanyl)methyl)thio) ethyl)-n-methyl-2-nitro-
ranitidinum (inn-latin)
BIDD:GT0179
AC-12712
STK619092
(e)-n-{2-[({5-[(dimethylamino)methyl]furan-2-yl}methyl)sulfanyl]ethyl}-n'-methyl-2-nitroethene-1,1-diamine
AKOS005552967
AB00052223-10
gavilast
n-[2-[[5-(dimethylaminomethyl)furan-2-yl]methylsulfanyl]ethyl]-n'-methyl-2-nitroethene-1,1-diamine
gtpl1234
1,1-ethenediamine, n-[2-[[[5-[(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]-n'-methyl-2-nitro-
quantor
dimethyl[(5-{[(2-{[(e)-1-(methylamino)-2-nitroethenyl]amino}ethyl)sulfanyl]methyl}furan-2-yl)methyl]amine
chembl512 ,
bdbm22893
PRESTWICK2_000201
taural
RND ,
ratic
mauran
ranitidine [usan:ban:inn]
ranisen
raticina
1,1-ethenediamine, n-(2-(((5-((dimethylamino)methyl)-2-furanyl)methyl)thio)ethyl)-n'-methyl-2-nitro-
ranitidine
cas-66357-59-3
tocris-1967
NCGC00024387-02
lopac-r-101
NCGC00015876-02
NCGC00015876-01
IDI1_000440
ranitidina
ranitidinum
(e)-n-{2-[({5-[(dimethylamino)methyl]-2-furyl}methyl)sulfanyl]ethyl}-n'-methyl-2-nitroethene-1,1-diamine
CHEBI:8776 ,
LOPAC0_001073
SPECTRUM5_001189
(e)-n1'-[2-[[5-(dimethylaminomethyl)-2-furyl]methylsulfanyl]ethyl]-n1-methyl-2-nitro-ethene-1,1-diamine
rantidine
1,1-ethenediamine, n-[2-[[[5-[(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]-n'-methyl-2-nitro-, (e)-
zantac (tn)
66357-35-5
ranitidine (usan/inn)
D00422
ranitidine (tn)
NCGC00094913-02
NCGC00094913-01
NCGC00094913-05
SPECTRUM1501151
NCGC00018108-01
NCGC00094913-03
NCGC00094913-04
HMS2092H15
NCGC00015876-08
L000504
HMS501F22
ranitidine impurity j
HMS1921L07
NCGC00015876-07
A835434
(e)-n1'-[2-[[5-[(dimethylamino)methyl]-2-furyl]methylsulfanyl]ethyl]-n1-methyl-2-nitro-ethene-1,1-diamine;ranitidine base
NCGC00018108-02
NCGC00018108-03
({5-[(2-{[(1e)-1-(methylamino)-2-nitrovinyl]amino}ethylthio)methyl](2-furyl)}m ethyl)dimethylamine
ranitidine base
NCGC00256269-01
tox21_302372
cas-66357-35-5
dtxcid00820068
n'-[2-[[5-(dimethylaminomethyl)-2-furyl]methylsulfanyl]ethyl]-n-methyl-2-nitro-ethene-1,1-diamine hydrochloride
pharmakon1600-01501151
nsc757851
tox21_110250
CCG-39025
NCGC00015876-06
NCGC00015876-04
NCGC00015876-09
NCGC00015876-05
NCGC00015876-03
EPITOPE ID:127515
S5662
NCGC00015876-11
tox21_110250_1
KS-5230
n-[2-[[5-[(dimethylamino)methyl]furfuryl]thio]ethyl]-n'-methyl-2-nitro-1,1-ethenediamine
n-[2-[[5-[(dimethylamino)methyl]furfuryl]thio]ethyl]-n'-methyl-2-nitro-1,1-ethylenediamine
AB00052223_11
AB00052223_12
sr-01000075288
SR-01000075288-3
n1'-[2-[[5-[(dimethylamino)methyl]-2-furanyl]methylthio]ethyl]-n1-methyl-2-nitroethene-1,1-diamine
CHEBI:92246
ranitidine (form i and form ii)
ranitidine hcl 1/2 type
HY-B0693
CS-0009591
SBI-0051043.P003
bdbm237183
BCP21325
ranitidine free base
66357-35-5 (free base)
(e)-n-(2-(((5-((dimethylamino)methyl)furan-2-yl)methyl)thio)ethyl)-n-methyl-2-nitroethene-1,1-diamine
mfcd00081180
(e)-n-(2-((5-((dimethylamino)methyl)furan-2-yl)methylthio)ethyl)-n-methyl-2-nitroethene-1,1-diamine
Q21971328
(e)-ranitidine
BRD-K70505054-001-02-9
SDCCGSBI-0051043.P004
HMS3886A16
NCGC00015876-16
n-(2-(((5-((dimethylamino)methyl)furan-2-yl)methyl)thio)ethyl)-n'-methyl-2-nitroethene-1,1-diamine
n-[2-[[[5-[(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]-n'-methyl-2-nitro-1,1-ethenediamine
A899862
n-[2-[[5-[(dimethylamino)methyl]furfuryl]thio]ethyl]-n'-methyl-2-nitrovinylidenediamine monohydrochloride;ranitidine hcl
D97790
{2-[({5-[(dimethylamino)methyl]furan-2-yl}methyl)sulfanyl]ethyl}[(e)-1-(methylamino)-2-nitroethenyl]amine
(1e)-n-[2-[[[5-[(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]-n'-methyl-2-nitro-1,1-ethenediamine
DTXSID101112063
n-[2-[[[5-[(dimethylamino)methyl]-2 -furanyl]methyl]thio]ethyl]-n'-methyl-2-nitro-1,1-ethanediamine
(e)-1-n'-[2-[[5-[(dimethylamino)methyl]furan-2-yl]methylsulfanyl]ethyl]-1-n-methyl-2-nitroethene-1,1-diamine
BR166204
82530-72-1
dimethyl[(5-{[(2-{[1-(methylamino)-2-nitroethenyl]amino}ethyl)sulfanyl]methyl}furan-2-yl)methyl]amine
EN300-97101

Research Excerpts

Toxicity

Ebrotidine 800 mg is as effective and safe as ranitidine 300 mg in healing duodenal ulcer, but ebrotidine appears to be superior. Ranitidine administration (50 mg per kg) enhanced acetaminophen hepatotoxicity.

ExcerptReferenceRelevance
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
" The pattern of adverse events reported during long-term treatment was similar to the adverse-event profile in short-term treatment with omeprazole (n = 2,818), ranitidine (n = 1,572) and cimetidine (n = 891)."( Safety experience from long-term treatment with omeprazole.
Joelson, IB; Joelson, S; Lundborg, P; Walan, A; Wallander, MA, 1992
)
0.28
"During the period from the first marketing of cimetidine in 1977 and until 31 March 1990, the Danish Committee on Adverse Drug Reactions received 494 reports concerning a total of 612 suspected adverse reactions to peptic ulcer drugs (ATC group A02B)."( [Adverse effects of ulcer drugs before and after release of cimetidine, ranitidine and sucralfate for over-the-counter sale].
Andersen, M; Schou, JS, 1991
)
0.28
"We previously reported that cimetidine but not ranitidine significantly enhances cyclophosphamide-induced bone marrow toxic effects and the appearance of cyclophosphamide alkylating species in a murine leukemia mouse model, and we advised caution in the use of cimetidine with microsomally metabolized anticancer drugs."( Lack of ranitidine effects on cyclophosphamide bone marrow toxicity or metabolism: a placebo-controlled clinical trial.
Alberts, DS; Dorr, RT; Mason-Liddil, N; Phillips, JG; Plezia, PM; Roe, DJ; Struck, RF, 1991
)
0.28
" In conclusion, omeprazole was far superior to ranitidine in preventing recurrence, a goal achieved without adverse events and significant abnormalities in the oxyntic mucosal exocrine or endocrine cells but with a moderate increase in basal gastrin levels."( Prevention of relapse of reflux esophagitis after endoscopic healing: the efficacy and safety of omeprazole compared with ranitidine.
Backman, L; Ekström, P; Enander, LK; Falkmer, S; Fausa, O; Grimelius, L; Havu, N; Lind, T; Lönroth, H; Lundell, L, 1991
)
0.28
" Both drugs were generally well tolerated, and the number of adverse events in the two treatment groups were similar."( The effect of omeprazole and ranitidine on ulcer healing, relief of symptoms, and incidence of adverse events in the treatment of duodenal ulcer patients.
Backman, L; Granström, L; Kager, L; Kollberg, B; Lindberg, G; Moberg, S; Nilsson, LH; Seensalu, R; Sidenvall, L; Sörstad, J, 1991
)
0.28
"Reports of adverse drug reactions due to histamine H2-receptor antagonists (H2RAs) are rare considering their wide usage."( Overview of the safety profile of the H2-receptor antagonists.
Hansten, PD, 1990
)
0.28
" The authors report increased serum clozapine levels and adverse side effects during clozapine and cimetidine treatment but not during clozapine and ranitidine treatment in a patient with chronic paranoid schizophrenia."( A case report of cimetidine-induced clozapine toxicity.
Cooper, T; Lieberman, JA; Masiar, S; Picou, D; Szymanski, S, 1991
)
0.28
" During maintenance therapy with omeprazole, no endoscopically verified relapses occurred, and no drug-related adverse effects were seen."( Efficacy and safety of omeprazole in the long-term treatment of peptic ulcer and reflux oesophagitis resistant to ranitidine.
Brunner, GH; Creutzfeldt, W; Lamberts, R, 1990
)
0.28
" This therapeutic advantage was achieved without adverse events and without significant abnormalities in the endocrine or exocrine cell population of the oxyntic mucosa."( Prevention of relapse of reflux oesophagitis after endoscopic healing: the efficacy and safety of omeprazole compared with ranitidine.
Lundell, L, 1990
)
0.28
", is a safe and effective treatment for gastric ulcer disease."( Efficacy and safety of rioprostil, 300 micrograms b.d., in the treatment of gastric ulcer: a comparison vs. ranitidine, 150 mg b.d., in a randomized multicentre study.
Barbier, P; Businger, JA; Demol, P; Rutgeerts, P; Simon, B; Vantrappen, G, 1989
)
0.28
" Diarrhoea is the main adverse event, but is generally mild and self-limiting."( Efficacy and safety of rioprostil, 300 micrograms b.d., in the treatment of duodenal ulcer: a double-blind, controlled multicentre clinical study vs. ranitidine.
Businger, JA; Coremans, G; Demol, P; Vantrappen, G, 1989
)
0.28
" The incidence of serious adverse events reported in comparative short-term studies with H2-receptor antagonists and placebo were similar."( The clinical safety of omeprazole.
Sölvell, L, 1989
)
0.28
" Adverse events were recorded without judgment of causality."( Safety of nizatidine in clinical trials conducted in the USA and Europe.
Cloud, ML, 1987
)
0.27
" Ratings of symptoms and adverse events were collated from patients' daily diaries, and endoscopy was repeated to verify healing after four weeks and, if appropriate, after six weeks."( Enprostil and ranitidine: comparative efficacy and safety in patients with duodenal ulcer.
Alp, M; Austad, WI; Byrnes, D; Cowen, A; Duggan, J; Mackinnon, M; Pirola, R; Thomas, M; Ward, M, 1987
)
0.27
" The 12 month report noted that cimetidine was being given, knowingly or unknowingly, in the late stages of many diseases and also to counter the adverse gastric effects of other drugs used in the treatment of serious disorders."( Postmarketing surveillance of the safety of cimetidine: mortality during second, third, and fourth years of follow up.
Colin-Jones, DG; Langman, MJ; Lawson, DH; Vessey, MP, 1985
)
0.27
" Ranitidine administration (50 mg per kg) enhanced acetaminophen hepatotoxicity throughout the toxic dose range of acetaminophen (600 to 1,000 mg per kg) and potentiation of acetaminophen hepatotoxicity by ranitidine was dose-dependent."( Ranitidine-acetaminophen interaction: effects on acetaminophen-induced hepatotoxicity in Fischer 344 rats.
Dent, JG; Leonard, TB; Morgan, DG,
)
0.13
" The results are summarized as follows: (1) Oral, intravenous, subcutaneous, intraperitoneal and intramuscular LD50 values of ranitidine hydrochloride in 5- and 12-weeks old mice and rats and 12-weeks old rabbits were ranged from ca."( [Acute toxicity of ranitidine and its metabolite in mice, rats and rabbits, and subacute oral toxicity of ranitidine in rats].
Ezaki, H; Hirai, K; Matsumoto, M; Miyamoto, H; Oda, S; Sato, N; Shirai, T; Tamura, J; Tokado, H, 1983
)
0.27
" In the 1000 mg/kg/day group, ten of 31 females died showing acute toxic signs."( [Chronic toxicity study of ranitidine hydrochloride orally administered in rats].
Iwata, M; Kaga, M; Kiguchi, M; Shimpo, K; Takeuchi, M; Tanabe, T; Yamaguchi, M, 1983
)
0.27
" A total of 6 adverse effects was reported by 5 out of 32 patients (18."( [Side effects and safety of the new histamine H2 receptor antagonist ranitidine in the long-term treatment of patients with stomach and duodenal ulcers].
Brunner, H; Meryn, S; Pamperl, H; Pesendorfer, FX; Pötzi, R, 1983
)
0.27
"Worldwide clinical experience has shown the short-term use of H2-blockers is safe and effective."( H2-blockers: how safe and how effective?
Spiro, HM, 1983
)
0.27
" In this model, liver injury is caused by toxic intermediates formed during metabolism of halothane by a reductive pathway."( Effects of cimetidine and ranitidine on halothane metabolism and hepatotoxicity in an animal model.
Cousins, MJ; Hall, PD; Jenner, MA; Plummer, JL; Wanwimolruk, S,
)
0.13
"Ebrotidine 800 mg is as effective and safe as ranitidine 300 mg in healing duodenal ulcer, but ebrotidine appears to be superior in promoting the healing of duodenal ulceration in smokers."( Efficacy and safety of ebrotidine compared with ranitidine in patients with duodenal ulcer.
Butruk, E; Dzieniszewski, J; Gabryelewicz, A; Konturek, SJ; Marlicz, K; Marquez, M; Nowak, A; Ortiz, JA; Torres, J, 1995
)
0.29
" The lack of significant adverse effects has revealed a degree of tolerability that, to write a review of the adverse effects, poses a difficult task."( A comparative overview of the adverse effects of antiulcer drugs.
Piper, DW, 1995
)
0.29
" No significant pathological findings were noted, and no adverse events were attributable to the study treatments."( Omeprazole v ranitidine for prevention of relapse in reflux oesophagitis. A controlled double blind trial of their efficacy and safety.
Dent, J; Hetzel, DJ; Mackinnon, M; Narielvala, FM; Reed, W; Shearman, DJ; Solcia, E; Yeomans, ND, 1994
)
0.29
" The incidence and type of adverse events were similar in the two age groups."( Association of age with the efficacy and safety of ranitidine and cimetidine in acute duodenal ulcer disease.
Dixon, JS; Ehsanullah, RS; Mills, JG; Wood, JR, 1993
)
0.29
"The authors conducted a retrospective review of 21 United States trials of ranitidine in acid peptic diseases and compared the adverse events in elderly (> or = 65 years) and nonelderly (< 65 years) patients."( The safety of ranitidine in elderly versus non-elderly patients.
Euler, AR; Mills, R; Sirgo, MA; Walker, S, 1993
)
0.29
" Adverse reactions to these agents are mild, transient and infrequent, and reports of serious adverse reactions are rare."( Review article: safety of bismuth in the treatment of gastrointestinal diseases.
Dixon, JS; Drake, FM; Tillman, LA; Wood, JR, 1996
)
0.29
" No adverse events were specifically attributed to ranitidine bismuth citrate."( The safety and efficacy of ranitidine bismuth citrate in combination with antibiotics for the eradication of Helicobacter pylori.
Bardhan, KD; Buckley, MJ; De Koster, EH; Duggan, AE; Gilvarry, J; Gummett, PA; Logan, RP; O'Morain, CA; Pounder, RE; Rauws, EA; Schaufelberger, HD; Wyeth, JW, 1996
)
0.29
" Analyses of post-marketing surveillance and a database of all spontaneously reported adverse events were also evaluated."( The safety of ranitidine in over a decade of use.
Fitzgerald, K; Koch, KM; Mills, JG; Sirgo, MA; Webster, C; Wood, JR, 1997
)
0.3
"Overall in the clinical trial programme adverse events were reported by 20% of those receiving ranitidine compared with 27% of those receiving placebo."( The safety of ranitidine in over a decade of use.
Fitzgerald, K; Koch, KM; Mills, JG; Sirgo, MA; Webster, C; Wood, JR, 1997
)
0.3
"Review of data from a large population of controlled clinical trials with analyses of postmarketing surveillance studies and spontaneously reported adverse events confirmed the excellent safety profile of ranitidine."( The safety of ranitidine in over a decade of use.
Fitzgerald, K; Koch, KM; Mills, JG; Sirgo, MA; Webster, C; Wood, JR, 1997
)
0.3
" Twenty-four patients experienced side-effects, but in only seven cases was treatment discontinued due to adverse events."( Efficacy and safety of three 7-day Helicobacter pylori eradication regimens containing ranitidine bismuth citrate.
Bazzoli, F; Cannizzaro, O; D'Angelo, A; Ederle, A; Fossi, S; Gerace, G; Iaquinto, G; Olivieri, A; Pozzato, P; Reina, G; Ricciardiello, L; Roda, E; Scarpulla, G; Spadaccini, A; Tosatto, R; Zagari, M, 1998
)
0.3
" Three novel RBC-based triple therapies proved to be safe and well tolerated, with discontinuations due to side-effects occurring in less than 5% of cases."( Efficacy and safety of three 7-day Helicobacter pylori eradication regimens containing ranitidine bismuth citrate.
Bazzoli, F; Cannizzaro, O; D'Angelo, A; Ederle, A; Fossi, S; Gerace, G; Iaquinto, G; Olivieri, A; Pozzato, P; Reina, G; Ricciardiello, L; Roda, E; Scarpulla, G; Spadaccini, A; Tosatto, R; Zagari, M, 1998
)
0.3
" Adverse events, laboratory value changes and gastric biopsy changes that occurred during treatment were compared statistically for differences between treatments."( Safety profile of Lansoprazole: the US clinical trial experience.
Freston, JW; Haber, M; Heller, CA; Jennings, D; Rose, PA, 1999
)
0.3
"The incidence of adverse events and number of patients discontinuing treatment because of adverse events was similar for lansoprazole and comparative agents."( Safety profile of Lansoprazole: the US clinical trial experience.
Freston, JW; Haber, M; Heller, CA; Jennings, D; Rose, PA, 1999
)
0.3
" One patient experienced a life-threatening adverse reaction within minutes of receiving the first dose."( Pegylated liposomal doxorubicin: tolerability and toxicity.
Goram, AL; Richmond, PL, 2001
)
0.31
" Histamine was applied at 10(-9),10(-8), 10(-7),10(-6), and 10(-5) M for 16 h into the cultures and the highest dose was found to be the most toxic one."( Contribution of the histaminergic receptor subtypes to histamine-induced cerebellar granular neurotoxicity.
Buyukokuroglu, ME; Gepdiremen, A; Hacimuftuoglu, A; Suleyman, H,
)
0.13
" Adverse events with grade 3 or above hematologic toxicity were oligochromemia (M: 24."( [Paclitaxel plus carboplatin in ovarian cancer-comparison of adverse effects between monthly and weekly administration].
Fujii, T; Komatsu, M; Kumagai, M; Kusuda, T; Naitou, H; Shinkou, S; Takehara, K, 2004
)
0.32
" Safety evaluations included adverse events and laboratory assessments."( Efficacy and safety of pantoprazole versus ranitidine in the treatment of patients with symptomatic gastroesophageal reflux disease.
Fischer, R; van Rensburg, C; van Zyl, J; Vieweg, W, 2004
)
0.32
" The results showed some adverse changes in rats treated with either 10 or 30 mg/kg."( Biochemical and histological studies on H2-receptor antagonist ranitidine-induced hepatotoxicity in rats.
Abdel-Hady, el-SK; Elnga, MA; Hemieda, FA, 2005
)
0.33
"In this experimental study both biological treatability of pharmaceuticals and their potential toxic effect in biological processes were evaluated."( Biodegradability and toxicity of pharmaceuticals in biological wastewater treatment plants.
Cappai, G; Carucci, A; Piredda, M, 2006
)
0.33
" In the present article, the adverse effects of PPIs are reviewed, with special emphasis on those related to their continued administration and on the special circumstances of patients, as in the case of the elderly, those with liver failure, pregnant and breastfeeding mothers and children."( [Safety of proton pump inhibitors].
Esplugues, JV; Martí-Cabrera, M; Ponce, J, 2006
)
0.33
" Pretreatment with antihistamines diminishes the incidence of adverse reactions (AR) such as large local and mild systemic reactions but it is suggested that it may mask a development of serious allergic reactions."( [Safety of venom immunotherapy in patients pretreated with antihistamines--a retrospective study].
Bocheńska-Marciniak, M; Kuna, P; Kupczyk, M; Kupryś-Lipińska, I; Tworek, D, 2006
)
0.33
" During the dose increase phase 10 systemic adverse reactions were observed."( [Safety of venom immunotherapy in patients pretreated with antihistamines--a retrospective study].
Bocheńska-Marciniak, M; Kuna, P; Kupczyk, M; Kupryś-Lipińska, I; Tworek, D, 2006
)
0.33
" A vast majority of systemic adverse reactions is of subjective and mild objective nature and appropriate treatment leads to containment of severe reactions."( [Safety of venom immunotherapy in patients pretreated with antihistamines--a retrospective study].
Bocheńska-Marciniak, M; Kuna, P; Kupczyk, M; Kupryś-Lipińska, I; Tworek, D, 2006
)
0.33
" Toxicity assessment by the Microtox® method revealed that some cyclic intermediates are more toxic than the parent molecule."( Electrochemical advanced oxidation for cold incineration of the pharmaceutical ranitidine: mineralization pathway and toxicity evolution.
Brillas, E; Buisson, D; Esposito, G; Olvera-Vargas, H; Oturan, MA; Oturan, N, 2014
)
0.4
"5%) from Group B had some type of adverse effect (p = 1."( Safety and efficacy of cetirizine versus cetirizine plus ranitidine in chronic urticaria: Double-blind randomized placebo-controlled study.
Bonilla-Lopez, S; Guevara-Gutierrez, E; Hernández-Arana, S; Tlacuilo-Parra, A, 2015
)
0.42
"Many adverse drug reactions are caused by the cytochrome P450 (CYP)-dependent activation of drugs into reactive metabolites."( Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Jones, LH; Nadanaciva, S; Rana, P; Will, Y, 2016
)
0.43
" Results obtained for SOT and RAN showed that acute adverse effects are not expected to occur on aquatic organisms at the concentrations at which these pharmaceuticals are usually found in fresh surface waters."( Assessment of the ecotoxicity of the pharmaceuticals bisoprolol, sotalol, and ranitidine using standard and behavioral endpoints.
Assano, PK; de Almeida Vergara Hidalgo, V; de Carvalho, LB; de Jesus Azevedo, CC; Domingues, I; Godoy, AA; Kummrow, F; Mori, V; Nogueira, AJA; Oliveira, ÁC; Taparo, JM, 2020
)
0.56

Pharmacokinetics

Ranitidine plasma concentrations were determined with a validated HPLC method with UV-detection. No significant relationship was found between age and weight-corrected ranitidine pharmacokinetic parameters in the final model. The covariate for cardiac failure or surgery was shown to reduce clearance significantly by a factor of 0.

ExcerptReferenceRelevance
" A comparison is also presented between several methods based on animal pharmacokinetic data, using the same set of proprietary compounds, and it lends further support for the use of this method, as opposed to methods that require the gathering of pharmacokinetic data in laboratory animals."( Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY, 2004
)
0.32
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" Serum ranitidine concentrations were measured for 12 h after the single dose and during the treatment period, to calculate individual pharmacokinetic variables."( Pharmacokinetics of ranitidine in a homogeneous population of intensive care unit patients during intermittent and continuous administration.
Geus, WP; Lamers, CB; Vinks, AA, 1992
)
0.28
"1 mg/l) and a long elimination half-life (7."( Pharmacokinetics of roxithromycin and influence of H2-blockers and antacids on gastrointestinal absorption.
Boeckh, M; Daeschlein, S; Höffken, G; Koeppe, P; Lode, H, 1992
)
0.28
"The potential pharmacokinetic interactions between didanosine, an acid-labile antiretroviral agent, and ranitidine, an H2-receptor antagonist, were evaluated by a crossover study of 12 male patients seropositive for the human immunodeficiency virus."( Pharmacokinetic-interaction study of didanosine and ranitidine in patients seropositive for human immunodeficiency virus.
Barbhaiya, RH; Dixon, RM; Graziano, FM; Knupp, CA, 1992
)
0.28
" A nonlinear least-squares regression analysis was used to establish a ranitidine pharmacokinetic dosing model."( Ranitidine pharmacokinetics and adverse central nervous system reactions.
Haug, MT; Pippenger, CE; Slugg, PH, 1992
)
0.28
" Pharmacodynamic alterations were assessed using card sorting, digit-symbol substitution, and short-term memory tests."( Ranitidine does not alter adinazolam pharmacokinetics or pharmacodynamics.
Brouwer, KL; Dukes, GE; Fleishaker, JC; Hak, LJ; Koruda, M; Songer, SS; Suttle, AB, 1992
)
0.28
" The changes in the pharmacokinetic parameters were not accompanied by discernible haemodynamic effects or any change in the tolerability of nimodipine."( Influence of the H2-receptor antagonists cimetidine and ranitidine on the pharmacokinetics of nimodipine in healthy volunteers.
Kuhlmann, J; Mück, W; Rämsch, KD; Seiberling, M; Wingender, W; Woelke, E, 1992
)
0.28
"The influence of usual regimens of the H2 blocking drugs, cimetidine, ranitidine, and nizatidine on the steady-state plasma concentrations and pharmacokinetic characteristics of theophylline was studied in seventeen patients with chronic obstructive pulmonary disease (COPD)."( Comparative investigation of the influence of nizatidine, ranitidine, and cimetidine on the steady-state pharmacokinetics of theophylline in COPD patients.
Bachmann, K; Jauregui, L; Levine, L; Martin, M; Mauro, LS; Sullivan, TJ, 1992
)
0.28
" A pharmacokinetic model incorporating discontinuous absorption was developed to simulate concentration-time profiles with double peaks."( Use of a pharmacokinetic model incorporating discontinuous gastrointestinal absorption to examine the occurrence of double peaks in oral concentration-time profiles.
Brouwer, KL; Pollack, GM; Suttle, AB, 1992
)
0.28
" Pharmacokinetic parameters were calculated according to the concentration of theophylline in the sera of patients in the second group."( [The effect of ranitidine on theophylline pharmacokinetics in patients with obstructive lung disease].
Bojović, I; Despotović, N; Dmitrović, V; Milovanović, M; Paranos, S; Vidanović, M,
)
0.13
" A pharmacodynamic model, relating ranitidine serum concentration to hourly acid secretion, was derived, which incorporated the circadian change in basal acid output."( Effect of basal gastric acid secretion on the pharmacodynamics of ranitidine.
Ballersteros, MA; Hogan, DL; Isenberg, JI; Koss, MA; Sanders, SW, 1991
)
0.28
" A pharmacokinetic method was designed to predict the resultant plasma concentrations of ranitidine."( Intragastric pH and pharmacokinetics of intravenous ranitidine during sinusoidal and constant-rate infusions.
Bishop, AL; Moore, JG; Sanders, SW, 1991
)
0.28
"A scintigraphic and pharmacokinetic study of the behaviour of (Bronchoretard forte, CAS 58-55-9) was carried out in 8 healthy male volunteers to evaluate the sensitivity of the preparation to changes in gastric pH."( Effect of pretreatment with ranitidine on the pharmacokinetics and gastrointestinal transit of a sustained release theophylline preparation.
Barkworth, MF; Blackshaw, PE; Greaves, JL; Perkins, AC; Rehm, KD; Washington, N; Wilson, CG, 1991
)
0.28
" Pharmacokinetic parameters were estimated by noncompartmental data analysis techniques."( Pharmacokinetics of ranitidine after partial gastrectomy in dogs.
Derendorf, H; Harrison, D; Hocking, MP; Kaltenbach, ML; Limberg, J; Makil, O, 1991
)
0.28
" Pharmacokinetic parameters were calculated according to the concentration of theophylline in the sera of patients in the second group."( [Effect of ranitidine on the pharmacokinetics of theophylline in patients with obstructive pulmonary disease].
Bojović, I; Bozović, M; Despotović, N; Dmitrović, V; Milovanović, M; Paranos, S; Vidanović, M, 1991
)
0.28
"Ranitidine may be used at doses of up to 300 mg twice daily in the healing of duodenal ulcers, and this study investigated the potential for a pharmacokinetic or pharmacodynamic interaction between nifedipine 10 mg three times daily and ranitidine 300 mg twice daily compared with cimetidine 800 mg daily and placebo in a randomised crossover study in 18 healthy male subjects."( The pharmacokinetics and pharmacodynamics of nifedipine at steady state during concomitant administration of cimetidine or high dose ranitidine.
Dixon, JS; Khan, A; Langley, SJ; Mullins, FG; Toon, S, 1991
)
0.28
" Gastric secretion inhibition over the 90 min of IGT correlated with peak concentration exclusively for the subpopulation with peak occurrence at T 150."( [Plasma pharmacokinetics of roxatidine in the healthy man: correlation with gastric antisecretory effect].
Bonfils, S; Chen, WW; Kolsky, H; Lewin, MJ, 1990
)
0.28
" In the first study there were no statistically significant differences between the pharmacokinetic variables for ranitidine in the presence or absence of piroxicam."( A lack of pharmacokinetic interaction between ranitidine and piroxicam.
Dixon, JS; Lacey, LF; Langley, SJ; Page, MC; Pickup, ME, 1990
)
0.28
" Co-administration of cimetidine significantly increased Cmax (27%) and AUC (44%) and prolonged the half-life (30%) of cifenline."( The effects of cimetidine and ranitidine on the pharmacokinetics of cifenline.
Aogaichi, K; Defeo, TM; Liguori, J; Massarella, JW; Passe, S, 1991
)
0.28
" There were no significant differences in the mean pharmacokinetic parameters of procainamide and NAPA after ranitidine coadministration compared to base line."( Ranitidine-induced changes in the renal and hepatic clearances of procainamide are correlated.
Ferguson, RK; Kosoglou, T; Rocci, ML; Vlasses, PH, 1989
)
0.28
"The effects of a new H2-receptor antagonist, roxatidine acetate, have been investigated in both clinical and pharmacodynamic trials in Europe and the United States."( Safety and efficacy of roxatidine acetate. Evidence from pharmacodynamic and clinical trials.
Bender, W; Labs, R; Merki, HS, 1989
)
0.28
" But bioavailability parameters of period I, such as maximum concentration of the first and second plasma peak (Cmax 1 and Cmax 2, respectively), time to first peak (tmax 1), AUC0-12, and AUC from time zero to infinity (AUC0-infinity), were correlated significantly with those of period II."( Inter- and intrasubject variations of ranitidine pharmacokinetics after oral administration to normal male subjects.
Hong, JS; Shim, CK, 1989
)
0.28
" Our data suggest that 300 mg ranitidine at night improves the gastroduodenal tolerability of both indomethacin and acemetacin without affecting main pharmacokinetic parameters of both antirheumatics."( [Ranitidine ameliorates acemetacin and indomethacin-induced changes of the gastroduodenal mucosa, without modifying the pharmacokinetic behavior of both antirheumatic drugs].
Dammann, HG; Langer, M; Leucht, U; Müller, P; Simon, B, 1989
)
0.28
" Elimination half-life was prolonged (3."( Pharmacokinetics of ranitidine in geriatric patients with multiple diseases.
Bauer, M; Eicher, H; Platt, D, 1989
)
0.28
"The pharmacokinetic parameters of ranitidine were studied following administration of a single intravenous dose in 9 critically ill infants."( Pharmacokinetics of ranitidine in critically ill infants.
Brundage, RC; Gillette, PC; O'Neal, W; Reigart, JR; Wiest, DB; Yost, RL, 1989
)
0.28
" Similarly, the H2 receptor antagonists did not alter the plasma bupivacaine against time curves, half-life or bupivacaine clearance in the three groups studied."( H2 antagonists and bupivacaine clearance.
Brighouse, D; Morgan, B; O'Sullivan, GM; Reynolds, F; Smith, M, 1988
)
0.27
"The reciprocal effects on pharmacokinetic parameters after a single oral dose of the nonsteroidal antiinflammatory drugs (NSAIDs) indomethacin and sulindac and repeated oral doses of the H2-receptor antagonists cimetidine and ranitidine were determined in two groups of nine healthy subjects each (indomethacin and sulindac groups)."( Pharmacokinetic interactions between NSAIDs (indomethacin or sulindac) and H2-receptor antagonists (cimetidine or ranitidine) in human volunteers.
Abel, L; Carbon, C; Delhotal-Landes, B; Flouvat, B; Liote, F; Meyer, P; Vinceneux, P, 1988
)
0.27
" The terminal half-life and renal clearance of tocainide were not altered by either H2-receptor antagonists, compared with placebo."( The effect of histamine-2 receptor antagonists on tocainide pharmacokinetics.
Kapil, RP; Lalonde, RL; Mattern, AL; North, DS, 1988
)
0.27
" The interaction resulted in a small attenuation of the pharmacodynamic response to triamterene."( Pharmacokinetic drug interactions between triamterene and ranitidine in humans: alterations in renal and hepatic clearances and gastrointestinal absorption.
Bochner, F; Muirhead, M; Somogyi, A, 1988
)
0.27
" Plasma pharmacokinetic data were first obtained from rabbits given 3 mg/kg doxorubicin."( The influence of ranitidine on the pharmacokinetics and toxicity of doxorubicin in rabbits.
Anthony, LB; Brenner, DE; Collins, JC; Halter, S; Hande, KR; Harris, NL, 1988
)
0.27
" After pretreatment with cimetidine, which inhibits the activity of cytochrome P-450, the peak plasma concentration and area under the plasma-time concentration curve for nifedipine were increased by a mean 84%."( Factors affecting the pharmacokinetics of nifedipine.
Challenor, VF; George, CF; Gruchy, B; Le Vie, J; Renwick, AG; Waller, DG, 1987
)
0.27
" No significant differences in elimination rate constant, peak concentration, time to peak concentration, volume of distribution, or elimination half-life were noted among treatments."( Effects of cimetidine or ranitidine on the pharmacokinetics of flurbiprofen.
Cox, SR; Rock, WL; Small, RE; Sullivan, KM; Willis, HE, 1986
)
0.27
" Peak plasma quinine concentration and the time of peak concentration were not altered after cimetidine or ranitidine pretreatment."( Effects of cimetidine and ranitidine on the pharmacokinetics of quinine.
Patamasucon, P; Pongmarutai, M; Sunbhanich, M; Wanwimolruk, S, 1986
)
0.27
"A pharmacokinetic study of ranitidine was performed in 14 patients with haematemesis divided into two groups according to the severity of blood loss."( Pharmacokinetics of ranitidine in acute upper gastrointestinal haemorrhage.
Advenier, C; Andrieu, J; Doll, J; Grosbuis, S; Pays, M; Trawale, JM; Varoquaux, O, 1985
)
0.27
" Ranitidine plasma concentration was measured by high performance liquid chromatography and appropriate polyexponential equations were fitted to concentration-time data to enable calculation of relevant pharmacokinetic parameters."( Pharmacokinetics of ranitidine in critically ill patients.
Cameron, PD; Ilett, KF; Nation, RL; Oh, TE; Thompson, WR; Tjokrosetio, R, 1986
)
0.27
"05) increase in diltiazem levels at most time points, in peak concentration and area under the concentration-time curve."( The effect of ranitidine and cimetidine on single-dose diltiazem pharmacokinetics.
Goodman, RP; McKenney, JM; Winship, LC; Wood, JH; Wright, JT,
)
0.13
"The aim of these studies was to further delineate pharmacokinetic characteristics of ranitidine, a new histamine H2-receptor antagonist."( Pharmacokinetics of ranitidine following oral administration with ascending doses and with multiple-fixed doses.
Eshelman, FN; Garg, DC; Weidler, DJ, 1985
)
0.27
"In our recent study, oral cimetidine increased carbamazepine plasma levels after a single oral dose by 26 percent and prolonged the elimination half-life by 18 percent."( Ranitidine does not alter single-dose carbamazepine pharmacokinetics in healthy adults.
Dalton, MJ; Messenheimer, JA; Powell, JR, 1985
)
0.27
"Ranitidine produces a blood concentration curve with a pronounced secondary peak when administered orally and parenterally."( Pharmacokinetics and bioavailability of ranitidine in humans.
Miller, R, 1984
)
0.27
"A sensitive and specific high pressure liquid chromatographic procedure for ranitidine estimation is described and pharmacokinetic studies in six healthy volunteers reported."( Pharmacokinetic and gastric secretory studies of ranitidine in man.
Anderson, A; Hanson, RG; Louis, WJ; McNeil, JJ; Mihaly, GW; Smallwood, RA; Yeomans, ND, 1981
)
0.26
" In non-ascitic cirrhotic patients, pharmacokinetic parameters are similar to those published in healthy subjects."( [Pharmacokinetics of intravenous ranitidine and its effect on gastric acid secretion stimulated by pentagastrin in the cirrhotic].
Allain, H; Bretagne, JF; Gastard, J; Gosselin, A; Reymann, JM; Tassou, JJ, 1983
)
0.27
"05, respectively) after MD than after SD, but the half-life (t1/2) and minimum concentration (Cmin) 12 h postdosing did not differ."( The pharmacokinetics of ranitidine in patients with chronic duodenal ulceration: a comparison of responders and non-responders.
Folb, PI; Marks, IN; McFadyen, ML; Miller, R; Moshal, MG, 1983
)
0.27
"The pharmacokinetic behaviour of a single oral 150 mg ranitidine dose was studied in six patients with severe chronic renal failure (CRF) (creatinine clearance 2-18 ml/min) and compared to that in ten patients with duodenal ulceration but normal renal function (N) (creatinine clearance 69-125 ml/min)."( Pharmacokinetics of ranitidine in patients with chronic renal failure.
Folb, PI; Keeton, GR; Marks, IN; McFadyen, ML; Miller, R, 1983
)
0.27
" The interaction of nifedipine and cimetidine is thus of clinical significance because of its pharmacodynamic effect."( [Effect of cimetidine and ranitidine on the pharmacokinetics and anti-hypertensive effect of nifedipine].
Heidemann, H; Janisch, HD; Kirch, W; Ohnhaus, EE; Rämsch, K, 1983
)
0.27
" Pharmacodynamic and pharmacokinetic differences exist between the drugs, some of which are of clinical significance."( Comparative pharmacodynamics and pharmacokinetics of cimetidine and ranitidine.
Richards, DA, 1983
)
0.27
" The elimination half-life is almost 2 hours and is somewhat longer after oral administration."( Clinical pharmacokinetics of ranitidine.
Roberts, CJ,
)
0.13
"A four-way crossover pilot study was conducted to compare the pharmacodynamic response of intermittent famotidine (20 mg every 12 hr) to continuous infusions of cimetidine (1200 mg/24 hr), ranitidine (150 mg/24 hr), and famotidine (40 mg/24 hr) in six normal male volunteers."( Pharmacodynamics of bolus famotidine versus infused cimetidine, ranitidine, and famotidine.
Amsden, GW; D'Andrea, DT; Goss, TF; Harrison, NJ; Schentag, JJ, 1994
)
0.29
" After the last dose the geometric mean for Cmax for 500 mg bid of GR122311X was 5 ng."( Comparative pharmacokinetics of bismuth from ranitidine bismuth citrate (GR122311X), a novel anti-ulcerant and tripotassium dicitrato bismuthate (TDB).
Frazer, NM; Keene, ON; Lacey, LF; Smith, JT, 1994
)
0.29
"Many aspects of drug/drug interaction studies, including aspects of the design, choice of pharmacokinetic characteristics, and statistical analysis can be adapted from bioequivalence studies [Steinijans et al."( Pharmacokinetic characteristics for extent of absorption and clearance in drug/drug interaction studies.
Hundt, HK; Luus, HG; Schall, R, 1994
)
0.29
"The possibility of a pharmacokinetic interaction between H2-receptor antagonists and alcohol consumed at lunchtime, was investigated in 24 healthy non-alcoholic male subjects, each receiving ranitidine 150 mg four times daily, cimetidine 400 mg four times daily, famotidine 20 mg four times daily and placebo in an open, four-way cross-over study."( Lack of effect of H2-receptor antagonists on the pharmacokinetics of alcohol consumed after food at lunchtime.
Braithwaite, R; Gibson, GJ; Hale, KA; Kendall, MJ; Langman, MJ; Spannuth, F; Walt, RP, 1994
)
0.29
" There was also a significant increase in tmax but not in Cmax."( The effect of renal function on the pharmacokinetics of ranitidine.
Borg-Costanzi, JM; Dixon, JS; Lacey, LF; Langley, SJ; Toon, S, 1994
)
0.29
" The variation between different subjects dominated the total variance for all of the pharmacokinetic parameters studied except the rate of disappearance of ethanol from blood (ko)."( Between-subject and within-subject variations in the pharmacokinetics of ethanol.
Jones, AW; Jönsson, KA, 1994
)
0.29
" Ranitidine tmax, t1/2 and clearances were independent of dose; however, AUC and Cmax were dose-related."( Anti-secretory effects and pharmacokinetics of low dose ranitidine.
Hogan, DL; Isenberg, JI; Koss, MA; Lane, J; Steinbach, JH, 1993
)
0.29
" Significant decreases in AUC (16 and 13%) were observed following administration of single- and multiple-dose cimetidine, and a significant decrease in Cmax (14%) was observed following a single dose of ranitidine--all given prior to alcohol ingestion in the morning."( Cimetidine and ranitidine. Lack of effect on the pharmacokinetics of an acute ethanol dose.
Chesher, GB; Dauncey, H; Palmer, RH, 1993
)
0.29
" Pharmacokinetic profiles and morning pre-dose electrocardiograms were obtained whilst the patients were on terfenadine alone and after the addition of cimetidine or rantidine."( Effect of concomitant administration of cimetidine and ranitidine on the pharmacokinetics and electrocardiographic effects of terfenadine.
Cantilena, LR; Conner, DP; Honig, PK; Mullin, JC; Wortham, DC; Zamani, K, 1993
)
0.29
" Famotidine's plasma half-life (4."( Pharmacokinetics and pharmacodynamics of ranitidine and famotidine in healthy elderly subjects: a double-blind, placebo-controlled comparison.
Bisson, C; LeBel, M; Michaud, JT; St-Laurent, M,
)
0.13
" Time to achieve the maximum plasma concentration, terminal half-life of elimination, and the total area under the plasma concentration-time curve of ritanserin were not altered in comparison with control experiments."( Effect of concomitantly administered cimetidine or ranitidine on the pharmacokinetics of the 5-HT2-receptor antagonist ritanserin.
Benn, HP; Buschmann, M; Jähnchen, E; Seiler, KU; Szathmary, S; Trenk, D, 1993
)
0.29
" Venous blood sampling for pharmacokinetic assessment was done over a complete dosing interval on day 7 of each phase."( Effects of cimetidine and ranitidine on the pharmacokinetics of a chronotherapeutically formulated once-daily theophylline preparation (Uniphyl).
Babul, N; Buttoo, KM; Fraser, IM; Stewart, JH; Walker, SE,
)
0.13
" At the lowest dose of ethanol studied the pharmacokinetic profile was largely first order but at the higher doses the usual zero order kinetics were seen."( Effect of ranitidine hydrochloride (150 mg twice daily) on the pharmacokinetics of increasing doses of ethanol (0.15, 0.3, 0.6 g kg-1).
Bye, A; Gupta, S; Lacey, LF; Powell, JR, 1996
)
0.29
" Ranitidine concentration in plasma was measured by high performance liquid chromatography and pharmacokinetic parameters were determined by non-compartmental analysis."( Pharmacokinetics of oral ranitidine in Mexicans.
Castañeda-Hernández, G; Flores-Murrieta, FJ; Granados-Soto, V; Herrera, JE; Herrera-Abarca, A; Hong, E; Pérez-Urizar, J, 1996
)
0.29
" The terminal half-life of ranitidine was 7% shorter and the oral apparent clearance 10."( Evaluation of sex differences in the pharmacokinetics of ranitidine in humans.
Abad-Santos, F; Carcas, AJ; Fernández, A; Frias, J; Gómez, E; Govantes, C; Guerra, P; Montuenga, C, 1996
)
0.29
"The area under the plasma concentration-time curve and the elimination half-life of lomefloxacin were significantly increased following coadministration with ranitidine."( Effect of ranitidine on renal clearance of lomefloxacin.
Fujimura, A; Harada, K; Ohmori, M; Sakamoto, K; Sudoh, T; Sunaga, K, 1996
)
0.29
"This discontinuous oral absorption pharmacokinetic model can be a useful tool in characterizing absorption phases, disposition, and bioavailability of drugs exhibiting two absorption peaks following oral administration."( Applications and simulations of a discontinuous oral absorption pharmacokinetic model.
Boudinot, FD; Witcher, JW, 1996
)
0.29
"We investigated the hypothesis that distributions of continuous pharmacokinetic variables are positively skewed in nature and that logarithmic transformation of these variables restores normality."( Common noncompartmental pharmacokinetic variables: are they normally or log-normally distributed?
Bye, A; Keene, ON; Lacey, LF; Pritchard, JF, 1997
)
0.3
" The ideal therapy for GORD will have linear pharmacokinetics, a relatively long plasma half-life (t1/2), a duration of action allowing once daily administration, and a stable effect independent of interactions with food, antacids and other drugs."( Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease.
Berstad, A; Hatlebakk, JG, 1996
)
0.29
" Cimetidine, however, resulted in a 21-23% increase in Cmax of unchanged nebivolol and of each enantiomer plus its hydroxylated metabolites."( A pharmacokinetic and pharmacodynamic interaction study between nebivolol and the H2-receptor antagonists cimetidine and ranitidine.
Ford, GA; Howes, A; Kamali, F; Snoeck, E; Thomas, SH, 1997
)
0.3
" Serial pharmacokinetic samples were obtained for up to 24 hours following eprosartan dosing."( Effect of ranitidine on the pharmacokinetics of orally administered eprosartan, an angiotensin II antagonist, in healthy male volunteers.
Boike, SC; Boyle, DA; Carr, AM; Ilson, BE; Jorkasky, DK; Lundberg, DE; Martin, DE; Tenero, DM, 1998
)
0.3
"A scintigraphic and pharmacokinetic study of the behavior of Bronchoretard forte (theophylline, CAS 58-55-9) was carried out in 8 healthy male volunteers to evaluate the sensitivity of the preparation to changes in gastric pH."( [The effect of pretreatment with ranitidine on the pharmacokinetics and gastrointestinal transit of a sustained-release theophylline preparation].
Barkworth, MF; Blackshaw, PE; Greaves, JL; Perkins, AC; Rehm, KD; Washington, N; Wilson, CG, 1998
)
0.3
" Serial blood samples, obtained over 12 hours in each treatment, were analyzed by HPLC to determine ranitidine AUC0-12 (ng*h/mL), as well as Cmax (ng/mL) and Tmax (min) of the first and subsequent peaks, if subsequent peaks were observed."( Effect of pancreatico-biliary secretions and GI transit time on the absorption and pharmacokinetic profile of ranitidine in humans.
Brouwer, KL; Burns, CB; Heizer, WD; Reynolds, KS; Sica, DA; Song, MH, 1998
)
0.3
"Ranitidine AUC0-12 and Cmax were not altered significantly by treatments; treatment effects on SBTT varied."( Effect of pancreatico-biliary secretions and GI transit time on the absorption and pharmacokinetic profile of ranitidine in humans.
Brouwer, KL; Burns, CB; Heizer, WD; Reynolds, KS; Sica, DA; Song, MH, 1998
)
0.3
" Serum concentrations and urinary recovery of (S)-(+)- and (R)-(-)-chlorpheniramine were unaffected by administration of ranitidine, indicating no pharmacokinetic drug-drug interaction."( Stereoselective pharmacokinetics of chlorpheniramine and the effect of ranitidine.
Davis, IM; Koch, KM; O'Connor-Semmes, RL; Yin, Y, 1998
)
0.3
"The present study was conducted to compare the pharmacokinetics and pharmacodynamics (PD) of paclitaxel between Phase I trials of 3- and 24-h infusions and to determine the most informative pharmacokinetic parameter to describe the PD."( Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion.
Miyata, Y; Nakanomyo, H; Nishiwaki, Y; Ohtsu, T; Saijo, N; Sasaki, Y; Tamura, T, 1995
)
0.29
"Fifteen patients with advanced cancer were enrolled of which 12 were evaluable, all of whom had pharmacokinetic blood sampling."( Effect of gastric pH on the relative oral bioavailability and pharmacokinetics of temozolomide.
Beale, P; Brada, M; Cutler, DL; Judson, I; Marco, A; Moore, S; Reidenberg, P; Statkevich, P, 1999
)
0.3
" There was no difference in the pharmacokinetic parameters of temozolomide or MTIC with or without the concomitant administration of ranitidine."( Effect of gastric pH on the relative oral bioavailability and pharmacokinetics of temozolomide.
Beale, P; Brada, M; Cutler, DL; Judson, I; Marco, A; Moore, S; Reidenberg, P; Statkevich, P, 1999
)
0.3
" To adjust for the variable drug dosing used among study patients, both Cmax and area under the concentration curve (AUC) were standardized to dose (CmaxST and AUCST, respectively) and were 217."( The pharmacokinetics of oral ranitidine in children and adolescents with cystic fibrosis.
Argao, EA; Farrar, HC; James, LP; Menendez, AA; Stowe, CD, 1999
)
0.3
" Pharmacokinetic parameters were determined from plasma and urinary dofetilide concentrations; prolongation of the QTc interval was determined from three-lead electrocardiograms."( Effect of cimetidine and ranitidine on pharmacokinetics and pharmacodynamics of a single dose of dofetilide.
Abel, S; Brearley, CJ; Eve, MD; Nichols, DJ, 2000
)
0.31
"To build a pharmacokinetic model taking into account a discontinuous absorption along the gut, from n successive sites, a non-absorbing intestinal segment being always in between two successive sites."( A pharmacokinetic model for multiple sites discontinuous gastrointestinal absorption.
Duthil, P; Efthymiopoulos, C; Houin, G; Plusquellec, Y, 1999
)
0.3
"This general discontinuous oral absorption pharmacokinetic model may be taken as a possible tool to characterize each site of absorption and to estimate the area under curves or bioavailability."( A pharmacokinetic model for multiple sites discontinuous gastrointestinal absorption.
Duthil, P; Efthymiopoulos, C; Houin, G; Plusquellec, Y, 1999
)
0.3
" Apparent half-life of ranitidine during dialysis with PS (2."( Ranitidine clearance during hemodialysis with high-flux membrane: comparison of polysulfone and cellulose acetate hemodialyzers.
Fujimura, A; Hayasaka, T; Saito, T; Sugimoto, KI; Tsuruoka, S, 2000
)
0.31
"The present study examines the pharmacodynamic interaction between the H(2)-receptor antagonist ranitidine and the prokinetic agent cisapride on the isolated rabbit intestine."( Synergistic and antagonistic pharmacodynamic interaction between ranitidine and cisapride: a study on the isolated rabbit intestine.
Batzias, GC; Kounenis, G; Koutsoviti-Papadopoulou, M; Nikolaidis, E, 2001
)
0.31
" Pharmacokinetic variables included a clearance of 511."( Pharmacokinetics and pharmacodynamics of ranitidine in critically ill children.
Cash, J; Harrison, AM; Lugo, RA; Sweeley, J; Vernon, DD, 2001
)
0.31
" There were no changes in the half-life of triazolam or alpha-hydroxytriazolam."( Effect of ranitidine on the pharmacokinetics of triazolam and alpha-hydroxytriazolam in both young (19-60 years) and older (61-78 years) people.
Kersey, K; Koch, KM; Lam, R; O'Connor-Semmes, RL; Williams, DH, 2001
)
0.31
" However, the pharmacokinetic and pharmacodynamic effects of over-the-counter histamine-2 receptor antagonists in the paediatric population are largely unknown."( Ranitidine, 75 mg, over-the-counter dose: pharmacokinetic and pharmacodynamic effects in children with symptoms of gastro-oesophageal reflux.
Blumer, JL; Ciociola, AA; Faessel, HM; Fung, K; Grunow, JE; Lavine, JE; Li, BU; McGuire, JA; Orenstein, SR; Treem, WR, 2002
)
0.31
" The pharmacokinetic and pharmacodynamic profiles were similar to those in adults."( Ranitidine, 75 mg, over-the-counter dose: pharmacokinetic and pharmacodynamic effects in children with symptoms of gastro-oesophageal reflux.
Blumer, JL; Ciociola, AA; Faessel, HM; Fung, K; Grunow, JE; Lavine, JE; Li, BU; McGuire, JA; Orenstein, SR; Treem, WR, 2002
)
0.31
" Maximum observed plasma concentration (Cmax), the time at which Cmax occurred (Tmax), plasma clearance (CL), steady-state volume of distribution (Vss), and terminal elimination half-life (t 1/2) were also assessed."( The effect of ranitidine on the pharmacokinetics of rosiglitazone in healthy adult male volunteers.
DiCicco, RA; Freed, MI; Miller, AK, 2002
)
0.31
"The modified two-portion absorption model may afford a useful approach to characterise the absorption phase and estimate pharmacokinetic parameters for drugs with two absorption peaks."( A modified two-portion absorption model to describe double-peak absorption profiles of ranitidine.
Chow, AH; Chow, MS; Tomlinson, B; Yin, OQ, 2003
)
0.32
" Concomitant ranitidine had no significant effect on voriconazole Cmax or AUCtau."( Histamine H2-receptor antagonists have no clinically significant effect on the steady-state pharmacokinetics of voriconazole.
Kleinermans, D; Nichols, D; Purkins, L; Wood, N, 2003
)
0.32
" Pharmacokinetic parameters were calculated with compartmental and non-compartmental analysis."( Pharmacokinetic interaction study between ranitidine and metoclopramide.
Farcău, D; Leucuţa, A; Nanulescu, M; Vlase, L, 2004
)
0.32
"Limited data characterize pharmacokinetic interactions between cephalexin and ranitidine, and no data exist for an interaction with proton pump inhibitors."( A randomized crossover study investigating the influence of ranitidine or omeprazole on the pharmacokinetics of cephalexin monohydrate.
Adejare, A; George, M; Madaras-Kelly, K; May, MP; Michas, P, 2004
)
0.32
" Pharmacokinetic parameters were calculated with compartmental and non-compartmental analysis."( No effect of short term ranitidine intake on diclofenac pharmacokinetics.
Farcau, D; Leucuţa, A; Nanulescu, M; Vlase, L, 2004
)
0.32
" Pharmacokinetic parameters were calculated with compartmental and non-compartmental analysis, using the computer program Kinetica (Inna Phase)."( A pharmacokinetic interaction study between omeprazole and the H2-receptor antagonist ranitidine.
Farcau, D; Leucuta, A; Nanulescu, M; Vlase, L, 2004
)
0.32
"This study was undertaken to examine whether the pharmacokinetic profiles of ranitidine and nizatidine, the H2 antagonists, differed with repeated doses in very elderly patients (>80 years old)."( Pharmacokinetics of ranitidine and nizatidine in very elderly patients.
Fujimura, A; Sasaki, M; Sudoh, T,
)
0.13
" DRUG-KNT--a pharmacokinetic software developed previously for fitting one and two compartment kinetics using the iterative curve stripping method--was modified and a revised subroutine was incorporated to solve double-peak models."( A simple pharmacokinetics subroutine for modeling double peak phenomenon.
Mahmoudian, M; Mirfazaelian, A, 2006
)
0.33
" The volunteers were given a single oral dose of 300 mg of ranitidine and blood samples were obtained, and some pharmacokinetic parameters were correlated with age."( Effect of age on the pharmacokinetics of ranitidine in healthy Mexican volunteers.
Camacho-Vieyra, A; Carrasco-Portugal, M; Flores Pérez, C; Flores-Pŕez, J; Guillé-Pérez, A; Juárez-Olguín, H; Lares-Asseff, I; Pérez-Guillé, G; Toledo-López, A, 2005
)
0.33
" Differences for AUC, t1/2 and Cmax are more evident between G1 and G3."( Effect of age on the pharmacokinetics of ranitidine in healthy Mexican volunteers.
Camacho-Vieyra, A; Carrasco-Portugal, M; Flores Pérez, C; Flores-Pŕez, J; Guillé-Pérez, A; Juárez-Olguín, H; Lares-Asseff, I; Pérez-Guillé, G; Toledo-López, A, 2005
)
0.33
" The non-compartmental method was used for pharmacokinetic analysis."( Pharmacokinetics and bioequivalence of ranitidine and bismuth derived from two compound preparations.
Jiang, B; Ruan, ZR; Xu, DH; Yuan, H; Zhou, Q, 2006
)
0.33
"Various pharmacokinetic parameters of ranitidine derived from the two compound preparations, including C(max), AUC( (0-t)), AUC( (0-infinity)), T(max) and T((1/2)), were nearly consistent with previous observations."( Pharmacokinetics and bioequivalence of ranitidine and bismuth derived from two compound preparations.
Jiang, B; Ruan, ZR; Xu, DH; Yuan, H; Zhou, Q, 2006
)
0.33
"Single-center, open-label, randomized, three-part crossover, pharmacokinetic pilot study."( Effect of food and ranitidine on saquinavir pharmacokinetics and gastric pH in healthy volunteers.
Falcon, RW; Kakuda, TN, 2006
)
0.33
" No correlation was found between pharmacokinetic parameters (C(max) and AUC) and gastric pH parameters, including maximum pH and pH at the time of drug delivery."( Effect of food and ranitidine on saquinavir pharmacokinetics and gastric pH in healthy volunteers.
Falcon, RW; Kakuda, TN, 2006
)
0.33
" A randomized, placebo controlled crossover oral pharmacokinetic study was conducted in 12 healthy male human volunteers and in vitro (everted sac) and in situ (intestinal loop) studies were conducted in rats to study the role of P-gp."( Effect of ketoconazole and rifampicin on the pharmacokinetics of ranitidine in healthy human volunteers: a possible role of P-glycoprotein.
Gundu, J; Machavaram, KK; Yamsani, MR, 2006
)
0.33
"Darunavir (DRV; TMC114; Prezista) is a human immunodeficiency virus (HIV) protease inhibitor used in combination with low-dose ritonavir (RTV) (DRV/r) as a pharmacokinetic enhancer."( Pharmacokinetic interaction between darunavir boosted with ritonavir and omeprazole or ranitidine in human immunodeficiency virus-negative healthy volunteers.
De Marez, T; De Paepe, E; De Pauw, M; Hoetelmans, RM; Lefebvre, E; Parys, W; Sekar, VJ, 2007
)
0.34
" Blood samples for pharmacokinetic profiling were taken up to 24 h post-dose, and ranitidine plasma concentrations were determined with a validated HPLC method with UV-detection."( Pharmacokinetics and bioequivalence study of ranitidine film tablets in healthy male subjects.
Erenmemişoglu, A; Gschwend, MH; Guserle, R; Hincal, AA; Kanzik, I; Martin, W; Tamur, U, 2007
)
0.34
" Pharmacokinetic parameter estimates (AUC(0-t last), C(max), and t(max)) and inhibition of platelet aggregation (IPA) by light transmission aggregometry were assessed at multiple time points after the LD and final MD."( Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel.
Ernest, CS; Farid, NA; Li, YG; Payne, CD; Salazar, DE; Small, DS; Winters, KJ, 2008
)
0.35
" As pharmacokinetic studies in this population are hampered by limitations in the number and volume of plasma samples, we developed an LC-MS/MS assay for the simultaneous determination of these medications in small volume human plasma specimens for pharmacokinetic evaluations in neonates."( A tandem mass spectrometry assay for the simultaneous determination of acetaminophen, caffeine, phenytoin, ranitidine, and theophylline in small volume pediatric plasma specimens.
Budha, NR; Christensen, ML; Mehrotra, N; Meibohm, B; Zhang, Y, 2008
)
0.35
" The pharmacokinetic parameters were compared between the two groups."( [Effects of ranitidine on pharmacokinetics of rhein from Dachengqi Decoction in rats after oral administration].
Gong, HL; Huang, X; Ren, YY; Tang, WF; Wan, MF, 2009
)
0.35
"The pharmacokinetic parameters of rhein in the DCQD group, including peak concentration (C(max)), area under the plasma concentration-time curve (AUC), distribution phase half-life (t(1/2alpha)), elimination rate constant (K(10)) and central to peripheral transfer rate constant (K(12)), were significantly different to those in the DCQD plus ranitidine group (P<0."( [Effects of ranitidine on pharmacokinetics of rhein from Dachengqi Decoction in rats after oral administration].
Gong, HL; Huang, X; Ren, YY; Tang, WF; Wan, MF, 2009
)
0.35
" This method was successfully applied to a pharmacokinetic study after oral administration of a dose (150 mg) of ranitidine."( A sensitive and rapid determination of ranitidine in human plasma by HPLC with fluorescence detection and its application for a pharmacokinetic study.
Tuncel, M; Ulu, ST, 2012
)
0.38
" Plasma samples were analysed using high-performance liquid chromatography, and the data were subjected to population pharmacokinetic analysis using nonlinear mixed-effects modelling."( Prophylactic ranitidine treatment in critically ill children--a population pharmacokinetic study.
Collier, PS; Halliday, HL; Hawwa, AF; McElnay, JC; Millership, JS; Nunn, AJ; Shields, MD; Thurley, G; Westwood, PM; Yakkundi, S, 2013
)
0.39
" DNV AUC0-∞, Cmax and C12h GMR% (90% CI) with ranitidine: 81."( Effect of meal and antisecretory agents on the pharmacokinetics of danoprevir/ritonavir in healthy volunteers.
Bech, N; Brennan, BJ; Morcos, PN; Moreira, SA; Navarro, MT; Quatkemeyer, A; Smith, PF, 2014
)
0.4
" No difference between drugs in clearance, volume of distribution and half-life (p > 0."( Pharmacokinetics and pharmacodynamics of famotidine and ranitidine in critically ill children.
Kauffman, R; Lai, ML; Lehr, VT; Madani, S; Sarniak, A; Simpson, P; Tolia, V, 2014
)
0.4
" Vandetanib + digoxin increased digoxin area under the concentration-time curve from zero to the last quantifiable concentration (AUC0-last) and Cmax by 23 and 29 %, respectively, versus digoxin alone, with only a 9 % decrease in CLR."( Pharmacokinetic evaluations of the co-administrations of vandetanib and metformin, digoxin, midazolam, omeprazole or ranitidine.
Johansson, S; Leese, PT; Li, Y; Lisbon, E; Martin, P; Mathews, D; Oliver, S; Read, J; Steinberg, M, 2014
)
0.4
"The aim of this study was to evaluate the effect of coadministration of acid-reducing agents on the pharmacokinetic exposure of orally administered epidermal growth factor receptor inhibitor erlotinib, a drug that displays pH-dependent solubility."( Effect of gastric pH on erlotinib pharmacokinetics in healthy individuals: omeprazole and ranitidine.
Abt, M; Ducray, PS; Giraudon, M; Hamilton, M; Kletzl, H; Lum, BL, 2015
)
0.42
" The compounds were designed with the objective of improving pharmacokinetic properties."( Second-Generation Phenylthiazole Antibiotics with Enhanced Pharmacokinetic Properties.
Abdelghany, TM; Bayoumi, SA; Disouky, AM; El-Morsy, A; Elshafeey, A; Mancy, AS; Mayhoub, AS; Mohammad, H; Seleem, MA; Seleem, MN, 2016
)
0.43
"A prospective, descriptive and pharmacokinetic study was carried out in 30 pre-term and 20 full-term babies."( Pharmacokinetics of ranitidine in preterm and term neonates with gastroesophageal reflux.
Asseff, IL; Gaucin, GB; Guillé, GP; López, AT; Nájera, JA; Olguín, HJ; Torres, FZ, 2016
)
0.43
"A series of in vitro dissolution and clinical pharmacokinetic studies were performed to support the design and introduction of a new formulation, understand the impact of changes in in vitro dissolution on in vivo performance for two fostamatinib formulations, to characterize the effects of food and ranitidine on exposure, and determine the absolute oral bioavailability."( Effects of ranitidine (antacid), food, and formulation on the pharmacokinetics of fostamatinib: results from five phase I clinical studies.
Flanagan, T; Gillen, M; Kruusmägi, M; Lisbon, E; Martin, P; Mathews, D, 2017
)
0.46
" Furthermore, a drug interaction study with trospium chloride after intravenous (2 mg) and oral dosing (30 mg) plus ranitidine (300 mg) was performed in 12 healthy subjects and evaluated by noncompartmental analysis and population pharmacokinetic modeling."( Pharmacokinetic Drug-Drug Interactions Between Trospium Chloride and Ranitidine Substrates of Organic Cation Transporters in Healthy Human Subjects.
Abebe, BT; Meyer, MJ; Modess, C; Neumeister, C; Scheuch, E; Schulz, HU; Schwantes, U; Siegmund, W; Tadken, T; Tzvetkov, M; Wegner, D; Weiss, M, 2020
)
0.56
" The current investigation was carried out as a single center, open label, two phase, single dose, randomized way in cross over manner to evaluate the potential of pharmacokinetic interaction among amoxicillin formulation and ranitidine in adult healthy male volunteers."( Evaluation of pharmacokinetic interactions of amoxicillin with ranitidine in healthy human volunteers of Karachi, Pakistan.
Ali, H; Gauhar, S; Perveen, S; Sheikh, AF; Yousuf, RI; Zafar, F, 2022
)
0.72

Compound-Compound Interactions

Rinitidine bismuth citrate (RBC) when given with metronidazole and either oxytetracycline or spiramycin. These parameters were somewhat higher when ceftibuten was administered with ranitidine, but they were still within the ranges seen in normal healthy volunteers.

ExcerptReferenceRelevance
"The renal drug-drug interaction between famotidine (an H(2) receptor antagonist) and probenecid has not been reproduced in rats."( Is the monkey an appropriate animal model to examine drug-drug interactions involving renal clearance? Effect of probenecid on the renal elimination of H2 receptor antagonists.
Chida, M; Fuse, E; Kusuhara, H; Sugiyama, Y; Tahara, H, 2006
)
0.33
" However, one study did demonstrate differences in the pharmacokinetics of 7-hydroxy-methotrexate, the active metabolite of MTX, when MTX was administered with aspirin."( Methotrexate and nonsteroidal antiinflammatory drug interactions.
Frenia, ML; Long, KS, 1992
)
0.28
" Since cimetidine--the predecessor drug of ranitidine--interacts with a variety of other agents and moreover ranitidine is often administered in combination with other drugs the interaction potential of ranitidine has been subject to extensive investigations."( The drug interaction potential of ranitidine: an update.
Klotz, U; Kroemer, HK, 1991
)
0.28
" It is concluded that aspirin concurrently administered with ranitidine is safe and does not delay the healing of uncomplicated duodenal ulcers."( Aspirin concurrently administered with ranitidine does not delay healing of duodenal ulcer.
Anand, BS; Kumar, N; Misra, SP, 1990
)
0.28
"The most widely used H2-receptor antagonist, cimetidine, is known to interact with cytochrome P-450 drug-metabolizing enzymes and, therefore, interacts with other drugs which may be administered concurrently."( Comparative effects of H2-receptor antagonists on drug interaction in rats.
Cocchetto, DM; Duggan, DE; Lin, JH; Yeh, KC,
)
0.13
" The potential of famotidine, a new H2-receptor antagonist with a guanylthiazole ring structure, to interact with the cytochrome P450 system has been extensively evaluated."( Famotidine: a notable lack of drug interactions.
Humphries, TJ, 1987
)
0.27
"The effect of intradermal ranitidine (administered alone and in combination with clemastine) on allergen-mediated wheal-and-flare reactions has been evaluated in a double-blind study on 10 healthy atopic volunteers."( The effect of ranitidine, alone and in combination with clemastine, on allergen-induced cutaneous wheal-and-flare reactions in human skin.
Browne, PD; Kirby, JD; Meyrick Thomas, RH, 1985
)
0.27
" The magnitude of the inhibitory effect of ranitidine, both administered alone and in combination with clemastine, suggests that in the production of histamine induced cutaneous weal and flare reactions, the contribution afforded by stimulation of cutaneous H2-histamine receptors is only small."( The influence of ranitidine, alone and in combination with clemastine, on histamine-mediated cutaneous weal and flare reactions in human skin.
Browne, PD; Kirby, JD; Thomas, RH, 1985
)
0.27
" The results of this study indicated that there was minimal drug-drug interaction between diclofenac and ranitidine."( Application of dual radiotelemetric technique in studying drug-drug interaction between diclofenac sodium and ranitidine HCl in volunteers.
Alioth, C; Blum, RA; Chan, KK; D'Andrea, DT; Kochak, GM; Schentag, JJ; Teng, L; Ziehmer, BA, 1993
)
0.29
" In conclusion, H pylori eradication rates using high dose ranitidine plus amoxycillin and metronidazole may be similar to that of low dose omeprazole in combination with the same antibiotics for omeprazole with clarithromycin."( Randomised controlled trial of ranitidine versus omeprazole in combination with antibiotics for eradication of Helicobacter pylori.
Bamford, KB; Collins, JS; Molloy, C; Sloan, JM; Tham, TC; Watson, RG, 1996
)
0.29
"This double-blind, randomized, phase III clinical trial was carried out in two parallel groups to assess the efficacy of ebrotidine (N-[(E)-[[2-[[[2-[(diaminomethylene) amino]-4-thiazolyl]methyl]thio]ethyl]amino] methylene]-4-bromo-benzenesulfonamide, CAS 100981-43-9, FI-3542) 400 mg and ranitidine 300 mg given in single evening dose, combined with amoxicillin 750 mg and metronidazole 500 mg three times daily for 14 days, in the eradication of Helicobacter pylori in patients with duodenal ulcer."( Efficacy of ebrotidine and ranitidine combined with amoxicillin and metronidazole in the eradication of Helicobacter pylori in patients with duodenal ulcer.
Fillat, O; Herrero, E; Karcz, D; Kulig, J; Márquez, M; Ortiz, JA; Popiela, T; Tabor, J; Torres, J, 1997
)
0.3
" pylori than ranitidine when given with amoxicillin plus metronidazole for the treatment of duodenal ulcer, as both early reinfection and ulcer recurrence are diminished."( Ranitidine versus colloidal bismuth subcitrate in combination with amoxicillin and metronidazole for eradicating Helicobacter pylori in patients with duodenal ulcer.
Blanco, M; Carpintero, P; Pajares, JM, 1997
)
0.3
" These parameters were somewhat higher when ceftibuten was administered with ranitidine, but they were still within the ranges seen in normal healthy volunteers."( Pharmacokinetic drug interaction study: administration of ceftibuten concurrently with the antacid mylanta double- strength liquid or with ranitidine.
Affrime, M; Cutler, D; Lin, CC; Nomeir, A; Radwanski, E, 1998
)
0.3
"To test eradication and adverse events of ranitidine bismuth citrate (RBC) when given with metronidazole and either oxytetracycline or spiramycin."( Spiramycin is comparable to oxytetracycline in eradicating H. pylori when given with ranitidine bismuth citrate and metronidazole.
Bang, CJ; Berstad, A; Coll, P; Hatlebakk, JG; Hausken, T; Nysaeter, G; Olafsson, S; Olafsson, T; Tefera, S, 1999
)
0.3
" The results from in vitro studies are related to the observed clinically significant in vivo drug-drug and drug-chemical interactions."( Drug interactions of H2-receptor antagonists involving cytochrome P450 (CYPs) enzymes: from the laboratory to the clinic.
Rendić, S, 1999
)
0.3
" Proton pump inhibitors and H(2)-antagonists are frequently used in the HIV-negative-infected population, and drug-drug interactions have been described with other antiretrovirals."( A pharmacokinetic study of etravirine (TMC125) co-administered with ranitidine and omeprazole in HIV-negative volunteers.
Bouche, MP; De Smedt, G; Hoetelmans, RM; Kakuda, TN; Peeters, M; Schöller-Gyüre, M; Vanaken, H; Woodfall, B, 2008
)
0.35
"This study aimed to estimate how prevalent potential drug-drug interactions (pDDIs) were in patients with cardiovascular diseases who were hospitalized for more than 24 hours, and to determine the risk factors associated with these pDDIs."( Detection and analysis of potential drug-drug interactions among patients admitted to the cardiac care unit in a tertiary care hospital.
Almaghaslah, D; Khaled, A; Makki, S; Nagib, R; Siddiqua, A, 2023
)
0.91

Bioavailability

Ranitidine HCl is an H2-antagonist that suffers from low oral bioavailability of 50%. The results indicated that lopinavir bioavailability was not affected by the coadministration of omeprazole or ranitidine.

ExcerptReferenceRelevance
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."( QSAR model for drug human oral bioavailability.
Topliss, JG; Yoshida, F, 2000
)
0.31
" Previously described THQ PFTIs had limitations of poor oral bioavailability and rapid clearance from the circulation of rodents."( Efficacy, pharmacokinetics, and metabolism of tetrahydroquinoline inhibitors of Plasmodium falciparum protein farnesyltransferase.
Ankala, S; Barrett, LK; Bauer, KD; Bendale, P; Buckner, FS; Chakrabarti, D; Floyd, D; Gelb, MH; Hamilton, AD; Hornéy, C; Hucke, O; Lombardo, LJ; Nallan, L; Rivas, KL; Smart, BP; Strickland, C; Van Voorhis, WC; Verlinde, CL; Williams, DK; Yokoyama, K, 2007
)
0.34
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010
)
0.36
" To show the importance of physicochemical properties, the classic QSAR and CoMFA of neonicotinoids and prediction of bioavailability of pesticides in terms of membrane permeability in comparison with drugs are described."( Importance of physicochemical properties for the design of new pesticides.
Akamatsu, M, 2011
)
0.37
" 2-Aminoquinoline-based scaffolds were designed with the hope that they could (a) mimic aminopyridines as potent, isoform-selective arginine isosteres and (b) possess chemical properties more conducive to oral bioavailability and CNS penetration."( Simplified 2-aminoquinoline-based scaffold for potent and selective neuronal nitric oxide synthase inhibition.
Chreifi, G; Cinelli, MA; Li, H; Martásek, P; Poulos, TL; Roman, LJ; Silverman, RB, 2014
)
0.4
" Nitrendipine bioavailability was increased by 89% when ranitidine was coadministered but the kinetic effect of this drug interaction is unlikely to be of clinical relevance since no adverse effects were observed in patients evaluated after ranitidine association."( Ranitidine increases the bioavailability of nitrendipine in patients with arterial hypertension.
Donzella, H; Kirch, W; Moreira-Filho, L; Santos, SR; Storpirtis, S, 1992
)
0.28
" The relative bioavailability after cecal administration was less than 15% of that observed after administration into the stomach or jejunum."( Influence of gastrointestinal site of drug delivery on the absorption characteristics of ranitidine.
Dukes, GE; Hak, LJ; Han, YH; Heizer, W; Hermann, DJ; Lampkin, T; Williams, MF, 1992
)
0.28
"An open two-way cross-over study in 12 healthy male volunteers was performed in order to determine the relative bioavailability of a 150 mg ranitidine (Zantic, CAS 66357-35-5) effervescent tablet sweetened with saccharine in comparison to the 150 mg standard ranitidine dispersible tablet (Trinkette)."( [Bioequivalence and bioavailability after single administration of effervescent ranitidine tablets].
Hartmann, B; Schmieder, G; Tetzloff, W; Töberich, H, 1992
)
0.28
"The pharmacokinetics of roxithromycin (300 mg orally) and the influence of the antacid aluminum magnesium hydroxide and the H2-blocker ranitidine on bioavailability of roxithromycin in ten healthy volunteers were studied."( Pharmacokinetics of roxithromycin and influence of H2-blockers and antacids on gastrointestinal absorption.
Boeckh, M; Daeschlein, S; Höffken, G; Koeppe, P; Lode, H, 1992
)
0.28
" These data demonstrate that administration of didanosine 2 h after ranitidine will result in a minor increase in the bioavailability of didanosine."( Pharmacokinetic-interaction study of didanosine and ranitidine in patients seropositive for human immunodeficiency virus.
Barbhaiya, RH; Dixon, RM; Graziano, FM; Knupp, CA, 1992
)
0.28
" When aluminum hydroxide, ferrous sulfate, and magnesium oxide were coadministered with DR-3355, the relative bioavailability of DR-3355 was decreased to 56, 81, and 78%, respectively, of that for DR-3355 (100 mg) alone."( Effects of antacids, ferrous sulfate, and ranitidine on absorption of DR-3355 in humans.
Aoki, H; Hakusui, H; Okazaki, O; Sakai, O; Shiba, K; Shimada, J, 1992
)
0.28
" Ranitidine pretreatment reduced enoxacin oral bioavailability by an average of 26%."( Effect of gastric acidity on enoxacin absorption.
Lebsack, ME; Nix, D; Norman, AM; Ryerson, B; Schentag, JJ; Sedman, AJ; Toothaker, RD; Welage, L, 1992
)
0.28
" and cimetidine 1000 mg/d for 7 days led to a significant increase of the relative bioavailability of nimodipine."( Influence of the H2-receptor antagonists cimetidine and ranitidine on the pharmacokinetics of nimodipine in healthy volunteers.
Kuhlmann, J; Mück, W; Rämsch, KD; Seiberling, M; Wingender, W; Woelke, E, 1992
)
0.28
" The effect of gastric emptying and GI transit rate constants (Kl and K1, respectively), number of hypothetical gut compartments, and absorption rate constant at each site (Ka1, Ka2) on the time of occurrence of each peak (Tp1, Tp2), the theoretical fraction of the dose absorbed at each site (phi 1, phi 2), and the contribution of the second site to systemic drug exposure (expressed as phi 2rel) were examined."( Use of a pharmacokinetic model incorporating discontinuous gastrointestinal absorption to examine the occurrence of double peaks in oral concentration-time profiles.
Brouwer, KL; Pollack, GM; Suttle, AB, 1992
)
0.28
" In this study, the absorption and bioavailability of oral doses of each of three H2RAs, which are possible factors in these effects, were studied in healthy volunteers."( Does H2 receptor antagonist-resistant ulcer exist?--A review based on bioavailability in man.
Kawai, K, 1992
)
0.28
"To determine whether the H2-receptor antagonist, ranitidine, which is a potent inhibitor of gastric alcohol dehydrogenase activity in vitro, increases the bioavailability of orally administered ethanol (0."( Effects of ranitidine on blood alcohol levels after ethanol ingestion. Comparison with other H2-receptor antagonists.
Baraona, E; DiPadova, C; Frezza, M; Gentry, RT; Lieber, CS; Roine, R, 1992
)
0.28
"Peak blood alcohol concentrations, areas under the blood alcohol curve, first-pass metabolism, and bioavailability of orally consumed ethanol."( Effects of ranitidine on blood alcohol levels after ethanol ingestion. Comparison with other H2-receptor antagonists.
Baraona, E; DiPadova, C; Frezza, M; Gentry, RT; Lieber, CS; Roine, R, 1992
)
0.28
" First-pass metabolism of ethanol was decreased from 70 +/- 10 to 31 +/- 9 mg/kg of body weight, with a corresponding increase in ethanol bioavailability of 79."( Effects of ranitidine on blood alcohol levels after ethanol ingestion. Comparison with other H2-receptor antagonists.
Baraona, E; DiPadova, C; Frezza, M; Gentry, RT; Lieber, CS; Roine, R, 1992
)
0.28
"Previous studies in animals and humans demonstrated that nocloprost, a stable prostaglandin E2 analogue, shows very high gastroprotective potency, relatively weak gastric inhibitory activity, and low systemic bioavailability after oral administration."( Effects of nocloprost on gastric functions in man.
Hebzda, Z; Konturek, SJ; Kwiecien, N; Maczka, J; Obtulowicz, W; Oleksy, J, 1991
)
0.28
"The pharmacokinetics and relative bioavailability of two different formulated ranitidine tablets were examined in 12 healthy young Chinese males at one week intervals in a randomized crossover design."( Pharmacokinetic properties of ranitidine in Chinese people.
Chung, PH; Hu, OY; Pao, LH; Tang, HS,
)
0.13
" One week later the subjects participated in a three-way crossover theophylline bioavailability study receiving at weekly intervals, single doses at 7 AM of (a) 5 x 100-mg immediate-release tablets, (b) 2 x 300-mg sustained-release theophylline tablets, and (c) 2 x 300-mg sustained-release theophylline tablets after ranitidine pretreatment of 150 mg every 4 hr beginning at 2 PM the previous day."( The effect of raising gastric pH with ranitidine on the absorption and elimination of theophylline from a sustained-release theophylline tablet.
Betlach, CJ; Bialer, M; González, MA; Liebermann, P; Meyer, MC; Straughn, AB; Vashi, VI, 1991
)
0.28
" This investigation studies the bioavailability of several oral dosage forms of ddI."( Pharmacokinetics of 2',3'-dideoxyinosine in patients with severe human immunodeficiency infection. II. The effects of different oral formulations and the presence of other medications.
Broder, S; Flora, KP; Hartman, NR; Johns, DG; Pluda, JM; Thomas, RV; Wyvill, KM; Yarchoan, R, 1991
)
0.28
" Relative ketoconazole bioavailability was compared between treatments."( Effects of ranitidine and sucralfate on ketoconazole bioavailability.
D'Andrea, DT; Goldstein, H; Goss, TF; Piscitelli, SC; Schentag, JJ; Wilton, JH, 1991
)
0.28
" Oral bioavailability parameters (area under the concentration-time curve from 0 to 12 h, area under the concentration-time curve from 0 h to infinity, time to maximum concentration of drug in plasma, and maximum concentration of drug in plasma) were obtained by noncompartmental techniques."( Influence of antacid and ranitidine on the pharmacokinetics of oral cefetamet pivoxil.
Ambros, RJ; Blouin, RA; Kneer, J; Stoeckel, K, 1990
)
0.28
" In vivo, therapeutic doses of cimetidine (but not of famotidine) increased blood ethanol levels when ethanol was given orally, but not when it was given intravenously, indicating a significant contribution of the gastric ADH to the bioavailability and thereby the potential toxicity of ethanol."( Human gastric alcohol dehydrogenase: its inhibition by H2-receptor antagonists, and its effect on the bioavailability of ethanol.
Baraona, E; Caballeria, J; Greenstein, R; Hernández-Muñoz, R; Lieber, CS; Uppal, R, 1990
)
0.28
" Cimetidine significantly increased the procainamide area under the serum concentration-time curve by 43%, decreased renal clearance by 36%, and decreased the ratio of systemic clearance of procainamide to bioavailability by 28%."( Interaction of steady-state procainamide with H2-receptor antagonists cimetidine and ranitidine.
Gallastegui, J; Jung, D; Paloucek, FP; Rodvold, KA, 1987
)
0.27
"This four-way crossover open-label study on eight healthy subjects was designed to investigate the effect on bioavailability of orally administered nizatidine given concurrently with an antacid (magnesium hydroxide-aluminium hydroxide mixture)."( Oral bioavailability of nizatidine and ranitidine concurrently administered with antacid.
Desager, JP; Harvengt, C,
)
0.13
" Percentages of relative bioavailability compared with control values were 15."( Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin.
Frost, RW; Goldstein, H; Krol, G; Lener, ME; Lettieri, J; Nix, DE; Schentag, JJ; Watson, WA, 1989
)
0.28
" The antacid, pirenzepine, and ranitidine had no influence on the bioavailability of amoxicillin, cephalexin, and amoxicillin-clavulanic acid."( Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid.
Deppermann, KM; Höffken, G; Kalz, C; Koeppe, P; Lode, H; Tschink, G, 1989
)
0.28
" But bioavailability parameters of period I, such as maximum concentration of the first and second plasma peak (Cmax 1 and Cmax 2, respectively), time to first peak (tmax 1), AUC0-12, and AUC from time zero to infinity (AUC0-infinity), were correlated significantly with those of period II."( Inter- and intrasubject variations of ranitidine pharmacokinetics after oral administration to normal male subjects.
Hong, JS; Shim, CK, 1989
)
0.28
" Cimetidine, when administered concurrently with metoprolol, could possibly cause an increase in plasma metoprolol concentrations or bioavailability through inhibition of hepatic P-450 metabolizing enzymes."( Effect of cimetidine and ranitidine on cardiovascular drugs.
Baciewicz, AM; Baciewicz, FA, 1989
)
0.28
" The bioavailability of ranitidine was 54."( Ranitidine bioavailability and disposition kinetics in patients undergoing chronic hemodialysis.
Comstock, TJ; Eshelman, F; Harford, A; Sica, DA, 1989
)
0.28
"The bioavailability of two brands of ranitidine tablets was studied in 10 healthy volunteers."( Bioequivalency of ranitidine tablets.
Ali-Gharaibeh, KI; Alkaysi, HN; Badwan, AA; el-Sayed, YM; Gharaibeh, AM; Salem, MA, 1989
)
0.28
" The simultaneous administration of cimetidine in patients treated with sustained-release anhydrous theophylline thus proved capable of seriously undermining the strategy of theophylline usage precisely on account of the high degree of bioavailability of theophylline in the sustained-release formulation."( H2-antagonist derangement of the kinetics of sustained-release oral theophylline.
Dal Negro, R; Pomart, C; Trevisan, F; Turco, P; Zoccatelli, O, 1985
)
0.27
" Comparison of parenteral to enteral potencies suggests that ORF 17578 was well absorbed from the gastrointestinal tract of both species with a bioavailability profile similar to that of ranitidine."( Pharmacology of ORF 17578, a new histamine H2-receptor antagonist: comparison with cimetidine and ranitidine.
Katz, LB; Scott, CK; Shriver, DA, 1986
)
0.27
" These data indicate that cimetidine, but not ranitidine, causes a decrease in the bioavailability of tocainide and that neither agent alters the apparent elimination rate of tocainide."( The effect of histamine-2 receptor antagonists on tocainide pharmacokinetics.
Kapil, RP; Lalonde, RL; Mattern, AL; North, DS, 1988
)
0.27
" Although not affecting the pharmacodynamics of metoprolol, cimetidine did produce an increase in the bioavailability of metoprolol through inhibition of enzymes responsible for the first-pass elimination of the beta-blocker."( The racemic metoprolol H2-antagonist interaction.
Batra, H; Bowes, RJ; Davidson, EM; Garstang, FM; Rowland, M; Toon, S, 1988
)
0.27
"The effect of aluminum phosphate on the bioavailability of ranitidine has been investigated in 10 young, healthy volunteers."( Effect of aluminum phosphate on the bioavailability of ranitidine.
Albin, H; Begaud, B; Bistue, C; Perez, P; Vinçon, G, 1987
)
0.27
"8 h, and the bioavailability was 69."( Ranitidine pharmacokinetics in continuous ambulatory peritoneal dialysis.
Comstock, T; Eshelman, F; Harford, A; Sica, DA, 1987
)
0.27
"8 hours (standard deviation [SD]), and the bioavailability of ranitidine was 43."( Pharmacokinetics of ranitidine in patients with renal failure.
Baltodano, N; Eshelman, FN; Garg, DC; Jallad, NS; Oster, JR; Perez, G; Weidler, DJ, 1986
)
0.27
" Thus, ranitidine bioavailability is not diminished by sucralfate and the two drugs can be given concomitantly."( Lack of clinically significant in vitro and in vivo interactions between ranitidine and sucralfate.
Derendorf, H; Gotz, VP; Mullersman, G; Russell, WL, 1986
)
0.27
" Bioavailability was virtually the same in patients and in normal subjects, and there was no significant difference between the two groups for total plasma clearance, intravenous elimination half-life, or volume of distribution."( Pharmacokinetics and bioavailability of ranitidine in normal subjects and cirrhotic patients.
Alexandre, C; Dhumeaux, D; Houin, G; Mavier, P; Morichau-Beauchant, M, 1986
)
0.27
" The bioavailability of ranitidine given orally averaged 48%."( Pharmacokinetic determination of ranitidine pharmacodynamics in pediatric ulcer disease.
Blumer, JL; Eshelman, FN; Kaplan, BS; Myers, CM; Reed, MD; Rothstein, FC; Yamashita, TS, 1985
)
0.27
" Lignocaine oral clearance, elimination half-life and oral bioavailability were unchanged after ranitidine pretreatment."( The effect of ranitidine on the disposition of lignocaine.
Birkett, DJ; Lillywhite, KJ; Miners, JO; Robson, RA; Wing, LM, 1985
)
0.27
" Moreover, oral bioavailability was similar in controls and cirrhotics."( Oral and intravenous pharmacokinetics of ranitidine in patients with liver cirrhosis.
Castelli, G; Iemmolo, RM; Lirussi, F; Muraca, M; Nassuato, G; Okolicsanyi, L; Orlando, R; Pastorino, AM; Strazzabosco, M; Venuti, M, 1984
)
0.27
"The present study was designed to investigate the effect of food and of a raised intragastric pH on the bioavailability of two prodrug beta-lactam, antibiotics, namely bacampicillin and cefuroxime axetil."( Influence of food and reduced gastric acidity on the bioavailability of bacampicillin and cefuroxime axetil.
Moncrieff, J; Schoeman, HS; Sommers, DK; van Wyk, M, 1984
)
0.27
" For example, the bioavailability of midazolam is significantly increased due to the influence of ranitidine on gastric pH and thus on absorption of midazolam, leading to an increased soporific effect of this benzodiazepine; an effect of ranitidine on oxidative liver metabolism also appears to be a contributory factor in this interaction."( Interactions and non-interactions with ranitidine.
Hoensch, H; Janisch, HD; Kirch, W,
)
0.13
"The bioavailability of oral and intravenous cimetidine and ranitidine was studied in patients with compensated liver cirrhosis."( The pharmacokinetics of H2 receptor blocking agents in compensated liver cirrhosis.
Iemmolo, RM; Lirussi, F; Nassuato, G; Okolicsányi, L; Orlando, R; Strazzabosco, M; Venuti, M, 1984
)
0.27
" The estimated elimination half-life was 140 minutes and the bioavailability of the oral drug was about 50%."( Ranitidine--a new H2-receptor antagonist.
Carey, P; Dixon, GT; Harrison, C; Richards, DA; Woodings, EP, 1980
)
0.26
" The higher peak levels and larger AUC indicate increased bioavailability in steady state."( The pharmacokinetics of ranitidine in patients with chronic duodenal ulceration.
Folb, PI; Lucke, W; Marks, IN; McFadyen, ML; Wright, JP, 1981
)
0.26
" Bioavailability was unaffected by food and AUC increased linearly with dose to 100 mg."( Pharmacokinetic and gastric secretory studies of ranitidine in man.
Anderson, A; Hanson, RG; Louis, WJ; McNeil, JJ; Mihaly, GW; Smallwood, RA; Yeomans, ND, 1981
)
0.26
"1 Ranitidine single dose pharmacokinetics and absolute bioavailability have been studied in five healthy male volunteers."( Ranitidine: single dose pharmacokinetics and absolute bioavailability in man.
de Schepper, PJ; Mullie, A; Tjandramaga, TB; van Hecken, AM; Verbesselt, R, 1982
)
0.26
" In the first of these bioavailability was 51 +/- 4% and half life 161 +/- 11 minutes after oral and 124 +/- 5 minutes after intravenous administration."( Effects of cirrhosis and ageing on the elimination and bioavailability of ranitidine.
Daneshmend, TK; Roberts, CJ; Young, CJ, 1982
)
0.26
" Administration of the H2-receptor blocker significantly increased bioavailability of the benzodiazepine and resulted in higher plasma levels for the first 6 h after taking midazolam."( Ranitidine influences the uptake of oral midazolam.
Collier, PS; Dundee, JW; Elwood, RJ; Hildebrand, PJ, 1983
)
0.27
" Bioavailability and/or biotransformation are the factors most likely to account for the differences observed between species, and between in vivo and in vitro studies for this long-acting antisecretory agent."( In vivo and in vitro effects of CM 57755, a new gastric antisecretory agent acting on histamine H2 receptors.
Aureggi, G; Bianchetti, A; Carminati, P; Lavezzo, A; Manzoni, L; Nisato, D, 1984
)
0.27
" Temazepam bioavailability after oral administration is unchanged after either H2 receptor antagonist, or after the emulsion antacid."( The influence of H2 receptor antagonists on the plasma concentrations of midazolam and temazepam.
Collier, PS; Dundee, JW; Elliott, P; Elwood, RJ, 1984
)
0.27
"To investigate the effect of antacid on the bioavailability and disposition of ranitidine six healthy volunteers were studied on two occasions one week apart."( High dose of antacid (Mylanta II) reduces bioavailability of ranitidine.
Jones, DB; Louis, WJ; Marino, AT; Mihaly, GW; Smallwood, RA; Webster, LK, 1982
)
0.26
" After doses of 100 mg both intravenously and orally ranitidine kinetics and bioavailability were investigated in a single dose two-way crossover study in 12 normal men."( Ranitidine bioavailability and kinetics in normal male subjects.
Eshelman, FN; Garg, DC; Weidler, DJ, 1983
)
0.27
" The oral bioavailability of ranitidine in these 5 patients showed wide variation (27-76%; mean 51%)."( The pharmacokinetics of ranitidine in patients with chronic duodenal ulceration: a comparison of responders and non-responders.
Folb, PI; Marks, IN; McFadyen, ML; Miller, R; Moshal, MG, 1983
)
0.27
" Within the CRF group there was a large variation in Cmax (CV = 38%) and AUC (46%) which may reflect variable bioavailability of ranitidine."( Pharmacokinetics of ranitidine in patients with chronic renal failure.
Folb, PI; Keeton, GR; Marks, IN; McFadyen, ML; Miller, R, 1983
)
0.27
" Systemic bioavailability is approximately 70% with cimetidine and 50% with ranitidine."( Comparative pharmacodynamics and pharmacokinetics of cimetidine and ranitidine.
Richards, DA, 1983
)
0.27
" The antacid had no significant effect on ranitidine absorption, but propantheline increased the relative bioavailability of ranitidine by 22%."( The effects of antacid and propantheline on the absorption of oral ranitidine.
Donn, KH; Eshelman, FN; Fabre, L; Plachetka, JR; Powell, JR,
)
0.13
" The bioavailability of ranitidine after oral administration is approximately 50% due to presystemic hepatic metabolism."( Clinical pharmacokinetics of ranitidine.
Roberts, CJ,
)
0.13
"Clinical studies were performed to examine the oral bioavailability of alendronate (4-amino-1-hydroxy-butylidene-1,1-bisphosphonate monosodium)."( Studies of the oral bioavailability of alendronate.
Freeman, A; Gertz, BJ; Holland, SD; Kline, WF; Lasseter, KC; Matuszewski, BK; Mucklow, JC; Porras, AG; Quan, H, 1995
)
0.29
" These findings show that ranitidine increases the bioavailability of low dose ethanol and has possible short term forensic, and longterm physical implications for moderate drinkers who are taking the drug."( Ranitidine increases the bioavailability of postprandial ethanol by the reduction of first pass metabolism.
Bennett, MK; Brown, AS; Day, CP; Fiaterone, JR; James, OF; Kelly, PJ, 1995
)
0.29
" Second, the effect of magnesium/aluminium hydroxide on the relative bioavailability of nizatidine, famotidine, cimetidine and ranitidine was evaluated in healthy volunteers."( Drug interactions of H2-receptor antagonists.
Bachmann, KA; Jauregui, L; Levine, L; Miller, K; Reese, J; Sullivan, TJ, 1994
)
0.29
" Oral CsA solution is highly lipophilic, and its bioavailability may be reduced in cystic fibrosis (CF) heart-lung transplant recipients with pancreatic, gastrointestinal, and hepatic insufficiency."( Cyclosporin pharmacokinetics in heart-lung transplant recipients with cystic fibrosis. Effects of pancreatic enzymes and ranitidine.
Heritier, F; Hodson, ME; Johnston, A; Leaver, N; Tsang, VT; Yacoub, M, 1994
)
0.29
" Pyridostigmine had a higher elimination (2 h-1) than the absorption rate constant (0."( Renal clearance of pyridostigmine in myasthenic patients and volunteers under the influence of ranitidine and pirenzepine.
Breyer-Pfaff, U; Eiermann, B; Maier, U; Schumm, F; Sommer, N; Winne, D, 1993
)
0.29
"The effect of ranitidine, the H2-receptor antagonist, on the systemic bioavailability of ethanol (0."( Ranitidine has no effect on postbreakfast ethanol absorption.
Fraser, AG; Hudson, M; Pounder, RE; Rosalki, SB; Sawyerr, AM; Sercombe, J; Smith, MS, 1993
)
0.29
" These effects are of minor clinical importance and seem most likely be due to a decrease of the rate of absorption of ritanserin during concurrent administration of cimetidine/ranitidine."( Effect of concomitantly administered cimetidine or ranitidine on the pharmacokinetics of the 5-HT2-receptor antagonist ritanserin.
Benn, HP; Buschmann, M; Jähnchen, E; Seiler, KU; Szathmary, S; Trenk, D, 1993
)
0.29
" This, in part, reflects the low systemic bioavailability of bismuth from these medicines: less than 1% of the bismuth dose administered is absorbed."( Review article: safety of bismuth in the treatment of gastrointestinal diseases.
Dixon, JS; Drake, FM; Tillman, LA; Wood, JR, 1996
)
0.29
" The model was also used to simulate bioavailability and plasma concentrations versus time profiles for various parameter values."( Applications and simulations of a discontinuous oral absorption pharmacokinetic model.
Boudinot, FD; Witcher, JW, 1996
)
0.29
" Simulations demonstrate the effects of various absorption parameters and gastroin-testinal tract transit parameters on bioavailability and plasma concentration profiles."( Applications and simulations of a discontinuous oral absorption pharmacokinetic model.
Boudinot, FD; Witcher, JW, 1996
)
0.29
"This discontinuous oral absorption pharmacokinetic model can be a useful tool in characterizing absorption phases, disposition, and bioavailability of drugs exhibiting two absorption peaks following oral administration."( Applications and simulations of a discontinuous oral absorption pharmacokinetic model.
Boudinot, FD; Witcher, JW, 1996
)
0.29
"Thirty-three healthy individuals participated in an open-label, randomized, three-way crossover study designed to compared the bioavailability of a single 200-mg oral dose of itraconazole when administered alone or after treatment with ranitidine, both with and without coadministration of a cola beverage."( Effect of a cola beverage on the bioavailability of itraconazole in the presence of H2 blockers.
Klausner, M; Lange, D; Pavao, JH; Wu, J, 1997
)
0.3
" Recently a new method has been proposed to determine absolute bioavailability in the absence of intravenous dose."( Prediction of absolute bioavailability for drugs using oral and renal clearance following a single oral dose: a critical view.
Mahmood, I, 1997
)
0.3
"7 ng/mL; and bioavailability (F) = 38%."( Plasma pharmacokinetics of ranitidine HCl in foals.
Brown, SA; Brumbaugh, GW; Holland, PS; Ruoff, WW, 1997
)
0.3
" The relative potency of the four H2-antagonists in causing an increase in the TEER correlated inversely with the oral bioavailability of these compounds in humans."( Modulation of the tight junctions of the Caco-2 cell monolayers by H2-antagonists.
Gan, LS; Thakker, DR; Yanni, S, 1998
)
0.3
"This investigation was carried out to evaluate the bioavailability of a new tablet formulation of ranitidine HCl (300 mg), Ranid, relative to the reference product, Zantac, (300 mg) tablets."( Comparative bioavailability of two tablet formulations of ranitidine hydrochloride in healthy volunteers.
Al-Khamis, KI; Al-Rashood, KA; Al-Yamani, MJ; Bawazir, SA; El-Sayed, YM; Gouda, MW; Niazy, EM, 1998
)
0.3
" A series of studies were conducted in humans to assess the effect of timing of meal, type of meal, gastric pH, change in the formulation and dose on the bioavailability of avitriptan."( Evaluation of the effect of food on the pharmacokinetics of avitriptan.
Barbhaiya, RH; Greene, DS; Kollia, GD; Marathe, PH, 1998
)
0.3
" At low pH, foscarnet decomposes via an acid-catalyzed decarboxylation; therefore, poor oral bioavailability might be due to decomposition of foscarnet in gastric acid."( The effect of increasing gastric pH upon the bioavailability of orally-administered foscarnet.
Barditch-Crovo, PA; Gambertoglio, J; Hafner, R; Kornhauser, DM; Kuwahara, S; Lietman, PS; Nerhood, LJ; Petty, BG, 1998
)
0.3
" Bioavailability parameters, maximum plasma concentration and area under the plasma concentration-time curve to infinity of ceftibuten were unaffected by treatment with antacid."( Pharmacokinetic drug interaction study: administration of ceftibuten concurrently with the antacid mylanta double- strength liquid or with ranitidine.
Affrime, M; Cutler, D; Lin, CC; Nomeir, A; Radwanski, E, 1998
)
0.3
" This study evaluated the effect of an increase in gastric pH, through the use of ranitidine, on the oral bioavailability and plasma pharmacokinetics of temozolomide and MTIC."( Effect of gastric pH on the relative oral bioavailability and pharmacokinetics of temozolomide.
Beale, P; Brada, M; Cutler, DL; Judson, I; Marco, A; Moore, S; Reidenberg, P; Statkevich, P, 1999
)
0.3
" Although there is no significant difference between proton pump inhibitors with respect to healing of esophagitis, symptom relief occurs earlier with lansoprazole than omeprazole, and this is probably due to the greater oral bioavailability and faster onset of action of lansoprazole when compared to omeprazole."( pH, healing rate, and symptom relief in patients with GERD.
Huang, JQ; Hunt, RH,
)
0.13
" A slightly faster rate of absorption of topotecan was also observed, which is unlikely to be of clinical significance."( Pretreatment with ranitidine does not reduce the bioavailability of orally administered topotecan.
Akhtar, S; Beckman, RA; Doyle, E; Fields, SZ; Mould, DR; Wright, J, 2000
)
0.31
" This method has been used to analyze several hundred human plasma samples for bioavailability studies."( Rapid determination of ranitidine in human plasma by high-performance liquid chromatography without solvent extraction.
Ahmadiani, A; Amini, H, 2001
)
0.31
"To determine the effect of concomitant administration of the antacid Maalox 70 or the histamine H2 receptor antagonist ranitidine on the bioavailability of moxifloxacin."( Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers.
Böttcher, MF; Ochmann, K; Stass, H, 2001
)
0.31
"3 mg/L x h with versus without ranitidine; relative bioavailability 103%, 90% confidence interval (CI) 97."( Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers.
Böttcher, MF; Ochmann, K; Stass, H, 2001
)
0.31
"The bioavailability of moxifloxacin is not affected by concurrent administration of ranitidine."( Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers.
Böttcher, MF; Ochmann, K; Stass, H, 2001
)
0.31
" Such metabolism may in part be responsible for the poor bioavailability of ranitidine from the colon."( Colonic metabolism of ranitidine: implications for its delivery and absorption.
Basit, AW; Lacey, LF, 2001
)
0.31
" The relative bioavailability of Formulation 2 with respect to Formulation 1 was 93."( Development of a sensitive high-performance thin-layer chromatography method for estimation of ranitidine in urine and its application for bioequivalence decision for ranitidine tablet formulations.
Patel, BD; Rathod, IS; Savale, SS; Shah, SA, 2002
)
0.31
"To investigate the effect of two prokinetic drugs, cisapride and metoclopramide, on the bioavailability of drugs, a marker drug, ranitidine, was administered to healthy volunteers following pre-treatments with or without the prokinetic agents."( Effect of prokinetic agents, cisapride and metoclopramide, on the bioavailability in humans and intestinal permeability in rats of ranitidine, and intestinal charcoal transit in rats.
Chung, SJ; Lee, HT; Lee, YJ; Shim, CK,
)
0.13
" By raising gastrointestinal pH levels, ranitidine may affect the bioavailability of coadministered drugs."( The effect of ranitidine on the pharmacokinetics of rosiglitazone in healthy adult male volunteers.
DiCicco, RA; Freed, MI; Miller, AK, 2002
)
0.31
"This article presents the absolute bioavailability of rosiglitazone, as well as the effects of ranitidine on the pharmacokinetics of rosiglitazone."( The effect of ranitidine on the pharmacokinetics of rosiglitazone in healthy adult male volunteers.
DiCicco, RA; Freed, MI; Miller, AK, 2002
)
0.31
" The absolute bioavailability of rosiglitazone was 99%."( The effect of ranitidine on the pharmacokinetics of rosiglitazone in healthy adult male volunteers.
DiCicco, RA; Freed, MI; Miller, AK, 2002
)
0.31
"In this study of 12 healthy adult male volunteers, the absolute bioavailability of rosiglitazone was 99%, and the oral and IV single-dose pharmacokinetics of rosiglitazone were unaltered by concurrent treatment with ranitidine."( The effect of ranitidine on the pharmacokinetics of rosiglitazone in healthy adult male volunteers.
DiCicco, RA; Freed, MI; Miller, AK, 2002
)
0.31
" Blood samples were taken over a 12 h period on each study day to allow a ranitidine plasma and subsequent absorption rate profile to be generated for each oral formulation."( Influence of polyethylene glycol 400 on the gastrointestinal absorption of ranitidine.
Basit, AW; Ell, PJ; Lacey, LF; Newton, JM; Podczeck, F; Waddington, WA, 2002
)
0.31
"The absolute bioavailability of ranitidine from the pellet formulation was significantly reduced by 31% (from 51% to 35%) and small intestinal liquid transit time was significantly shortened by 37% (from 226 min to 143 min) as a consequence of PEG 400 in the test preparation."( Influence of polyethylene glycol 400 on the gastrointestinal absorption of ranitidine.
Basit, AW; Ell, PJ; Lacey, LF; Newton, JM; Podczeck, F; Waddington, WA, 2002
)
0.31
"Is well known that food can affect the bioavailability of several drugs, its impact is major for those drugs that have to act near of drug absorption."( Bioavailability of ranitidine in healthy Mexican volunteers: effect of food.
Camacho, A; Carrasco, M; Flores, C; Flores, J; Guillé, A; Hernández, G; Juárez-Olguín, H; Lares, I; Pérez, G; Toledo, A, 2002
)
0.31
" Sucralfate had no impact on the bioavailability of ABT-773."( ABT-773: pharmacokinetics and interactions with ranitidine and sucralfate.
Allewelt, M; Bulitta, J; Burkhardt, O; Lode, H; Pletz, MW; Preechachatchaval, V, 2003
)
0.32
" The method was successfully used in a bioavailability study of a ranitidine tablet in healthy volunteers."( Validated HPLC method for the determination of ranitidine in plasma.
Arancibia, A; Castro, A; Gai, MN; Romero, P, 2003
)
0.32
" The mean absolute bioavailability of ranitidine from the immediate release, small intestinal release and colonic release formulations were 50."( The use of formulation technology to assess regional gastrointestinal drug absorption in humans.
Basit, AW; Ell, PJ; Lacey, LF; Newton, JM; Podczeck, F; Waddington, WA, 2004
)
0.32
" In order to establish if this requirement is adequate, the bioavailability of two formulations that did not meet this similarity were compared."( Comparative bioavailability of two oral formulations of ranitidine.
del Carmen Carrasco-Portugal, M; Flores-Murrieta, FJ; Herrera, JE; Medina-Santillán, R; Reyes-García, G; Rodríguez-Silverio, J; Toledo, A, 2006
)
0.33
"The bioavailability was measured in 20 healthy male Chinese volunteers following a single oral dose (equivalent to 200 mg of ranitidine and 220 mg of bismuth) of the test or reference products in the fasting state."( Pharmacokinetics and bioequivalence of ranitidine and bismuth derived from two compound preparations.
Jiang, B; Ruan, ZR; Xu, DH; Yuan, H; Zhou, Q, 2006
)
0.33
"To assess the relative bioavailability of saquinavir after administration with ranitidine alone, ranitidine and food, and food alone; and to investigate the mechanism underlying the effects of pH and food on saquinavir absorption."( Effect of food and ranitidine on saquinavir pharmacokinetics and gastric pH in healthy volunteers.
Falcon, RW; Kakuda, TN, 2006
)
0.33
" Compared with treatment C (control), saquinavir's bioavailability was 15."( Effect of food and ranitidine on saquinavir pharmacokinetics and gastric pH in healthy volunteers.
Falcon, RW; Kakuda, TN, 2006
)
0.33
" It can be postulated that food does not increase the bioavailability of saquinavir through its effect on gastric pH."( Effect of food and ranitidine on saquinavir pharmacokinetics and gastric pH in healthy volunteers.
Falcon, RW; Kakuda, TN, 2006
)
0.33
" In diabetic beagle dogs, the bioavailability of this formulation was up to 15."( In vitro and in vivo evaluation of a novel oral insulin formulation.
Duan, MX; Liu, Z; Ma, EL; Ma, H; Zheng, GX, 2006
)
0.33
" The enhanced bioavailability and elimination half-life observed in the present study may be due to the floating nature of the dosage form."( Controlled release calcium silicate based floating granular delivery system of ranitidine hydrochloride.
Agrawal, GP; Jain, AK; Jain, SK; Yadav, A, 2006
)
0.33
" Ranitidine was shown to be a P-gp substrate in vivo in human volunteers and it was found that oral bioavailability of ranitidine was influenced at the intestinal absorption phase."( Effect of ketoconazole and rifampicin on the pharmacokinetics of ranitidine in healthy human volunteers: a possible role of P-glycoprotein.
Gundu, J; Machavaram, KK; Yamsani, MR, 2006
)
0.33
"The aim of the present study was to compare the bioavailability of ranitidine (CAS 66357-35-5) from two different ranitidine hydrochloride (CAS 66357-59-3) film tablets (Ranitab 150 mg film tablets as test preparation and 150 mg film tablets of the originator product as reference preparation)."( Pharmacokinetics and bioequivalence study of ranitidine film tablets in healthy male subjects.
Erenmemişoglu, A; Gschwend, MH; Guserle, R; Hincal, AA; Kanzik, I; Martin, W; Tamur, U, 2007
)
0.34
" The hypothesis that a leaky enteric-coated pellets formulation may maintain or increase the bioavailability of drugs that have a window of absorption is still to be confirmed by further in vivo studies."( Leaky enteric coating on ranitidine hydrochloride beads: dissolution and prediction of plasma data.
Ayres, JW; Bendas, ER, 2008
)
0.35
" The results indicated that lopinavir bioavailability was not affected by the coadministration of omeprazole or ranitidine."( Effects of acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir and ritonavir-boosted atazanavir.
Beck, K; Cai, Y; Causemaker, SJ; Chiu, YL; Doan, T; Esslinger, HU; Hanna, GJ; King, KR; Klein, CE; Podsadecki, TJ, 2008
)
0.35
"The real issue in the development of oral controlled release dosage forms is not just to prolong the delivery of drugs but also to prolong the presence of dosage forms in the stomach in order to improve the bioavailability of drugs with a 'narrow absorption window'."( In vitro and in vivo evaluation of ranitidine hydrochloride ethyl cellulose floating microparticles.
Dandagi, PM; Gadad, AP; Kulkarni, AR; Mastiholimath, VS; Mathews, R, 2008
)
0.35
"The aim of this study was to investigate the effects of different doses of polyethylene glycol 400 (PEG 400) on the bioavailability of ranitidine in male and female subjects."( Polyethylene glycol 400 enhances the bioavailability of a BCS class III drug (ranitidine) in male subjects but not females.
Ashiru, DA; Basit, AW; Patel, R, 2008
)
0.35
" These correspond to increases in bioavailability of 34%, 63%, 49%, 43% and 6% over the control treatment."( Polyethylene glycol 400 enhances the bioavailability of a BCS class III drug (ranitidine) in male subjects but not females.
Ashiru, DA; Basit, AW; Patel, R, 2008
)
0.35
"Previous in vivo studies using PEG 400 showed an enhancement in the bioavailability of ranitidine."( The effect of polyoxyethylene polymers on the transport of ranitidine in Caco-2 cell monolayers.
Ashiru-Oredope, DA; Basit, AW; Forbes, B; Patel, N; Patel, R, 2011
)
0.37
"Posaconazole has an important role in the prophylaxis and salvage treatment of invasive fungal infections (IFIs), although poor and variable bioavailability remains an important clinical concern."( Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration.
Chen, SC; Dolton, MJ; McLachlan, AJ; Ng, K; Pont, L; Ray, JE, 2012
)
0.38
"As the bioavailability of erlotinib is dependent on gastric pH, an increase in gastric pH via the concurrent use of gastric acid suppressive medications (AS) may reduce its bioavailability and efficacy."( An evaluation of the possible interaction of gastric acid suppressing medication and the EGFR tyrosine kinase inhibitor erlotinib.
Bradbury, PA; Hilton, JF; Seymour, L; Shepherd, FA; Tu, D, 2013
)
0.39
" Thus, this approach can be used for enhancement of the oral bioavailability of the drug."( Preparation, characterization and evaluation of ranitidine hydrochloride-loaded mucoadhesive microspheres.
Awasthi, R; Dhamija, K; Dhankar, V; Garg, G,
)
0.13
"A reliable prediction of the oral bioavailability in humans is crucial and of high interest for pharmaceutical and food industry."( A new approach to predict human intestinal absorption using porcine intestinal tissue and biorelevant matrices.
Grossouw, D; Krul, CA; van de Steeg, E; Verwei, M; Westerhout, J; Wortelboer, HM; Zeijdner, EE, 2014
)
0.4
" The intestinal absorption rate for each drug was acquired by deconvolution, using historical intravenous data as reference, and used with the intestinal surface area and the dose remaining in the lumen to estimate the Peff."( Human in vivo regional intestinal permeability: quantitation using site-specific drug absorption data.
Dahlgren, D; Lennernäs, H; Roos, C; Sjögren, E, 2015
)
0.42
"Ranitidine HCl is an H2-antagonist that suffers from low oral bioavailability of 50%."( Gastroretentive Ranitidine Hydrochloride Tablets with Combined Floating and Bioadhesive Properties: Factorial Design Analysis, In Vitro Evaluation and In Vivo Abdominal X-Ray Imaging.
Abduljabbar, HN; Aldawsari, HM; Badr-Eldin, SM, 2015
)
0.42
" Promising members of our previously reported 2-aminoquinoline class of nNOS inhibitors, although orally bioavailable and brain-penetrant, suffer from unfavorable off-target binding to other CNS receptors, and they resemble known promiscuous binders."( Phenyl Ether- and Aniline-Containing 2-Aminoquinolines as Potent and Selective Inhibitors of Neuronal Nitric Oxide Synthase.
Cinelli, MA; Kang, S; Li, H; Martásek, P; Pensa, AV; Poulos, TL; Roman, LJ; Silverman, RB, 2015
)
0.42
" The aim of this work was to investigate whether rodents are a good model in which to study sex-specific effects of polyethylene glycol 400 (PEG 400) on the bioavailability of ranitidine."( Sex differences in excipient effects: Enhancement in ranitidine bioavailability in the presence of polyethylene glycol in male, but not female, rats.
Afonso-Pereira, F; Basit, AW; Murdan, S; Sousa, J; Veiga, F, 2016
)
0.43
" The absolute oral bioavailability of fostamatinib was 54."( Effects of ranitidine (antacid), food, and formulation on the pharmacokinetics of fostamatinib: results from five phase I clinical studies.
Flanagan, T; Gillen, M; Kruusmägi, M; Lisbon, E; Martin, P; Mathews, D, 2017
)
0.46
"The absolute oral bioavailability of fostamatinib was ~55 %."( Effects of ranitidine (antacid), food, and formulation on the pharmacokinetics of fostamatinib: results from five phase I clinical studies.
Flanagan, T; Gillen, M; Kruusmägi, M; Lisbon, E; Martin, P; Mathews, D, 2017
)
0.46
"This open-label, randomized, phase 1 crossover study investigated the effect of elevated gastric pH level (>5) on the relative bioavailability and pharmacokinetic profile of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib."( Effect of Sustained Elevated Gastric pH Levels on Gefitinib Exposure.
Masson, E; Tang, W; Tomkinson, H, 2017
)
0.46
"The pharmaceutical excipient, polyethylene glycol 400 (PEG 400), unexpectedly alters the bioavailability of the BCS class III drug ranitidine in a sex-dependent manner."( Excipient-mediated alteration in drug bioavailability in the rat depends on the sex of the animal.
Afonso-Pereira, F; Basit, AW; Mai, Y; Murdan, S, 2017
)
0.46
" Pharmacokinetic experiments show oral bioavailability through gastric absorption."( Pharmacology and in vivo efficacy of pyridine-pyrimidine amides that inhibit microtubule polymerization.
Cescon, DW; Hansen, MD; Hoj, JP; Siddiqui-Jain, A, 2018
)
0.48
"The notion that certain formerly regarded "inert" pharmaceutical excipients are capable of modifying the bioavailability of oral drugs has gained increasing attention in recent years."( Establishing an in vitro permeation model to predict the in vivo sex-related influence of PEG 400 on oral drug absorption.
Awadi, M; Basit, AW; Mai, Y; Murdan, S, 2018
)
0.48
" Pharmacokinetic studies indicate that 1 has an oral bioavailability with an average F-value of 27."( An antimycobacterial pleuromutilin analogue effective against dormant bacilli.
Eslamimehr, S; Franzblau, SG; Kong, Y; Kurosu, M; Lemieux, MR; Mitachi, K; Park, F; Pressly, JD; Siricilla, S; Wang, Y; Yang, D, 2018
)
0.48
" Dependently, floating oil-entrapped alginate beads of RHCl were developed and evaluated as an approach to site-specific delivery avoiding colonic degradation and enhancing both bioavailability and the proposed local effect."( Oil-entrapped ranitidine HCl beads heal peptic ulcers via local and systemic mechanisms.
Abd Ellah, NH; Abdelmalek, DA; El-Mahdy, M; Ismail, S, 2019
)
0.51
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
"Trospium chloride, a muscarinic receptor blocker, is poorly absorbed with different rates from areas in the jejunum and the cecum/ascending colon."( Pharmacokinetic Drug-Drug Interactions Between Trospium Chloride and Ranitidine Substrates of Organic Cation Transporters in Healthy Human Subjects.
Abebe, BT; Meyer, MJ; Modess, C; Neumeister, C; Scheuch, E; Schulz, HU; Schwantes, U; Siegmund, W; Tadken, T; Tzvetkov, M; Wegner, D; Weiss, M, 2020
)
0.56
"Ranitidine HCl, a selective, competitive histamine H2-receptor antagonist with a short biological half-life, low bioavailability and narrow absorption window, is an ideal candidate for gastro-retentive drug delivery system (GRDDS)."( Design, development and optimization of sustained release floating, bioadhesive and swellable matrix tablet of ranitidine hydrochloride.
Belete, A; Gebre-Mariam, T; Nigusse, B, 2021
)
0.62
" Additionally, an ∼85% correlation was obtained between PAMPA pH 5 permeability and in vivo oral bioavailability in mice and rats."( Using in vitro ADME data for lead compound selection: An emphasis on PAMPA pH 5 permeability and oral bioavailability.
Itkin, M; Kabir, M; Mathé, EA; Nguyễn, ÐT; Padilha, EC; Shah, P; Shinn, P; Siramshetty, V; Wang, AQ; Williams, J; Xu, X; Yu, KR; Zhao, T, 2022
)
0.72
"Niclosamide, a widely-used anthelmintic drug, inhibits SARS-CoV-2 virus entry through TMEM16F inhibition and replication through autophagy induction, but the relatively high cytotoxicity and poor oral bioavailability limited its application."( Design, synthesis and biological evaluations of niclosamide analogues against SARS-CoV-2.
Chang, SY; Chao, TL; Chou, YT; Jan, JT; Juang, YP; Liang, PH; Lin, RX; Ma, HH, 2022
)
0.72
"The mechanism of action of excipients eliciting sex differences in drug bioavailability is poorly understood."( Sex-specific effects of excipients on oral drug bioavailability.
Basit, AW; Madla, CM; Mai, Y; Merchant, HA; Murdan, S; Qin, Y; Shao, H, 2022
)
0.72
" The studies show that complexation with famotidine or ranitidine may affect the bioavailability of sparfloxacin."( Simultaneous interaction, degradation, and kinetic study of sparfloxacin with H2 receptor antagonist.
Amir Hassan, -; Fouzia Shafi, -; Iffat Sultana, -; Maria Qureshi, -; Nazia Tabassum, -; Qurat Ul Aen Ismail, -; Sadia Iqbal, -; Shereen, -; Sohail Hassan, -; Tahreem Mujtaba, -, 2023
)
0.91

Dosage Studied

We determined the dosage necessary to maintain gastric pH at or above 4 in 40 critically ill children. 11 healthy subjects were randomized to receive ranitidine infusions of up to 600 mg/24 hours. Compared with the control treatment, cimetidine increased the glibenclamide AUC.

ExcerptRelevanceReference
" However, PB-93 was rapidly cleared, and dosing every 12 h failed to cure the rats."( Efficacy, pharmacokinetics, and metabolism of tetrahydroquinoline inhibitors of Plasmodium falciparum protein farnesyltransferase.
Ankala, S; Barrett, LK; Bauer, KD; Bendale, P; Buckner, FS; Chakrabarti, D; Floyd, D; Gelb, MH; Hamilton, AD; Hornéy, C; Hucke, O; Lombardo, LJ; Nallan, L; Rivas, KL; Smart, BP; Strickland, C; Van Voorhis, WC; Verlinde, CL; Williams, DK; Yokoyama, K, 2007
)
0.34
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."( FDA-approved drug labeling for the study of drug-induced liver injury.
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011
)
0.37
" These candidates were subjected to a dose-response bioactivity assay, measuring an increase in α-tubulin K40 acetylation in two neuronal cell lines, which yielded five compounds bioactive in both cell lines and eight compounds bioactive in at least one of the cell lines tested."( Development and characterization of 3-(benzylsulfonamido)benzamides as potent and selective SIRT2 inhibitors.
Choi, SH; Kazantsev, AG; Khanfar, MA; Quinti, L; Silverman, RB; Wang, H, 2014
)
0.4
"5% of the 27 patients were treated with a maintenance dosage of H2 blockers and 29."( Peptic ulcer in cirrhotic patients: a short- and long-term study with antisecretory drugs.
Battaglia, G; Burra, P; Di Mario, F; Dotto, P; Germanà, B; Gottardello, L; Grassi, SA; Leandro, G; Salvagnini, M; Vianello, F,
)
0.13
" There was no significant difference of integrated 6-h plasma ethanol concentration, peak ethanol concentration, or time to reach peak ethanol concentration after dosing with either ranitidine, cimetidine or famotidine or placebo."( Ranitidine, cimetidine, famotidine have no effect on post-prandial absorption of ethanol 0.8 g/kg taken after an evening meal.
Fraser, AG; Hudson, M; Pounder, RE; Rosalki, SB; Sawyerr, AM; Smith, M, 1992
)
0.28
" Plasma samples were collected at periodic time intervals for 12 hr following each dosing and analyzed for ranitidine concentration by high-pressure liquid chromatography."( Influence of gastrointestinal site of drug delivery on the absorption characteristics of ranitidine.
Dukes, GE; Hak, LJ; Han, YH; Heizer, W; Hermann, DJ; Lampkin, T; Williams, MF, 1992
)
0.28
" during concomitant twice daily dosing with 400 micrograms misoprostol, 150 mg ranitidine or placebo."( Co-administration of misoprostol or ranitidine with indomethacin: effects on pharmacokinetics, abdominal symptoms and bowel habit.
Gibson, R; Kendall, MJ; Walt, RP, 1992
)
0.28
" Symptomatic relief was achieved within 24 hours after starting either dosage of ranitidine."( Ranitidine for erosive oesophagitis: a double-blind, placebo-controlled study. Glaxo Erosive Esophagitis Study Group.
Barish, C; Belsito, A; Robinson, M; Roufail, W; Rubin, A, 1992
)
0.28
" A nonlinear least-squares regression analysis was used to establish a ranitidine pharmacokinetic dosing model."( Ranitidine pharmacokinetics and adverse central nervous system reactions.
Haug, MT; Pippenger, CE; Slugg, PH, 1992
)
0.28
" Also this result differs from what most authors have observed: they maintain that Horton's arteritis has become rather resistant to the cortisone therapy and required high dosage for a very long time."( [Horton's bitemporal arteritis. A case report].
Carmenini, G; Di Maio, F; Martusciello, S; Meloni, F; Nicoletti, M; Scioli, A, 1992
)
0.28
"Prolonged fasting and longer time between dosing and sampling reduced the plasma gastrin concentrations after omeprazole (80 mumol/kg x 2 for 14 days) treatment in male rats whereas the amounts of tissue gastrin were essentially unchanged during these initial experiments."( Effects of omeprazole and ranitidine on plasma gastrin concentration and stomach gastrin content in rats.
Girma, K; Nilsson, G; Romell, B; Seensalu, R, 1992
)
0.28
" To assess tolerance during repeated dosing with ranitidine, the same infusion regimens were given before and after 6 days oral dosing with ranitidine 300 mg four times daily."( pH-feedback controlled infusions of ranitidine are no more effective than fixed-dose infusions in reducing gastric acidity and variability in antisecretory responses.
Häcki, W; Halter, F; Merki, HS; Wilder-Smith, CH, 1992
)
0.28
"0 throughout the normal dosing interval in the majority of patients."( Pharmacokinetics and pharmacodynamics of ranitidine after burn injury.
Bishop, AL; Martyn, JA; Oliveri, MF, 1992
)
0.28
" dosing of this selective compound is necessary for achieving adequate results."( Famotidine in gastroesophageal reflux disease (GERD).
Wesdorp, IC, 1992
)
0.28
" Patients were dosed to steady-state with an oral, sustained-release formulation of theophylline given in therapeutic doses twice daily for 2 weeks."( Comparative investigation of the influence of nizatidine, ranitidine, and cimetidine on the steady-state pharmacokinetics of theophylline in COPD patients.
Bachmann, K; Jauregui, L; Levine, L; Martin, M; Mauro, LS; Sullivan, TJ, 1992
)
0.28
" Dosing included continuous intravenous infusion ranitidine (50 mg bolus followed by 12."( Circadian differences in pharmacological blockade of meal-stimulated gastric acid secretion.
Day, GM; Moore, JG; Sanders, SW; Tolman, KG, 1992
)
0.28
"07), and a statistically significant increase in mean peak plasma alcohol concentration after dosing with ranitidine (4."( Short report: the effect of ranitidine on the post-prandial absorption of a low dose of alcohol.
Fraser, AG; Hudson, M; Pounder, RE; Rosalki, SB; Sawyerr, AM, 1992
)
0.28
" These data support the superiority of nocturnal dosing with H2-antagonists."( Night-time or morning dosing with H2-receptor antagonists: studies on acid inhibition in normal subjects.
Patel, N; Primrose, JN; Rogers, MJ; Ward, U, 1992
)
0.28
" However, many authors report that an H2RA resistant ulcer can be cured by increasing the dosage of H2RA, or using another H2RA."( Does H2 receptor antagonist-resistant ulcer exist?--A review based on bioavailability in man.
Kawai, K, 1992
)
0.28
" While very safe, clinicians need to know correct dosing guidelines, drug interactions, and side effect profiles."( The clinical use of histamine-2 receptor antagonists.
Michocki, RJ; Richardson, JP, 1992
)
0.28
" An early evening dose of ranitidine is probably more effective and dosage reduction may be applicable for the healing of duodenal ulcers."( The magnitude of nocturnal acid suppression by ranitidine 300 mg given at 18.00 hours.
Chamsai, M; Niyomthai, N; Ovartlarnporn, B; Prichaworawach, S; Tansakool, U; Wuthi, S, 1992
)
0.28
" A statistically significant rise in nocturnal acidity was observed after all regimens, except after dosing with famotidine."( Rebound intragastric hyperacidity after abrupt withdrawal of histamine H2 receptor blockade.
Nwokolo, CU; Pounder, RE; Sawyerr, AM; Smith, JT, 1991
)
0.28
" The aim of this study was to determine whether tolerance occurs with repeated dosing of H2-receptor antagonists in patients with duodenal ulcer."( Tolerance and rebound to H2-receptor antagonists: intragastric acidity in patients with duodenal ulcer.
Halter, F; Merki, HS; Wilder-Smith, CH, 1991
)
0.28
" Dosage of theophylline from patients' sera was monitored prior and at 3, 6, and 12 hours beginning with the initial morning dose."( [The effect of ranitidine on theophylline pharmacokinetics in patients with obstructive lung disease].
Bojović, I; Despotović, N; Dmitrović, V; Milovanović, M; Paranos, S; Vidanović, M,
)
0.13
" Further studies are needed to elucidate a higher ranitidine dosage may be required for Chinese to achieve the desired plasma level."( Pharmacokinetic properties of ranitidine in Chinese people.
Chung, PH; Hu, OY; Pao, LH; Tang, HS,
)
0.13
"A multicentre clinical trial was conducted in 114 Italian endoscopy centres in order to evaluate the comparative efficacy of four different ranitidine dosage regimens in the short-term treatment of active duodenal ulcer."( Different dosage regimens of ranitidine in the short-term therapy of duodenal ulcer: a multicentre trial.
Castelli, G; Squassante, L; Uleri, S; Zanferrari, G, 1991
)
0.28
" In these studies ranitidine was given in doses ranging from 150 mg to 1200 mg per day administered in 9 different dosage regimens."( Ranitidine in the treatment of duodenal ulcer disease: relationship between antisecretory effect and ulcer healing rate.
Dixon, JS; McIsaac, RL; Mills, JG; Wood, JR, 1991
)
0.28
" This randomized, double-blind multicentre trial studied the dose-response relationship of lansoprazole on ulcer healing and compared it with ranitidine in 314 out-patients with endoscopically assessed, symptomatic duodenal ulcer."( Dose-related healing of duodenal ulcer with the proton pump inhibitor lansoprazole.
Barth, H; Dammann, HG; Hengels, KJ; Kleinert, R; Londong, W; Müller, P; Rohde, H; Simon, B, 1991
)
0.28
" Each group had a control study and a repeat study after 7 days dosing with either placebo or an H2-receptor antagonist (300 mg ranitidine nocte, 800 mg cimetidine nocte, or 40 mg famotidine nocte)."( The effect of ranitidine, cimetidine or famotidine on low-dose post-prandial alcohol absorption.
Fraser, AG; Hudson, M; Pounder, RE; Prewett, EJ; Rosalki, SB; Sawyerr, AM, 1991
)
0.28
"Twelve healthy male subjects were dosed with six regimens: ranitidine and De-Noltab (tripotassium dicitrato bismuthate; Gist-Brocades Ltd."( The effect of histamine H2-receptor blockade on bismuth absorption from three ulcer-healing compounds.
Hudson, M; Nwokolo, CU; Pounder, RE; Prewett, EJ; Sawyerr, AM, 1991
)
0.28
"Repeated dosing with an H2-receptor antagonist results in a modest decrease in antisecretory potency termed "tolerance."( Tolerance during 5 months of dosing with ranitidine, 150 mg nightly: a placebo-controlled, double-blind study.
Hudson, M; Lim, S; Nwokolo, CU; Pounder, RE; Prewett, EJ; Sawyerr, AM, 1991
)
0.28
" Cimetidine was also tested in these subjects at half the dosage administered to the first group of subjects."( Inhibition of gastric acid secretion reduces zinc absorption in man.
D'Inca, R; D'Odorico, A; Martin, A; Montino, MC; Naccarato, R; Rossetto, L; Sturniolo, GC, 1991
)
0.28
" This investigation studies the bioavailability of several oral dosage forms of ddI."( Pharmacokinetics of 2',3'-dideoxyinosine in patients with severe human immunodeficiency infection. II. The effects of different oral formulations and the presence of other medications.
Broder, S; Flora, KP; Hartman, NR; Johns, DG; Pluda, JM; Thomas, RV; Wyvill, KM; Yarchoan, R, 1991
)
0.28
" Dosage of theophylline from patients sera was monitored at 3, 6 and 12 hours, beginning with the initial morning dose."( [Effect of ranitidine on the pharmacokinetics of theophylline in patients with obstructive pulmonary disease].
Bojović, I; Bozović, M; Despotović, N; Dmitrović, V; Milovanović, M; Paranos, S; Vidanović, M, 1991
)
0.28
"The acid-inhibitory action of H2-receptor antagonists was shown to decrease after one to two weeks of dosing in healthy volunteers."( Tolerance to oral H2-receptor antagonists.
Ernst, T; Gennoni, M; Halter, F; Merki, HS; Wilder-Smith, CH; Zeyen, B, 1990
)
0.28
" Each subject received, in an open-labeled, randomized, three-way crossover design, a single oral dose of 1,000 mg (two tablets) of cefetamet pivoxil 10 min after a standard breakfast during each of the following treatments: treatment A, control period; treatment B, antacid (80 ml of suspension; Maalox 70) administered on the evening before cefetamet pivoxil dosing (-12."( Influence of antacid and ranitidine on the pharmacokinetics of oral cefetamet pivoxil.
Ambros, RJ; Blouin, RA; Kneer, J; Stoeckel, K, 1990
)
0.28
"In a double-blind study of Latin square design, twelve healthy male subjects were dosed with combinations of ranitidine 300 mg or placebo (at 08."( Intravenous pentagastrin can induce the illusion of 'tolerance' to a single dose of an H2-blocker in man.
Nwokolo, CU; Pounder, RE; Sawyerr, A; Smith, JT, 1990
)
0.28
"The magnitude and duration of changes in nocturnal intragastric acidity caused by 25 days of dosing with the antisecretory drugs ranitidine and omeprazole were investigated in a double-blind study of 22 healthy subjects."( Nocturnal intragastric acidity during and after a period of dosing with either ranitidine or omeprazole.
Hudson, M; Nwokolo, CU; Pounder, RE; Prewett, EJ; Sawyerr, AM, 1991
)
0.28
"5 mumol/L when she was receiving a comparable dosage of theophylline (300 mg five to six times a day, depending on the need for a nighttime dose)."( Ranitidine-theophylline interaction--fact or fiction?
Gilbert, RP; Hegman, GW, 1991
)
0.28
" Phase 2 consisted of concurrent monitoring of iv ranitidine solely to assess the appropriateness of the iv dosage form at our hospital."( Conversion of intravenous ranitidine to oral therapy.
Baciewicz, AM, 1991
)
0.28
" During maintenance treatment with ranitidine at half the acute dosage five of the six patients who had shown no improvement in gastroesophageal reflux after acute healing, relapsed."( [Reflux esophagitis: therapy with H2-blockers, and motility disorders].
Bianchi Porro, G; Pace, F; Sangaletti, O; Zhu, H, 1991
)
0.28
"To assess the effect of indomethacin on gastric acidity and to identify a potential pharmacodynamic interaction between indomethacin and ranitidine, we measured nocturnal acidity on half-hourly aliquots of gastric contents from 10 volunteers on the seventh day of four dosing regimens given in a randomized double-blind manner."( Effect of ranitidine and indomethacin on nocturnal gastric acidity in normal subjects.
Daneshmend, TK; Langman, MJ; Prichard, P; Walt, RP, 1990
)
0.28
" In order to verify if longer periods of treatment and/or higher dosage of drug can increase the healing rate, we performed a single-center double blind trial of 12 to 24 week duration on 75 patients with erosive/ulcerative reflux oesophagitis, comparing two ranitidine regimens, 150 vs 300mg bd."( Short and long-term effect of two different dosages of ranitidine in the therapy of reflux oesophagitis.
Bianchi Porro, G; Pace, F; Sangaletti, O, 1990
)
0.28
" Snacks taken after evening dosing with ranitidine also significantly decreased pharmacodynamic efficacy."( Effect of food on H2-receptor blockade in normal subjects and duodenal ulcer patients.
Allemann, P; Halter, F; Kempf, M; Merki, HS; Roehmel, J; Walt, RP; Wilder-Smith, C; Witzel, L, 1990
)
0.28
" Ranitidine reduced the expected acetaminophen-induced hepatoxicity in a dose-response manner."( Effect of ranitidine on acetaminophen-induced hepatotoxicity in dogs.
Barone, M; Bell, S; Demetris, J; Guglielmi, FW; Makowka, L; Panella, C; Polimeno, L; Prelich, JG; Rizzi, S; Van Thiel, DH, 1990
)
0.28
" The procedures used in conjunction can be applied to the quality assurance and stability assessments of both the drug substance and its dosage forms and serve to establish the identity, strength and purity of this drug used in the treatment of peptic ulcer and related conditions."( Chromatographic methods for determining the identity, strength and purity of ranitidine hydrochloride both in the drug substance and its dosage forms--an exercise in method selection, development, definition and validation.
Evans, MB; Haywood, PA; Johnson, D; Martin-Smith, M; Munro, G; Wahlich, JC, 1989
)
0.28
"To investigate the efficacy of standard and low dosage of omeprazole in the healing of duodenal ulcer, 270 patients with endoscopically active duodenal ulcer were randomized to receive omeprazole, 10 mg or 20 mg every morning, or ranitidine, 150 mg twice daily, using the double-dummy technique."( Omeprazole and ranitidine in duodenal ulcer healing and subsequent relapse: a randomized double-blind study with weekly endoscopic assessment.
Branicki, FJ; Hui, WM; Lai, CL; Lam, SK; Lau, WY; Lok, AS; Ng, MM; Poon, GP, 1989
)
0.28
" We have studied both techniques in a practical pharmacologic study, comparing early evening versus nighttime dosing with ranitidine and nizatidine against placebo."( Validation of pH dataloggers for pharmacologic studies.
Burget, DW; Chiverton, SG; Hunt, RH, 1989
)
0.28
"Twenty-four-hour intragastric acidity was measured in 10 patients with a past history of duodenal ulcer on the fourth day of dosing with placebo, and either 150 mg ranitidine given twice or four times daily."( Twenty-four-hour intragastric acidity in duodenal ulcer patients during dosing with placebo, and 150 mg ranitidine twice or four times daily.
Howden, CW; Reid, JL; Tsai, HH, 1989
)
0.28
"H2-receptor antagonists administered in conventional dosage regimens fail to heal a significant proportion of patients with moderate or severe reflux oesophagitis."( Acute treatment of reflux oesophagitis: a multicentre trial to compare 150 mg ranitidine b.d. with 300 mg ranitidine q.d.s.
Boyd, EJ; Johnson, NJ; Mills, JG; Wood, JR, 1989
)
0.28
" In the pH study (n = 17 subjects), there was a lead-in period done under fasting conditions, followed by randomization to a four-way crossover of pentagastrin (6 micrograms/kg, subcutaneously), ranitidine (150 mg orally, 10 and 2 hours before dosing with the antibiotic), sodium bicarbonate (12."( The effects of gastric pH and food on the pharmacokinetics of a new oral cephalosporin, cefpodoxime proxetil.
Barker, KB; Batts, DH; Euler, AR; Heald, DL; Hughes, GS; Patel, RK; Spillers, CR; Watts, KC, 1989
)
0.28
" Our results suggest that the recommended dosage of enteric coated preparations is insufficient for adult patients with severe chronic pancreatitis."( Pancreatic enzyme replacement therapy. Importance of gastric acid secretion, H2-antagonists, and enteric coating.
Girdwood, A; Marks, IN; Marotta, F; O'Keefe, SJ; Young, G, 1989
)
0.28
" No changes in DNA synthesis, percentage of labelled nuclei and transaminase were detected when the agents were added to the hepatocytes in culture at concentrations within the effective pharmacological dosage and 30 times higher."( Effect of cimetidine, ranitidine, famotidine and omeprazole on hepatocyte proliferation in vitro.
Amoruso, A; Barone, M; Di Leo, A; Francavilla, A; Ingrosso, M; Makowka, L; Panella, C; Polimeno, L; Starzl, TE, 1989
)
0.28
" At a dosage one fifth of Cimetidine (0."( Anti-acid secretion activity of drugs cimetidine, ranitidine, tiotidine D 15,144 in dogs fixed with gastric fistulae.
Jais, AM; Ridzwan, BH; Waton, NG, 1989
)
0.28
" It was found that non-toxic dosage of cimetidine had no significant effect on CFU-s of the normal mouse, but it inhibited CFU-GM growth with a dosage-dependent relationship and the recovery of CFU-s formation from sublethal gamma-ray irradiation."( [Effects of histamine H2-receptor antagonists on hemopoietic reconstruction in bone marrow].
Du, XX; Xu, YH; Zhou, YJ, 1989
)
0.28
" Continuous infusion regimens, with a dosage adjustment for the time of day, may be the optimal dosage regimen for patients requiring continuous protection from gastric damage by hydrochloric acid."( Pharmacodynamics of intravenous ranitidine after bolus and continuous infusion in patients with healed duodenal ulcers.
Bishop, AL; Buchi, KN; Moore, JG; Sanders, SW, 1989
)
0.28
" The dosage was 1 g sucralfate twice per day or 150 mg ranitidine before going to bed."( Sucralfate versus ranitidine in the treatment of gastric ulcer. Randomized clinical results in short-term and maintenance therapy.
Herrerias-Gutierrez, JM; Pardo, L; Segu, JL, 1989
)
0.28
"The validity of the Giusti-Hayton method for dosage regimen adjustment in patients with renal impairment was investigated using ranitidine."( Dosage regimen of ranitidine in patients with renal impairment.
Asano, Y; Ebihara, A; Ikeda, T; Kondo, K; Nakazawa, K; Ohashi, K; Tabei, K; Tagawa, H; Yamakado, M; Yuhara, M, 1989
)
0.28
" The ranitidine suspension should be well shaken, the dosage should be measured immediately after shaking, and the suspension should be used within seven days of compounding."( Concentration uniformity of extemporaneously prepared ranitidine suspension.
Garnett, WR; Harris, SR; Karnes, HT; March, C, 1989
)
0.28
" Phenylbutazone was administered at a dosage of 10 mg/kg of bodyweight (BW) per day, intravenously (IV), in equally divided doses to three of the groups."( The protective effects of sucralfate and ranitidine in foals experimentally intoxicated with phenylbutazone.
Geor, RJ; Papich, MG; Petrie, L; Rousseaux, C, 1989
)
0.28
" This endotoxin dosage resulted in 50% mortality in rats."( Disposition kinetics of cimetidine and ranitidine in endotoxin pretreated rats.
al-Khamis, KI; Kaka, JS; Tanira, MO, 1989
)
0.28
"7 h of the dosing interval with a wide degree of variability."( Pharmacokinetics of ranitidine in critically ill infants.
Brundage, RC; Gillette, PC; O'Neal, W; Reigart, JR; Wiest, DB; Yost, RL, 1989
)
0.28
" The dose-response curve for histamine in each culture was progressively displaced to the right with increasing concentrations of the histamine H2 receptor antagonist cimetidine."( Demonstration of histamine H2 receptors on human melanoma cells.
Evanson, JM; Hart, IR; Taylor, DJ; Whitehead, RJ; Woolley, DE, 1988
)
0.27
" According to the two dosing schedules adopted to evaluate the duration of action, mifentidine, compared to cimetidine and ranitidine, required considerably lower oral dosages to display its protective effect."( Cimetidine, ranitidine and mifentidine in specific gastric and duodenal ulcer models.
Cereda, E; Del Soldato, P; Donetti, A; Ghiorzi, A, 1985
)
0.27
" For all substances a dose-response curve concerning the change of vessel diameters was obtained."( The microvasculature of the small-intestinal mucosa of the rat: quantification of hemodynamic effects of topically applied cimetidine, ranitidine, somatostatin, and vasopressin.
Anliker, M; Frick, P; Knoblauch, M; Métry, JM; Neff, M, 1985
)
0.27
" In the second set of experiments, equiactive doses (that is the respective ED50s calculated from the previously established dose-response curves) of all the compounds were infused during dimaprit-induced acid hypersecretion, in order to evaluate their duration of action."( Effect of the new H2-receptor antagonist mifentidine on gastric acid secretion in the cat: comparison with cimetidine and ranitidine.
Bertaccini, G; Scarpignato, C; Tangwa, M; Tramacere, R, 1985
)
0.27
" the respective ED50s calculated from the previously established dose-response curves) of all the three antagonists was completely different."( The effect of the new H2-receptor antagonist mifentidine on gastric secretion, gastric emptying and experimental gastric and duodenal ulcers in the rat: comparison with cimetidine and ranitidine.
Del Soldato, P; Scarpignato, C; Tangwa, M; Tramacere, R, 1986
)
0.27
" The maximum pepsin output obtained from a set of complete dose-response curves of dimaprit was not statistically different from basal values."( Comparison of the effects of structurally different H2-antagonists on acid and pepsin activity stimulated by dimaprit in conscious cats.
Barocelli, E; Chiavarini, M; Impicciatore, M; Molina, E; Morini, G; Plazzi, PV, 1985
)
0.27
" A dose-response relationship for cimetidine and ranitidine was developed, confirming the greater potency of cimetidine."( Effect of H2-receptor antagonists on steady-state extraction of indocyanine green and lidocaine by the perfused rat liver.
Heath, CA; Johnson, RF; Roberts, RK; Schenker, S; Speeg, KV, 1986
)
0.27
" The other five patients, who were free of complication, initially received a standard regimen of omeprazole 60 mg orally once a day; dosage was subsequently adjusted until the basal acid output, measured 1 hr before the next dose of the drug, was less than 10 mmol/hr."( Effectiveness of omeprazole in seven patients with Zollinger-Ellison syndrome resistant to histamine H2-receptor antagonists.
Bader, JP; Cortot, A; Delchier, JC; Goldfain, D; Isal, JP; Mignon, M; Soule, JC; Travers, B, 1986
)
0.27
" ORF 17910 retains 43 and 37% of its antisecretory potency 16 hr after dosing in dogs and rats, respectively, suggesting a long duration of action, whereas ranitidine is either inactive (rats) or loses 97% of its potency (dogs) at this time."( Pharmacological comparison of ORF 17910, a potent, long-acting histamine H2-receptor antagonist, to cimetidine and ranitidine.
Katz, LB; Scott, CK; Shriver, DA, 1986
)
0.27
" Patients received either ranitidine (150 mg twice daily) or famotidine at one of three different dosage regimens: 40 mg at bedtime, 40 mg twice daily, or 20 mg twice daily."( A multicenter, randomized, double-blind study comparing famotidine with ranitidine in the treatment of active duodenal ulcer disease.
McCullough, AJ, 1986
)
0.27
" Gastric acid hypersecretion was controlled in seven patients with less frequent dosing with famotidine than with cimetidine or ranitidine."( Famotidine in the therapy of gastric hypersecretory states.
Gardner, JD; Howard, JM; Jensen, RT; Maton, PN; Slaff, JI; Vinayek, R; Wank, SA, 1986
)
0.27
" Enprostil in a dosage of 35 or 70 micrograms BID had no effect on intragastric pH, but when enprostil was given in combination with ranitidine, postprandial and nocturnal intragastric alkalinity was accentuated along with a return of duodenal and antral G-cells and a loss of the antral D-cell hyperplasia."( Synergistic interaction between an H2-receptor antagonist and enprostil on 24-hour intragastric pH, serum gastrin concentration, and tissue immunoperoxidase staining for gastrin, somatostatin, and serotonin in a patient with metastatic gastrinoma.
Brunet, MK; Jewell, LD; Kirdeikis, P; Mahachai, V; Pinchbeck, B; Salkie, ML; Sherbaniuk, R; Walker, K; Yacoub, W; Zuk, L, 1986
)
0.27
" At UC Davis, we compared constant infusion with intermittent dosing (300 mg of cimetidine every six hours) in patients admitted to the intensive care unit with upper gastrointestinal bleeding."( A dosage alternative for H2-receptor antagonists--constant infusion.
Siepler, JK, 1986
)
0.27
" However, when the preparations were precontracted with histamine (10(-5)M), dose-response curves for relaxation were shifted to the right, and low-concentrations of all three histamine H2-antagonists augmented histamine-induced tone."( Direct effects of H2-receptor antagonists on airway smooth muscle and on responses mediated by H1- and H2-receptors.
Hashimoto, Y; Iwatsuki, N; Koga, Y, 1987
)
0.27
" The dosage was increased to 975 mg every 6 hours, and he has had no further hypotensive episodes on this regime for 2 years."( Systemic mastocytosis: management of an unusual case with histamine (H1 and H2) antagonists and cyclooxygenase inhibition.
Crawhall, JC; Wilkinson, RD, 1987
)
0.27
"32 mumol kg-1 h-1) caused a parallel displacement of the dose-response curve to dimaprit to the right, without reducing the maximum response to the stimulant, thus behaving as a competitive antagonist, like ranitidine."( Inhibitory effect of famotidine on cat gastric secretion.
Bertaccini, G; Coruzzi, G; Dobrilla, G; Noci, MT, 1986
)
0.27
" The current trend in therapy is toward less frequent dosing patterns with more attention toward controlling nocturnal acid secretion."( H2-receptor antagonists: development and application.
Feldman, S,
)
0.13
"The disposition of diazepam (D) after a single oral dose of 10 mg was evaluated in nine healthy male volunteers under the following conditions (randomized, double-blind, crossover design): D + comedication of placebo and D + nocturnal dosing with 300 mg ranitidine or 300 mg nizatidine."( Nocturnal doses of ranitidine and nizatidine do not affect the disposition of diazepam.
Dammann, HG; Gottlieb, W; Keohane, PP; Klotz, U, 1987
)
0.27
" These data are at variance with those previously published, and the slight effect of the single nightly doses of H2 blockers on daytime acidity seems to confirm further that the suppression of nocturnal acidity may really be the decisive factor in the success of this dosing schedule in treating duodenal ulcer."( Once and twice daily doses of H2 antagonists revisited, using continuous intragastric pH monitoring.
Celle, G; Fera, G; Mela, GS; Savarino, V; Scalabrini, P; Sumberaz, A; Zentilin, P, 1988
)
0.27
" Therefore, the two dosing schedules of each H2 antagonist increased intragastric pH differently, but both the half and the standard large regimens produced similar overnight virtual anacidity."( Overnight comparable anacidity by standard large and half-single bedtime doses of H2 antagonists in duodenal ulcer patients: a clinical pharmacological study.
Celle, G; Fera, G; Mela, GS; Savarino, V; Scalabrini, P; Sumberaz, A; Zentilin, P, 1988
)
0.27
"Nine healthy volunteers were studied on the seventh day of dosing at 21:00 h with nizatidine 150 mg (N 150), nizatidine 300 mg (N 300), ranitidine 300 mg (R 300), or placebo, given in a predetermined random order."( Twenty four hour intragastric acidity and plasma gastrin concentration in healthy volunteers taking nizatidine 150 mg, nizatidine 300 mg, ranitidine 300 mg, or placebo at 21:00 h.
Chronos, NA; Dalgleish, D; Hamilton, MR; Lanzon-Miller, S; Pounder, RE; Raymond, F, 1988
)
0.27
"In a series of double-blind randomised studies in normal volunteers with continuous intragastric pH monitoring, the effects of different dosage regimens of roxatidine acetate, a new H2-receptor antagonist, were compared with placebo and ranitidine."( The effects of roxatidine acetate on 24-hour intragastric acidity. Investigations in healthy volunteers and comparison with ranitidine and placebo.
Kaufmann, D; Kempf, M; Merki, HS; Neumann, J; Röhmel, J; Scheurle, E; Walt, RP; Witzel, L, 1988
)
0.27
" Therefore, the same dosage schedule as in uraemia may be applied in patients with dialysis."( Pharmacokinetics of histamine (H2)-receptor antagonists, including roxatidine, in chronic renal failure.
Brockmeier, D; Lameire, N; Rosenkranz, B, 1988
)
0.27
" In three double-blind randomized studies in normal volunteers the effects of different dosage regimens of roxatidine acetate were compared with placebo and ranitidine."( Assessment of intragastric acidity in man: modern aspects, reproducibility of intragastric pH-monitoring, and pharmacodynamic results obtained with H2-receptor antagonists.
Kaufmann, D; Kempf, M; Merki, HS; Muessig, V; Neumann, J; Roehmel, J; Scheurle, E; Walt, RP; Witzel, L, 1988
)
0.27
" Ranitidine (3 x 112 mg) was given intravenously until enteral feeding started, usually for the first 4 days, after oral nutrition had started the dosage was reduced to 3 x 56 mg/day."( Preventive measures for stress ulcers in burn patients.
Meissl, G; Rath, T; Walzer, LR, 1988
)
0.27
"In a series of double-blind randomized studies in normal volunteers using continuous intragastric pH monitoring, the effects of different dosage regimens of roxatidine, a new H2-receptor antagonist, were compared with placebo and ranitidine."( The effects of roxatidine acetate (HOE-760) on 24-hour intragastric acidity in healthy volunteers: comparison with ranitidine and placebo.
Kaufmann, D; Kempf, M; Merki, HS; Müssig, V; Neumann, J; Röhmel, J; Scheurle, E; Walt, RP; Witzel, L, 1988
)
0.27
" The 20 control subjects received either no ranitidine or ranitidine in the same dosage as the surgical patients."( Ranitidine for prevention of postoperative suppression of delayed hypersensitivity.
Kehlet, H; Moesgaard, F; Nielsen, HJ, 1989
)
0.28
" In contrast, the steady-state midazolam concentration after ranitidine dosing (61."( Effect of single doses of cimetidine and ranitidine on the steady-state plasma levels of midazolam.
Arvela, P; Klotz, U; Rosenkranz, B, 1985
)
0.27
" The increase in intragastric pH achieved by the two dosage regimens did not differ significantly throughout the 24 hour period."( A comparison of two ranitidine intravenous infusion regimens in critically ill patients.
Marchant, J; McIsaac, RL; Summers, K; Wood, JR, 1988
)
0.27
" The prolonged protection against aspirin-induced bleeding achieved with twice daily dosing with ranitidine has clinical potential in the management of patients taking anti-inflammatory drugs."( Prophylaxis of aspirin-induced gastric mucosal bleeding with ranitidine.
Hawkey, CJ; Marshall, S; Somerville, KW, 1988
)
0.27
" However, no such intoxication has been reported with CBS used at its recommended dosage in the acute treatment of peptic ulcer disease, and no other serious adverse effects have been associated with CBS."( Colloidal bismuth subcitrate. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in peptic ulcer disease.
Benfield, P; Monk, JP; Wagstaff, AJ, 1988
)
0.27
" These results showed that the ranitidine is a potent antisecretory drug; the dosage of 150 mg twice a day which is considered as the regular treatment for ulcer disease seems adequate."( [Ranitidine inhibition of gastric secretion stimulated by pentagastrin. Results in 30 cases of duodenal ulcer].
Bosc, F; Pagniez, R; Rousselet, J; Toulet, J; Vienne, JL; Viteau, JM,
)
0.13
" The findings suggest that enprostil can be given in a twice daily dosage in the treatment of benign gastric ulcers."( [Stomach ulcer healing with enprostil, an orally effective prostaglandin E2 analog: direct comparative study with ranitidine].
Beckenbach, HP; Daake, H; Dammann, HG; Hüttemann, W; Jancke, T; Kalek, HD; Kühn, V; Martens, W; Müller, P; Rohner, HG, 1986
)
0.27
" Compared with the control treatment, cimetidine increased the glibenclamide AUC (973 vs 710 ng ml-1 h), but during ranitidine dosing glibenclamide AUC (726 ng ml-1 h) was not significantly different from the control."( The paradoxical effect of cimetidine and ranitidine on glibenclamide pharmacokinetics and pharmacodynamics.
Antal, EJ; Juhl, RP; Kubacka, RT, 1987
)
0.27
" A combination of the two drugs both in "standard" and modified dosage resulted in the greatest reduction in the wheal and flare."( Effect of terfenadine and ranitidine on histamine and suxamethonium wheals.
Bödeker, RH; Paul, E; Pfeffer, M, 1988
)
0.27
" Comparison of profiles with the immediate release dosage form indicated that dose dumping did not occur in any subject."( Elevation of gastric pH with ranitidine does not affect the release characteristics of sustained release ibuprofen tablets.
Berardi, RR; Dressman, JB; Elta, GH; Szpunar, GJ,
)
0.13
" Once-daily dosing with 300 mg ranitidine had no significant effect on theophylline pharmacokinetics."( The effects of once-daily dosing with ranitidine and cimetidine on theophylline pharmacokinetics.
McEwen, J; McMurdo, ME; Moreland, TA,
)
0.13
" Once daily dosing of 150 mg ranitidine does not result in excessive accumulation, and drug loss during hemodialysis is small."( Ranitidine accumulation in patients undergoing chronic hemodialysis.
Comstock, TJ; Davis, J; Garnett, WR; Karnes, HT; Sica, DA; Stone, S; Warner, CW, 1988
)
0.27
" All of the volunteers also had better inhibition before midnight with the earlier dosing, but after midnight the gastric inhibition was significantly less after the 1815 h than after the 2200 h dosing with ranitidine."( Time of administration influences gastric inhibitory effects of ranitidine.
Johnston, DA; Wormsley, KG, 1988
)
0.27
" Increasing the ranitidine dosage to 300 mg/day did not provide additional control."( A randomized clinical trial comparing ranitidine and antacids in critically ill patients.
Anderson, BJ; Grace, M; Johnston, RG; Konopad, E; Noseworthy, TW; Shustack, A, 1987
)
0.27
" Multiple blood and urine samples were collected throughout a dosing interval after chronic administration of triamterene alone, ranitidine alone or the two in combination."( Pharmacokinetic drug interactions between triamterene and ranitidine in humans: alterations in renal and hepatic clearances and gastrointestinal absorption.
Bochner, F; Muirhead, M; Somogyi, A, 1988
)
0.27
"We determined the ranitidine dosage necessary to maintain gastric pH at or above 4 in 40 critically ill children."( Ranitidine prophylaxis in acute gastric mucosal damage in critically ill pediatric patients.
Albajara Velasco, L; Codoceo, R; Delgado Dominguez, MA; Jimenez, E; Lopez-Herce Cid, J; Ruza Tarrio, F, 1988
)
0.27
" Patients received either cimetidine or ranitidine via continuous infusion, with dosage adjustments for patients with renal insufficiency."( The comparative efficacy of cimetidine and ranitidine in controlling gastric pH in critically ill patients.
Bayliff, CD; Reid, SR, 1986
)
0.27
" After an overnight fast the same dosage of tablets was given 2 h before introduction of two fiberoptic transducers, the tips of which were localized to the mid-portion of the gastric antrum and the upper third of the duodenum."( The effect of ranitidine on the gastroduodenal motility as determined by the maximal pressure periods.
Hansen, T; Larsen, S; Myren, J; Ness, K; Osnes, M, 1986
)
0.27
" Dosing schedules are inexact and there remains a need to develop predictive models for its administration."( Approaches to the problem of individual doxorubicin dosing schedules.
Brenner, DE, 1987
)
0.27
" Thus, at the dosage used in our trial, ranitidine is more efficient for healing DU at 4 weeks than cimetidine but not for pain relief."( [Comparative effectiveness of ranitidine (150 mg X 2) and cimetidine (400 mg x 2) in the treatment of acute duodenal ulcer. A French multicenter controlled clinical trial].
Cortot, A; Henry-Amar, M; Pappo, M; Paris, JC, 1987
)
0.27
" It is concluded that patients with severe liver cirrhosis could have elevated plasma level of ranitidine and that a reduction of ranitidine dosage is warranted in these patients."( Ranitidine disposition in severe hepatic cirrhosis.
Arancibia, A; Chesta, J; Gonzalez-Martin, G; Novoa, X; Paulos, C; Veloso, B, 1987
)
0.27
" Cimetidine produced a significant increase in the AUC of both single and steady state dosing of nifedipine."( Ranitidine and cimetidine; drug interactions with single dose and steady-state nifedipine administration.
Beerahee, A; Jack, DB; Kendall, MJ; Lobo, J; Smith, SR; Wilkins, MR, 1987
)
0.27
" This was not achieved with dosing at 1800 h although the duration of inhibition of gastric acidity was longer."( Large single daily dose of histamine H2 receptor antagonist for duodenal ulcer. How much and when? A clinical pharmacological study.
Burland, WL; Deakin, M; Glenny, HP; Mills, JG; Ramage, JK; Williams, JG, 1987
)
0.27
" A dosage regimen for ranitidine is proposed based on ranitidine kinetics in patients undergoing CAPD."( Ranitidine pharmacokinetics in continuous ambulatory peritoneal dialysis.
Comstock, T; Eshelman, F; Harford, A; Sica, DA, 1987
)
0.27
" By this the necessary daily dosage could be reduced essentially."( [Lattice structure antacids and antacid mixtures].
Miederer, SE; Schmidt, C, 1987
)
0.27
" Rats were dosed orally for 4 days with the histamine H2-receptor antagonist ranitidine or the H+,K+-sensitive ATPase inhibitor omeprazole, and examined on day 5 for effects on gastric acid secretion and serum gastrin."( Use of a five-day test to predict the long-term effects of gastric antisecretory agents on serum gastrin in rats.
Katz, LB; Schoof, RA; Shriver, DA, 1987
)
0.27
" The same drug was continued per os for two month at a dosage of 150 mg twice daily followed by 150 once daily for 8 months; during this period no relapses were observed and an endoscopic control did show the anatomical recovery of the ulcer."( [Ranitidine in primary peptic ulcer in childhood complicated by acute hemorrhage].
Buoncompagni, A; Cordone, G; Fasce, L; Iester, A; Ricci, F; Venzano, V,
)
0.13
"The dose-response effects of intravenous ranitidine given 45 min to 5 h earlier on gastric pH and volume were evaluated in six groups of 25 outpatients, each undergoing elective surgery under general anesthesia."( Dose-response effects of intravenous ranitidine on gastric pH and volume in outpatients.
Colliver, JA; Demeyer, RG; Grow, JB; Hadley, CH; Manchikanti, L; Roush, JR, 1986
)
0.27
" The expected antisecretory effect of a particular dosage regimen in patients with duodenal ulcer can be predicted mathematically from data derived from studies in normal volunteers."( Comparison of the effects of gastric antisecretory agents in healthy volunteers and patients with duodenal ulcer.
Burget, DW; Howden, CW; Hunt, RH; Jones, DB, 1986
)
0.27
" Acetaminophen, cimetidine, or ranitidine were begun 24 hours prior to oxaprozin dosage and continued for the 10-day duration of each trial."( Interaction of oxaprozin with acetaminophen, cimetidine, and ranitidine.
Greenblatt, DJ; Harmatz, JS; Matlis, R; Scavone, JM, 1986
)
0.27
" Achlorhydria, induced by omeprazole at a dosage of 250-500 times that required for effective acid inhibition in man and animals, therefore resulted in reciprocal changes in gastrin and somatostatin cells."( Gastric regulatory peptides in rats with reduced acid secretion.
Allen, JM; Bishop, AE; Bloom, SR; Carlsson, E; Daly, MJ; Larsson, H; Polak, JM, 1986
)
0.27
" In contrast, tiotidine produced both a dextral shift of the log dose-response curve, as well as a previously unreported suppression in the maximal response produced by histamine."( Antagonistic activity of tiotidine and ranitidine on guinea-pig and rabbit atria.
Hughes, MJ; Kilpatrick, C; Light, KE; Serbus, DC, 1986
)
0.27
" The drugs were administered by intravenous infusion, and up to three dosage increments fo each of the drugs were titrated against the pH of the aspirated gastric juice."( Randomized, prospective trial of cimetidine and ranitidine for control of intragastric pH in the critically ill.
Boutagy, JS; More, DG; Munro, IA; Raper, RF; Shenfield, GM; Watson, CJ, 1985
)
0.27
" These results indicate that ranitidine kinetics are not appreciably altered in cirrhotic patients and that reduction of dosage is not required in such patients unless their renal function is impaired."( Pharmacokinetics and bioavailability of ranitidine in normal subjects and cirrhotic patients.
Alexandre, C; Dhumeaux, D; Houin, G; Mavier, P; Morichau-Beauchant, M, 1986
)
0.27
"Oral ranitidine was given to 68 healthy subjects between 18 and 75 years old at a dosage of 150 mg twice a day for seven doses."( The effect of age on ranitidine pharmacokinetics.
Anslow, JA; Greene, DS; Hooper, JW; Szego, PL, 1986
)
0.27
" The minor alterations in prednisolone kinetics during concomitant cimetidine dosing are not likely to induce clinically significant alterations in steroid effect."( Effects of cimetidine and ranitidine on the conversion of prednisone to prednisolone.
Eshelman, FN; Ferguson, RK; Rocci, ML; Sirgo, MA; Vlasses, PH, 1985
)
0.27
" These results suggest that the dose of ranitidine should be adjusted in patients with severe renal failure who are undergoing hemodialysis, and a suitable schedule for dosing such patients is suggested."( Pharmacokinetics of ranitidine after intravenous administration in hemodialysis patients.
Baltodano, N; Garg, DC; Jallad, NS; Oster, JR; Perez, GO; Weidler, DJ, 1985
)
0.27
" In 5 cases gastric pH monitoring was repeated after continuation of the ranitidine treatment; healing of ulcer was observed in 4 cases, always associated with a nocturnal pH score lower than 10 (in 2 cases after increasing the dosage of ranitidine)."( [Does nocturnal monitoring of gastric pH permit the prediction of therapeutic response in severe duodenal ulcer treated with ranitidine?].
Colin, R; Denis, P; Galmiche, JP; Guillard, JF; Lehur, PA; N'Djitoyap, C; Tranvouez, JL,
)
0.13
" All volunteers were dosed with both bacampicillin and cefuroxime axetil under the above regimens."( Influence of food and reduced gastric acidity on the bioavailability of bacampicillin and cefuroxime axetil.
Moncrieff, J; Schoeman, HS; Sommers, DK; van Wyk, M, 1984
)
0.27
" With ranitidine under the dosage mentioned above, a prophylactic sufficient control, yet not a complete control of intragastric pH-value was accomplished."( [Control of the intragastric pH value in infection and peritonitis by ranitidine versus cimetidine. A double-blind study].
Hölscher, AH; Ketterl, R; Siewert, JR; Weiser, HF, 1984
)
0.27
" The more convenient dosage schedule of ranitidine may be important for patient compliance with initial therapy of peptic ulcer disease, and the greater duration of ranitidine antisecretory effects may enhance effectiveness of long-term maintenance therapy by providing more complete inhibition of nocturnal acid secretion."( Review of peptic ulcer maintenance trials.
Robinson, M, 1984
)
0.27
" Most of the commercially available and investigational compounds have similar efficacy; therefore the optimal drug may be the one associated with the fewest adverse effects and the most convenient dosing regimen."( Problems associated with medical treatment of peptic ulcer disease.
Zimmerman, TW, 1984
)
0.27
" Mepyramine alone displaced the histamine dose-response curve to the right."( Antagonism of vasodepressor and gastric secretory responses to histamine by the H2-receptor antagonists, ranitidine and cimetidine, in the anaesthetized dog.
Daly, MJ; Humphray, JM; Stables, R, 1981
)
0.26
"The H2-receptor antagonists ranitidine and cimetidine were tested against gastric secretory dose-response curves to histamine, pentagastrin and bethanechol in the Heidenhain-pouch dog."( The effect of ranitidine on gastric acid secretory response curves to histamine, pentagastrin or bethanechol in the dog with a Heidenhain pouch.
Bunce, KT; Daly, MJ; Humphray, JM; Stables, R, 1981
)
0.26
"Gastric mucosal lesions were produced in rats by dosing orally with aspirin, 300 mg/kg."( H2-receptor antagonists protect against aspirin-induced gastric lesions in the rat.
Bunce, KT; Daly, MJ; Humphray, JM; Stables, R, 1981
)
0.26
" Furthermore, chronic dosing with cimetidine does not result in tolerance to the inhibitory effect."( Inhibition of microsomal drug metabolism by histamine H2-receptor antagonists studied in vivo and in vitro in rodents.
Avant, GR; Mitchell, MC; Patwardhan, RV; Schenker, S; Speeg, KV, 1982
)
0.26
" Twice-daily dosage improved compliance."( Clinical and endocrine aspects of treatment with ranitidine.
Boyd, EJ; Browning, MC; Peden, NR; Saunders, JH; Wormsley, KG, 1981
)
0.26
" The reversal of the CMss/CFss gradient with the change from maternal to fetal administration and the low binding of the drug shows that the gradient following maternal dosage cannot be explained by ion-trapping or differential plasma protein binding."( Placental transfer of ranitidine during steady-state infusions of maternal and fetal sheep.
Cockbain, S; Hardy, KJ; MacLellan, D; Marshall, AW; Mihaly, GW; Morgan, DJ; Smallwood, RA, 1982
)
0.26
" It is suggested that dosage reduction is advisable in patients with severe renal failure and a suitable schedule for such patients is described."( Plasma ranitidine concentrations after intravenous administration in normal volunteers and haemodialysis patients.
Curtis, JR; Dixon, GT; Harrison, C; Roberts, AP, 1983
)
0.27
" In the recommended dosage of 150 mg twice daily, ranitidine is as effective as cimetidine in healing duodenal and gastric ulcers and has the advantages of less frequent dosing and fewer side effects."( Pharmacology and clinical efficacy of ranitidine, a new H2-receptor antagonist.
Helman, CA; Tim, LO,
)
0.13
" The recommended dosage schedules, however, are not satisfactory in a clinical routine practice."( [Ranitidine (Zantic) for aspiration prevention].
Schaer, H, 1983
)
0.27
" A dose-response relationship between ranitidine and PRL was established, and a dose of 65 mg ranitidine was found to be the minimal effective PRL-releasing dose."( Comparison between dose-responses of prolactin, thyroid stimulating hormone and growth hormone to two different histamine H-2 receptor antagonists in normal men.
Christiansen, PM; Dejgarrd, A; Knigge, U; Thuesen, B; Wollesen, F, 1981
)
0.26
" The 10 responders were studied both after a single 150 mg dose (SD) and after multiple dosing (MD) with ranitidine 150 mg twice daily for 4 weeks."( The pharmacokinetics of ranitidine in patients with chronic duodenal ulceration: a comparison of responders and non-responders.
Folb, PI; Marks, IN; McFadyen, ML; Miller, R; Moshal, MG, 1983
)
0.27
"The pharmacology, pharmacokinetics, clinical efficacy, adverse reactions, drug interactions, and dosage of ranitidine are reviewed; specific comparisons are made of this new H2-receptor antagonist with the older agent, cimetidine."( Ranitidine: a new H2-receptor antagonist.
Berner, BD; Conner, CS; Sawyer, DR; Siepler, JK,
)
0.13
" Nocturnal acid output was controlled significantly better with ranitidine at night, twice daily dosage of ranitidine, and cimetidine at night, than by the twice daily dosage of cimetidine."( Single nocturnal dose of an H2 receptor antagonist for the treatment of duodenal ulcer.
Buck, M; Gledhill, T; Howard, OM; Hunt, RH; Paul, A, 1983
)
0.27
" A significant difference was not found between the two cimetidine dosages, indicating dose independence of the interaction over the dosage range studied."( Inhibition of theophylline clearance by cimetidine but not ranitidine.
Cross, RE; Eshelman, FN; Powell, JR; Rogers, JF; Wargin, WA, 1984
)
0.27
" Lipid content is increased by ranitidine in livers of rats dosed with ethanol."( Effects of cimetidine and ranitidine on the "lipoperoxide" and lipid content of liver of rats treated with CCl4, colchicine, ethanol, ethionine and emetine.
Agostini, C; Di Segni, M, 1984
)
0.27
" From these results we conclude that, following endoscopic hemostasis of bleeding ulcers, Omeprazol has no advantage over Ranitidin using our dosage regimes."( [Do proton pump inhibitors after endoscopic control of acute ulcer hemorrhage have an advantage over H2 receptor antagonists?].
Barnert, J; Fleischmann, R; Hendrich, H; Prassler, R; Richter, G; Wienbeck, M, 1995
)
0.29
" A practical dosing recommendation, derived from these findings and reflective of the long-term nature of therapy for a disease such as osteoporosis, is that patients take the drug with water after an overnight fast and at least 30 minutes before any other food or beverage."( Studies of the oral bioavailability of alendronate.
Freeman, A; Gertz, BJ; Holland, SD; Kline, WF; Lasseter, KC; Matuszewski, BK; Mucklow, JC; Porras, AG; Quan, H, 1995
)
0.29
" Subsequently, this dosage of 200 units/ml rIL-2, which may respond to 10(6) units in vivo, was used alone or in combination with ranitidine (0."( Effect of ranitidine and low-dose interleukin-2 in vitro on NK-cell activity in peripheral blood from patients with liver metastases from colorectal cancer.
Hammer, JH; Moesgaard, F; Nielsen, HJ, 1995
)
0.29
"Blood ethanol concentrations after separate oral dosing and intravenous infusion of ethanol (0."( Ranitidine increases the bioavailability of postprandial ethanol by the reduction of first pass metabolism.
Bennett, MK; Brown, AS; Day, CP; Fiaterone, JR; James, OF; Kelly, PJ, 1995
)
0.29
" The drug dosage can be reduced, freeing the patient of the adverse reaction, but leaving behind a background activity adequate to produce a therapeutically beneficial effect."( A comparative overview of the adverse effects of antiulcer drugs.
Piper, DW, 1995
)
0.29
" All patients received 150 mg bd for 2 weeks, with those responding to treatment continuing on the same dosage for a further 2-week period and 'non-responders' having the dosage increased to 150 mg qds for a further 2 weeks."( The effect of ranitidine on symptom relief and quality of life of patients with gastro-oesophageal reflux disease.
Chal, KL; Sacks, GE; Stacey, JH,
)
0.13
"The involvement of immunological reactivity to ranitidine base (R-b) and ranitidine hydrochloride (R-HCl) in the development of occupationally related symptomatology was analyzed in 40 subjects employed in a pharmaceutical plant producing ranitidine and in 33 nonexposed controls, using a specific dose-response lymphocyte proliferative test (lymphocyte transformation test: LTT)."( Immunological reactivity in ranitidine factory workers.
Pagani, M; Pezzini, A; Riviera, AP; Rocca, M; Tridente, G; Zanoni, G, 1995
)
0.29
" Dosage requirements vary according to age and clinical condition, and children require a relatively higher drug dosage (mg/kg) than adults."( Do H2 receptor antagonists have a therapeutic role in childhood?
Kelly, DA, 1994
)
0.29
"The aim of this study was to identify dosage regimens using intravenous omeprazole and ranitidine that would elevate and consistently maintain intragastric pH > 6 in the first 24 hr of therapy."( Effect of repeated boluses of intravenous omeprazole and primed infusions of ranitidine on 24-hour intragastric pH in healthy human subjects.
Chari, ST; Scheid, J; Singer, MV; Teyssen, S, 1995
)
0.29
"-azithromycin dosage regime (83%) (95% CI = 52-98%) compared to the 250-mg-b."( Azithromycin triple therapy for Helicobacter pylori infection: azithromycin, tetracycline, and bismuth.
al-Assi, MT; Cole, RA; Genta, RM; Graham, DY; Karttunen, TJ, 1995
)
0.29
" Thirty minutes after dosing each subject was given 375 ml of 99mTc-DTPA (diethylene triaminepentaacetic acid) labelled Clinifeed-ISO."( Ranitidine bismuth citrate and ranitidine do not affect gastric emptying of a radio-labelled liquid meal.
Bedding, AW; Farr, SJ; Forster, ER; Parikh, R; Smith, JT; Sweetland, J, 1994
)
0.29
" Clemizole and reserpine treatment did not produce any modification of the dose-response curve to histamine."( Effect of histamine on the longitudinal and circular muscle of the oestrogen dominated rat uterus.
Estañ, L; Herrero, J; Martínez-Mir, I; Morales-Olivas, FJ; Rubio, E, 1993
)
0.29
" We conclude that gastric mucosal concentrations of histamine H2-receptor blockers achieved after oral dosing are probably too low to cause significant inhibition of gastric ADH in vivo."( Inhibition of gastric alcohol dehydrogenase activity by histamine H2-receptor antagonists has no influence on the pharmacokinetics of ethanol after a moderate dose.
Bergmann, JF; Blanc, LE; Delchier, JC; Dhumeaux, D; Dutreuil, C; Mallat, A; Roudot-Thoraval, F; Simonneau, G; Trout, H, 1994
)
0.29
" The inclusion of oral and intravenous dosage data of alcohol is mandatory to positively identify first-pass metabolism in any individuals."( H2-antagonists and alcohol. Do they interact?
Gugler, R, 1994
)
0.29
" Schedule dependency and dose-response evaluations involving Taxol were studied in the SC M109 model."( Taxol-based combination chemotherapy and other in vivo preclinical antitumor studies.
Rose, WC, 1993
)
0.29
" A program designed to reduce dosages to maintenance therapy after eight weeks at treatment dosage was developed by the Pharmacy and Therapeutics Committee with staff physician input."( Antiulcer prescribing program in a state correctional system.
Cason, DM; Helling, DK; Keith, MR, 1994
)
0.29
"The follow-up DUE showed the mean daily dosage for prescribed histamine2-receptor antagonists decreased (cimetidine from 694 to 454 mg, ranitidine from 280 to 183 mg) and the mean duration of therapy decreased from 14 to 10 months."( Antiulcer prescribing program in a state correctional system.
Cason, DM; Helling, DK; Keith, MR, 1994
)
0.29
" Histamine-2 receptor antagonist therapy is used prophylactically to treat gastric bleeding, but it is not known whether bolus dosing or continuous infusion dosing is more effective."( Effects of two dosing regimens of intravenous ranitidine on gastric pH in critically ill children.
Banner, W; Osteyee, JL, 1994
)
0.29
"To compare the effects of continuous infusion intravenous ranitidine and intravenous bolus dosing of ranitidine on gastric pH in critically ill children and to look for correlation between illness severity scores and gastric pH."( Effects of two dosing regimens of intravenous ranitidine on gastric pH in critically ill children.
Banner, W; Osteyee, JL, 1994
)
0.29
"Both bolus dosing and continuous infusion dosing of 4 mg/kg per day of intravenous ranitidine were effective at raising and maintaining gastric pH in critically ill children."( Effects of two dosing regimens of intravenous ranitidine on gastric pH in critically ill children.
Banner, W; Osteyee, JL, 1994
)
0.29
", in the dosage used and in a selected group of patients with gastrointestinal bleeding, is similar."( [The treatment of upper digestive hemorrhage of peptic origin: intravenous ranitidine versus intravenous omeprazole].
Blasco Colmenarejo, MM; Cabot Lozano, A; Caneiro Alcubilla, E; García Molinero, MJ; García-Rayo Somoza, M; Herrero Quirós, C; Pérez Flores, R, 1994
)
0.29
" These 9 subjects received each of the regimens for 72 h, and a wash-out period of at least 48 h followed each dosing period."( A dose-ranging study of ranitidine and its effect on intragastric and intra-oesophageal acidity in subjects with gastro-oesophageal reflux disease.
Babiuk, L; Bowes, K; Kirdeikis, P; Marriage, B; Thomson, AB; Zuk, L, 1994
)
0.29
" The subjects consumed 50 g alcohol after a standard lunch on the eighth day of dosing with study medication."( Lack of effect of H2-receptor antagonists on the pharmacokinetics of alcohol consumed after food at lunchtime.
Braithwaite, R; Gibson, GJ; Hale, KA; Kendall, MJ; Langman, MJ; Spannuth, F; Walt, RP, 1994
)
0.29
" After establishing a dose-response relationship for single or fractionated light dose illumination of the skin, drugs known to scavenge radicals, quench singlet oxygen or interfere with histamine release were tested for their protective effect."( Partial protection of photodynamic-induced skin reactions in mice by N-acetylcysteine: a preclinical study.
Baas, P; Oppelaar, H; Stewart, FA; van der Valk, MA; van Zandwijk, N, 1994
)
0.29
"High-dose once daily oral omeprazole dosing can inhibit acid secretion almost completely but several days elapse before maximum efficacy is established."( Comparison of acid inhibition by either oral high-dose ranitidine or omeprazole.
Abbühl, B; Halter, F; Hurlimann, S; Inauen, W, 1994
)
0.29
" Twenty-eight healthy volunteers were randomly assigned to a 2-week dosing with omeprazole or ranitidine in a double-blind, double-dummy, parallel-group study design."( Comparison of acid inhibition by either oral high-dose ranitidine or omeprazole.
Abbühl, B; Halter, F; Hurlimann, S; Inauen, W, 1994
)
0.29
" Prolonged high-dose histamine H2-receptor dosing compromises the feedback mechanism regulating gastrin release, whilst this is maintained during dosing with omeprazole."( Comparison of acid inhibition by either oral high-dose ranitidine or omeprazole.
Abbühl, B; Halter, F; Hurlimann, S; Inauen, W, 1994
)
0.29
" The ability of individually titrated ranitidine infusions to overcome circadian patterns of gastric acidity and tolerance during prolonged dosing was assessed."( Diurnal secretory patterns and tolerance during individually titrated infusions of ranitidine.
Halter, F; Merki, HS; Wilder-Smith, CH, 1993
)
0.29
"Eleven healthy subjects were randomized to receive ranitidine infusions of up to 600 mg/24 hours by a pH feedback-regulated pump before and after 9 days of oral dosing with ranitidine, 300 mg four times daily, beginning either in the evening or in the morning in a cross-over, third party-blinded and placebo-controlled study design."( Diurnal secretory patterns and tolerance during individually titrated infusions of ranitidine.
Halter, F; Merki, HS; Wilder-Smith, CH, 1993
)
0.29
"The reduced responsiveness to ranitidine in the evening and the tolerance to ranitidine with repeated dosing were not overcome by individually titrated, high intravenous doses of ranitidine."( Diurnal secretory patterns and tolerance during individually titrated infusions of ranitidine.
Halter, F; Merki, HS; Wilder-Smith, CH, 1993
)
0.29
"To investigate the effects of multiple dosing with ranitidine (300 mg four times a day) on the absorption of a moderate dose of alcohol (0."( Absence of effect of ranitidine on blood alcohol concentrations when taken morning, midday, or evening with or without food.
Holt, BI; Khan, AZ; Langley, SJ; Mullins, FG; Rowland, MM; Toon, S, 1994
)
0.29
"5 g/kg) of ethanol under four challenge conditions: (a) a single dose of placebo prior to alcohol ingestion in the morning, (b) a single dose of H2-antagonist prior to alcohol ingestion in the morning, (c) 14-day chronic dosing with H2-antagonist prior to alcohol ingestion in the evening, and (d) 28-day chronic dosing with H2-antagonist prior to alcohol ingestion in the morning."( Cimetidine and ranitidine. Lack of effect on the pharmacokinetics of an acute ethanol dose.
Chesher, GB; Dauncey, H; Palmer, RH, 1993
)
0.29
" It is possible that higher dosage regimen of ranitidine would be useful in patients with more severe duodenal ulcer disease."( [Effectiveness and safety of 150 mg vs 300 mg ranitidine twice a day in duodenal ulcer].
Carri, J; Hoffenberg, P; Jorge, A; Mendoza, S; Orillac, J; Padua-Videla, M; Pereyra, JC; Schraier, M; Villalobos, J; Waserstein, M, 1993
)
0.29
" In addition to the patient's age and the prescriber's medical specialty, specific DUE criteria included the reason given in the medical record for use; dosage regimen and adjustments made on the basis of the patient's renal function; other GI drugs taken concurrently; pharmacist intervention; simultaneous use of oral medications; occurrence of adverse events; H2-antagonist use with specified drug products known to affect serum drug concentrations of one or both medications; and use of gastric pH monitoring."( Use of i.v. cimetidine, ranitidine, and famotidine in 40 hospitals.
Ben-Joseph, R; Oh, T; Russell, WL; Segal, R, 1993
)
0.29
" They were obtained by the chi-square (chi 2) goodness-of-fit test, recently applied for the evaluation of dose-response curves."( Modern approach to the evaluation of combined effects of single-dose trials and clinical time-course studies, exemplified by combinations of pirenzepine and H2-receptor antagonists.
Londong, W; Pöch, G, 1993
)
0.29
" Gastric pH and dosing requirements were compared."( Do continuous infusions of omeprazole and ranitidine retain their effect with prolonged dosing?
Merki, HS; Wilder-Smith, CH, 1994
)
0.29
"Twenty-four-hour integrated intragastric acidity and 24-hr integrated plasma gastrin concentration was measured twice in 23 healthy male volunteers on the seventh day of oral dosing with placebo or ranitidine 150 mg four times a day."( Effects of ranitidine 150 mg four times a day on 24-hour intragastric acidity and 24-hour plasma gastrin concentration.
Fraser, AG; Hudson, M; Pounder, RE; Sawyerr, AM; Smith, M, 1994
)
0.29
" Serial blood samples were obtained for up to 12 hr after dosing and drug levels were determined by validated HPLC methods."( Application of dual radiotelemetric technique in studying drug-drug interaction between diclofenac sodium and ranitidine HCl in volunteers.
Alioth, C; Blum, RA; Chan, KK; D'Andrea, DT; Kochak, GM; Schentag, JJ; Teng, L; Ziehmer, BA, 1993
)
0.29
" The only risk factor for ranitidine was for patients who did not have their dosage corrected for renal function ("overdose"); these patients were twice as likely to experience a PADR compared with patients who received the correct dosage as determined by their renal function."( Risk for adverse events among patients receiving intravenous histamine2-receptor antagonists.
Ben-Joseph, R; Russell, WL; Segal, R, 1993
)
0.29
" From these data, we conclude that personalized maintenance therapy with omeprazole is the most cost-effective: a dosage of 20 mg/day is extremely effective in maintaining remission, and is therefore most indicated in patients at risk; omeprazole 20 mg/day every-other-day affords better compliance, lower costs and fewer relapses with respect to standard H2-antagonist dosages."( [Evaluation of the cost of maintenance therapy (6 months) with 150 mg ranitidine vs 20 mg omeprazole vs 20 mg omeprazole every other day in duodenal ulcer].
Battaglia, G; Chiozzini, G; De Bona, M; De Boni, M; Di Mario, F; Grasso, GA; Pasquino, M; Saggioro, A; Vianello, F, 1993
)
0.29
" This implies that concomitant dosing with ranitidine will not increase the adverse effects of moderate doses of ethanol on concentration and psychomotor function."( Comparative trial in volunteers to investigate possible ethanol-ranitidine interaction.
Ertl, D; Kleine, MW,
)
0.13
"During development of a ranitidine effervescent oral solution dosage form, a marked decrease was observed in the extent of ranitidine absorption relative to the conventional oral tablet."( Effect of sodium acid pyrophosphate on ranitidine bioavailability and gastrointestinal transit time.
Digenis, GA; Donn, KH; Koch, KM; Parr, AF; Powell, JR; Sandefer, EP; Tomlinson, JJ, 1993
)
0.29
" Twenty normal male subjects (age, 19-26 yr) were studied on the morning of the 8th day of twice-daily dosing with either 150 mg ranitidine or placebo."( Ranitidine has no effect on postbreakfast ethanol absorption.
Fraser, AG; Hudson, M; Pounder, RE; Rosalki, SB; Sawyerr, AM; Sercombe, J; Smith, MS, 1993
)
0.29
" There was no difference between the latter two dosing schedules in terms of both potency and duration of action in all the time intervals considered."( Twenty-four-hour control of gastric acidity by twice-daily doses of placebo, nizatidine 150 mg, nizatidine 300 mg, and ranitidine 300 mg.
Celle, G; Cutela, P; Mela, GS; Mele, R; Savarino, V; Zentilin, P, 1993
)
0.29
" Twenty four men with duodenal ulcers were studied before and on the 8th day of dosing with either ranitidine bismuth citrate 800 mg twice daily or ranitidine 300 mg twice daily (double blind, randomised, parallel groups)."( Effect of ranitidine bismuth citrate on postprandial plasma gastrin and pepsinogens.
Fraser, AG; Hudson, M; Lam, WM; Luk, YW; Pounder, RE; Samloff, IM; Sawyerr, AM; Sercombe, J, 1993
)
0.29
" Venous blood sampling for pharmacokinetic assessment was done over a complete dosing interval on day 7 of each phase."( Effects of cimetidine and ranitidine on the pharmacokinetics of a chronotherapeutically formulated once-daily theophylline preparation (Uniphyl).
Babul, N; Buttoo, KM; Fraser, IM; Stewart, JH; Walker, SE,
)
0.13
"To determine whether bismuth penetrates the gastric mucosa after dosing with ranitidine bismuth citrate."( Gastric persorption of bismuth from ranitidine bismuth citrate.
Fraser, AG; Lewin, JF; Pounder, RE, 1995
)
0.29
"Bismuth particles were found to be interposed between epithelial cells in the antral mucosa of three of eight patients who were dosed with ranitidine bismuth citrate."( Gastric persorption of bismuth from ranitidine bismuth citrate.
Fraser, AG; Lewin, JF; Pounder, RE, 1995
)
0.29
"Penetration of bismuth particles into the gastric mucosa may occur after oral dosing with ranitidine bismuth citrate."( Gastric persorption of bismuth from ranitidine bismuth citrate.
Fraser, AG; Lewin, JF; Pounder, RE, 1995
)
0.29
" Based on the observation that neither cimetidine nor ranitidine had a significant effect on serum concentrations of zidovudine or zidovudine glucuronide, a change in the dosage of zidovudine is not warranted."( The effect of cimetidine and ranitidine administration with zidovudine.
Balfour, HH; Fletcher, CV; Henry, WK; Noormohamed, SE; Rhame, FS,
)
0.13
" Subsequent treatment was allocated according to symptomatic response: responders remained on the initial dose for the remaining two weeks of the study, non-responders had their dosage increased to qds."( The effect of ranitidine (as effervescent tablets) on the quality of life of GORD patients.
Miocevich, ML; Sacks, GE; Stacey, JH, 1996
)
0.29
" Hourly dosing with hydrochloric acid reversed the protective effect of ranitidine, cimetidine and loxtidine on macroscopic damage and, histologically, this was associated with the widespread appearance of antral ulcers and a reduction in the proportion of mucosal damage caused by superficial erosions."( The role of acid in the pathogenesis of indomethacin-induced gastric antral ulcers in the rat.
Clayton, NM; Oakley, I; Trevethick, MA; Williams, LV, 1996
)
0.29
" is the currently recommended dosage in the United States for the treatment of erosive oesophagitis."( Ranitidine 300 mg twice daily and 150 mg four-times daily are effective in healing erosive oesophagitis.
Morrill, BB; Murdock, RH; Silver, MT; Sue, SO, 1996
)
0.29
"Subjects received extended-release oral theophylline at a constant dosage over 4 weeks to yield a serum concentration (Cp) between 5 and 10 micrograms/mL."( Effect of ranitidine on theophylline metabolism in healthy Koreans living in China.
Harralson, AF; Jones, DW; Kehoe, WA; Lan, HH; Long, LF; Sands, CD; Shin, HT, 1996
)
0.29
" For these reasons, we carried out a prospective pharmacodynamic investigation in 48 patients with endoscopically proven duodenal ulcer using the well-established once daily dosing schedule of H2 blockers."( Absence of tolerance in duodenal ulcer patients treated for 28 days with a bedtime dose of roxatidine or ranitidine.
Belicchi, M; Celle, G; Cutela, P; Di Mario, F; Ferrana, M; Malesci, A; Mela, GS; Savarino, V; Termini, R; Vigneri, S; Zentilin, P, 1996
)
0.29
" Blood samples (n = 18) were taken for 8 h after dosing and blood ethanol concentrations (BAC) were determined by head space analysis using a validated gas liquid chromatographic method."( Effect of ranitidine hydrochloride (150 mg twice daily) on the pharmacokinetics of increasing doses of ethanol (0.15, 0.3, 0.6 g kg-1).
Bye, A; Gupta, S; Lacey, LF; Powell, JR, 1996
)
0.29
" The aim of this study was to evaluate which dosage of PHT can maintain the therapeutic range in the early postoperative period."( Peri-operative prophylaxis with phenytoin: dosage and therapeutic plasma levels.
Boselli, L; Levati, A; Savoia, G; Tommasino, C; Zoppi, F, 1996
)
0.29
"Twenty-four healthy subjects were dosed with either famotidine 10 mg, ranitidine 75 mg or placebo in a balanced three-period cross-over design."( Early and late effects of low-dose famotidine, ranitidine or placebo on pentagastrin-stimulated gastric acid secretion in man.
Cottrell, J; Grimley, CE; Loft, DE; Mann, SG; Nwokolo, CU; Stauffer, L; West, JM, 1996
)
0.29
" During the late period (7-9 h post-dose), when the subjects were dosed with placebo, mean gastric acid output was 41."( Early and late effects of low-dose famotidine, ranitidine or placebo on pentagastrin-stimulated gastric acid secretion in man.
Cottrell, J; Grimley, CE; Loft, DE; Mann, SG; Nwokolo, CU; Stauffer, L; West, JM, 1996
)
0.29
" Thus, where it is therapeutically indicated to achieve greater suppression of acid secretion, doubling the total daily dose by dosing with twice daily versus once daily night time nizatidine or ranitidine is efficacious."( Twice daily nizatidine or ranitidine is superior to once daily dosing in elevating 24 h intragastric pH in patients with duodenal ulcer disease.
Bailey, RJ; Jamali, F; Kirdeikis, P; Mahachai, V; Marriage, B; Simpson, I; Thomson, AB; Zuk, L, 1996
)
0.29
"The twice-daily dosage of ranitidine was the only regimen found to reduce heartburn symptoms when compared with the baseline (P < ."( Double-blind, placebo-controlled study of ranitidine for gastroesophageal reflux symptoms during pregnancy.
Larson, JD; Miner, PB; Patatanian, E; Rayburn, WF; Robinson, MG, 1997
)
0.3
"Individual data from 1154 patients included in five independently conducted, randomized, long-term clinical trials of the efficacy of different dosage regimens of omeprazole, standard ranitidine treatment and placebo for the prevention of relapse of oesophagitis were pooled for this meta-analysis."( Prognostic factors influencing relapse of oesophagitis during maintenance therapy with antisecretory drugs: a meta-analysis of long-term omeprazole trials.
Carlsson, R; Dent, J; Frison, L; Galmiche, JP; Lundell, L, 1997
)
0.3
" Linkage to cisapride was probable, promoted by high dosage and cisapride metabolism inhibition by ranitidine, but its plasma concentration was not measured."( [Syncope with long QT interval in a 39 day-old infant treated with cisapride].
Autret, E; Champel, V; Jonville-Bera, AP; Olivier, C; Valdes, L, 1997
)
0.3
"This case report stresses the problem of cisapride dosage in infants and the question of an interaction between cisapride and ranitidine."( [Syncope with long QT interval in a 39 day-old infant treated with cisapride].
Autret, E; Champel, V; Jonville-Bera, AP; Olivier, C; Valdes, L, 1997
)
0.3
"Disposition pharmacokinetics of bismuth following oral dosing of ranitidine bismuth citrate are complicated and variable."( Modeling of trough plasma bismuth concentrations.
Bennett, JE; Lacey, LF; Wakefield, JC, 1997
)
0.3
"Profiles of 20-h intragastric acidity were measured simultaneously in 24 healthy subjects who were dosed (at 12."( Inhibition of intragastric acidity in healthy subjects dosed with ranitidine 75 mg: a comparative study with cimetidine and placebo.
Constantinides, S; Grimley, CE; Mills, JG; Nwokolo, CU; Snell, CC, 1997
)
0.3
" (i) Daytime (0-10 h post-dose): when dosed with placebo the weighted intragastric acidity was 31."( Inhibition of intragastric acidity in healthy subjects dosed with ranitidine 75 mg: a comparative study with cimetidine and placebo.
Constantinides, S; Grimley, CE; Mills, JG; Nwokolo, CU; Snell, CC, 1997
)
0.3
"30 h and were dosed (at 19."( Nocturnal intragastric acidity after over-the-counter doses of famotidine, ranitidine or placebo.
Cottrell, J; Grimley, CE; Mann, SG; Nwokolo, CU; Stauffer, L, 1997
)
0.3
" Ambulatory 24-hour intragastric pH values were monitored in each subject at baseline (2 days before crossover period 1) and again before dosing on day 5 of each of the four crossover treatment periods."( The comparative effects of lansoprazole, omeprazole, and ranitidine in suppressing gastric acid secretion.
Blum, RA; Greski-Rose, PA; Hunt, RH; Karol, MD; Shi, H,
)
0.13
"On a randomly selected day the clinical charts of 3685 inpatients were reviewed by a gastroenterologist and data were collected concerning the drug used, its dosage and indications for the prescription."( Are we correctly using the inhibitors of gastric acid secretion and cytoprotective drugs? Results of a multicentre study.
Comin, U; Cortelezzi, C; Curzio, M; Ferrara, A; Ferraris, L; Gullotta, R; Minoli, G; Prada, A; Rocca, F, 1997
)
0.3
" The possibility of an association between absorption kinetics from dosage forms in humans and Caco-2 monolayer permeability may allow for a direct kinetic interpretation of human oral absorption from Caco-2 monolayer permeability values."( Human drug absorption kinetics and comparison to Caco-2 monolayer permeabilities.
Ginski, MJ; Polli, JE, 1998
)
0.3
" pylori-negative patients, current dosing with a proton-pump inhibitor may result in insufficient acid control for optimal treatment of gastro-oesophageal reflux disease (GORD)."( Is the sensitivity to gastric acid inhibition Helicobacter pylori status-dependent?
Smout, AJ, 1998
)
0.3
" Such a synergistic effect probably explains the increased efficacy of RBC-clarithromycin dual therapies compared with clarithromycin dosed with acid-suppressive agents such as H2-receptor antagonists or proton-pump inhibitors."( New options in Helicobacter pylori eradication: efficacy, resistance and synergy.
Pipkin, GA; Williamson, R; Wood, JR, 1998
)
0.3
" The drug is marketed in a variety of dosage forms including tablets, syrups and injection solutions."( Optimisation, validation and application of a capillary electrophoresis method for the determination of ranitidine hydrochloride and related substances.
Altria, KD; Clark, BJ; Grace, C; Kelly, MA, 1998
)
0.3
" After dosing with bismuth alone or in association with ranitidine hydrochloride, bismuth was detected in several organs and deposition was not influenced by gastric pH."( Distribution of bismuth in the rat after oral dosing with ranitidine bismuth citrate and bismuth subcitrate.
Canena, J; Leitão, J; Pinheiro, T; Pinto, AS; Quina, MG; Reis, J; Santos, AM, 1998
)
0.3
" dosing schedule: RBC 400 mg plus clarithromycin 250 mg and tinidazole 500 mg (RBCCT): RBC 400 mg plus clarithromycin 500 mg and amoxycillin 1 g (RBCCA); RBC 400 mg plus tinidazole 500 mg and amoxycillin 1 g (RBCTA)."( Efficacy and safety of three 7-day Helicobacter pylori eradication regimens containing ranitidine bismuth citrate.
Bazzoli, F; Cannizzaro, O; D'Angelo, A; Ederle, A; Fossi, S; Gerace, G; Iaquinto, G; Olivieri, A; Pozzato, P; Reina, G; Ricciardiello, L; Roda, E; Scarpulla, G; Spadaccini, A; Tosatto, R; Zagari, M, 1998
)
0.3
" The data presented in this paper demonstrate the usefulness of NMR imaging in solid dosage form development."( Use of NMR imaging in the optimization of a compression-coated regulated release system.
Blazek, A; Chopra, SK; Fahie, BJ; Fyfe, CA; Grondey, H; Nangia, A, 1998
)
0.3
" Dosage and treatment duration were evaluated, along with the way in which morbidity, self-evaluated health, the demographic pattern and life-style characteristics influence drug prescription."( Antacid (A02A) and antiulcer (A02B) drug prescription patterns: predicting factors, dosage and treatment duration.
Girbes Pelechano, VJ; Llopis-González, A; Morales Suárez-Varela, MM; Pérez-Benajas, MA, 1998
)
0.3
" The effects of a minimum of 2 weeks of dosing with cimetidine, ranitidine and omeprazole were examined."( Omeprazole, ranitidine, and cimetidine have no effect on peak blood ethanol concentrations, first pass metabolism or area under the time-ethanol curve under 'real-life' drinking conditions.
Brown, AS; James, OF, 1998
)
0.3
"04 micrograms/kg IV cholecystokinin (CCK) sufficient to cause gall bladder emptying into the duodenum, and ranitidine 30 min after inflation of an occlusive duodenal balloon located approximately 10 cm distal to the pylorus to prevent pancreatico-biliary secretions from reaching the dosing port or beyond."( Effect of pancreatico-biliary secretions and GI transit time on the absorption and pharmacokinetic profile of ranitidine in humans.
Brouwer, KL; Burns, CB; Heizer, WD; Reynolds, KS; Sica, DA; Song, MH, 1998
)
0.3
" Repeat breath tests were completed on the last day of antisecretory dosing and study patients were immediately crossed over to the other ranitidine dose."( Effect of standard and high dose ranitidine on [13C]urea breath test results.
Brooks, E; Cutler, AF; Elnaggar, M; O'Mara, K, 1998
)
0.3
"Gastric pH was determined at the end of the ranitidine dosing interval, 1 hr after the dose, and at the midpoint between doses."( Gastric pH control in critically ill children receiving intravenous ranitidine.
Harrison, AM; Lugo, RA; Vernon, DD, 1998
)
0.3
" Among these patients, the pH at the end of the dosing interval was significantly lower than the pH measured at 1 hr or at the midpoint between doses (p < ."( Gastric pH control in critically ill children receiving intravenous ranitidine.
Harrison, AM; Lugo, RA; Vernon, DD, 1998
)
0.3
" When administered as a 50 mg 14C-labeled solution after a standard high fat meal, bioavailability of avitriptan decreased although the decrease was less compared with that observed for a capsule dosage form."( Evaluation of the effect of food on the pharmacokinetics of avitriptan.
Barbhaiya, RH; Greene, DS; Kollia, GD; Marathe, PH, 1998
)
0.3
"In a 1400-bed teaching hospital, an audit (by specially trained personnel) was conducted to monitor inpatient prescribing of omeprazole (1) in preference to H2-antagonists and other drugs according to agreed criteria (Helicobacter pylori eradication, severe reflux esophagitis, rapid ulcer healing deemed urgent because of severe symptoms or complications, high-dose steroid therapy of > or =30 mg/day prednisolone) and (2) appropriateness of intravenous dosing (oral route not feasible or contraindicated)."( Antiulcer drug prescribing in hospital successfully influenced by "immediate concurrent feedback".
Chan, CK; Cheung, E; Ching, TY; Chu, KM; Kong, Y; Kou, M; Kumana, CR; Lam, SK; Seto, WH, 1998
)
0.3
"BPD per se does not greatly affect the pharmacokinetic behavior of ranitidine, and therefore a conventional dosage regimen appears adequate for the prophylaxis and therapy of gastric ulcers associated with this operation."( Orally administered ranitidine plasma concentrations before and after biliopancreatic diversion in morbidly obese patients.
Caccia, S; Coppola, M; Cossu, ML; Fais, E; Fracasso, C; Nacca, A; Noya, G; Ruggiu, M, 1999
)
0.3
"At Cabrini Medical Center, drug usage evaluation (DUE) and monthly purchasing data analysis were used to determine the indications for which H2 antagonists were being used, the appropriateness of parenteral therapy, the use of extended dosing intervals, and the cost effectiveness of cimetidine (Tagamet)."( Multi-purpose evaluation of H2-antagonist usage.
Gianarkis, D, 1992
)
0.28
" Forty hospitals provided data about purchase prices for each IV H2-RA dosage form purchased (cimetidine, ranitidine, and famotidine), the number of each dosage form used during the 12-month study period, purchase price and extent of usage for supplies, labor costs for preparing and administering IV H2-RAs, and IV H2-RA dosage schedules."( A pharmacoeconomic analysis of IV H2-receptor antagonist use in 40 hospitals.
Ben-Joseph, R; Oh, T; Russell, WL; Segal, R, 1994
)
0.29
"To provide effective ranitidine therapy at the lowest possible cost to institutions and patients, the main study objectives were to develop a dosage intervention strategy for intermittent intravenous ranitidine and to document the resultant cost savings through cost-minimization analysis."( Adjusting dosage intervals of intermittent intravenous ranitidine according to creatinine clearance: a cost-minimization analysis.
Connelly, JF, 1994
)
0.29
" Major reasons for noncompliance among these patients were an absence of symptoms and an inconvenient dosage schedule."( Compliance with therapy for ulcer disease: clinical experience and review of the literature.
Battaglia, G; Bo, ND; DiMario, F; Ferrana, M; Mela, GS; Pilotto, A; Salandin, S; Savarino, V; Vianello, F; Vigneri, S,
)
0.13
"While the analysis of in vitro dissolution-in vivo absorption relationships from oral solid dosage forms provides biopharmaceutical insight and regulatory benefit, no well developed method exists to predict dissolution-absorption relationships a priori to human studies."( Prediction of dissolution-absorption relationships from a dissolution/Caco-2 system.
Ginski, MJ; Polli, JE, 1999
)
0.3
"To compare the efficacy of dosing ranitidine 75 mg or placebo 30 min prior to a proven heartburn-provoking meal in completely preventing or reducing subsequent heartburn symptoms."( A double-blind, placebo-controlled study of the efficacy and safety of non-prescription ranitidine 75 mg in the prevention of meal-induced heartburn.
Buaron, KS; Ciociola, AA; Mussari, KL; Pappa, KA; Payne, JE; Williams, BO, 1999
)
0.3
" The ranitidine 75 mg and 125 mg doses provided sustained relief (relief within 60 min of dosing that lasted throughout the 4-h evaluation period) to a greater proportion of patients for each individual episode (43-56% for 75 mg and 42-57% for 125 mg) than the ranitidine 25 mg dose (35-50%) or placebo (21-29%)."( An evaluation of increasing doses of ranitidine for treatment of heartburn.
Buaron, K; Giefer, EE; Pappa, KA; Payne, JE; Sirgo, MA, 1999
)
0.3
"In order to improve the efficacy and simplicity of the FDA-approved regimen of ranitidine bismuth citrate (RBC) and clarithromycin dual therapy, we added an inexpensive antibiotic (metronidazole), changed the dosage scheme to twice daily dosing, and decreased the duration of therapy to 1 week."( Efficacy of a 1-week regimen of ranitidine bismuth citrate in combination with metronidazole and clarithromycin for Helicobacter pylori eradication.
Cave, DR; Hoffman, JS; Katz, LM, 1999
)
0.3
" One group was dosed with lansoprazole 30 mg at 08."( The effect of Helicobacter pylori eradication on intragastric pH during dosing with lansoprazole or ranitidine.
Mulder, PG; Samsom, M; Smout, AJ; van Herwaarden, MA; van Nispen, CH, 1999
)
0.3
" Pre-treatment with a proton pump inhibitor, higher doses or more frequent dosing may be necessary to increase the cure rate of short duration regimens."( Comparison of two 3-day Helicobacter pylori eradication regimens with a standard 1-week regimen.
Cross, R; Grimley, CE; Illing, RC; Lismore, JR; Loft, DE; Nwokolo, CU; O'sullivan, M; Penny, A; Shebani, M, 1999
)
0.3
"To characterize the relationship between the pharmacokinetics and the acid inhibitory effect of ranitidine during prolonged dosing on the basis of a physiologic indirect-response model."( Pharmacodynamic modeling of the acid inhibitory effect of ranitidine in patients in an intensive care unit during prolonged dosing: characterization of tolerance.
Geus, WP; Mathôt, RA, 1999
)
0.3
" Overall, these results confirm that ranitidine can be formulated into pellet dosage forms with little or no MCC by the extrusion-spheronization process."( Formulation of ranitidine pellets by extrusion-spheronization with little or no microcrystalline cellulose.
Basit, AW; Lacey, LF; Newton, JM, 1999
)
0.3
" To adjust for the variable drug dosing used among study patients, both Cmax and area under the concentration curve (AUC) were standardized to dose (CmaxST and AUCST, respectively) and were 217."( The pharmacokinetics of oral ranitidine in children and adolescents with cystic fibrosis.
Argao, EA; Farrar, HC; James, LP; Menendez, AA; Stowe, CD, 1999
)
0.3
" Creatinine clearance was impaired in 26% of patients, though only one had dosage reduction."( The use of intravenous H2-receptor antagonists in a tertiary care hospital.
Byfield, F; Dettmer, RM; Green, PH; Riley, TH, 1999
)
0.3
" pylori eradication rate with a standard triple therapy regardless of the regimen utilized, the dosage and/or the duration of the therapy used appearing not to be sufficient to eradicate the infection efficiently."( Efficacy of different Helicobacter pylori eradication regimens in patients affected by insulin-dependent diabetes mellitus.
Armuzzi, A; Gasbarrini, A; Gasbarrini, G; Ghirlanda, G; Ojetti, V; Pitocco, D; Pola, P; Silveri, NG, 2000
)
0.31
" It is particular noteworthy that this weekly dosing schedule resulted in almost negligible toxicities."( Treatment of recurrent Kaposi's sarcoma of an AIDS patient with weekly paclitaxel.
Chen, MY; Cheng, AL; Hsu, CH,
)
0.13
") at a dosage of 300 or 450 mg/kg of body weight or subcutaneously (s."( Role of cytoprotectants and nitric oxide inhibition in nonsteroidal anti-inflammatory drug-induced gastroduodenal injury in the rat.
Albassam, MA; Lillie, LE; Macallum, GE; Percy, DH; Turner, PV, 2000
)
0.31
"Analysis of daily diary data during the first 4 weeks and for the entire 8 weeks of treatment revealed that patients who were treated with either dosage of lansoprazole reported significantly (P<."( Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease.
Campbell, DR; Fludas, C; Huang, B; Kahrilas, PJ; Richter, JE, 2000
)
0.31
" These studies show that it is possible to detect the active ingredients in the intact dosage form, even where the substance comprises <1% of the total mass of the tablet."( Evaluation of solid-state forms present in tablets by Raman spectroscopy.
Langkilde, FW; Taylor, LS, 2000
)
0.31
" treatment it is advisable to change antibiotics according to the probability of resistance, to increase dosage and duration of treatment and to include bismuth compounds in the second line regimen."( [Treatment of Helicobacter pylori infections].
Hentschel, E, 2000
)
0.31
" Flow-through electrodes, selective to chlorpromazine, amitriptyline, propantheline, cimetidine, and ranitidine, have been constructed and used for the dissolution studies of 18 dosage forms using the rotating basket apparatus."( Dissolution studies of drug formulations using ion-selective electrodes as sensors in an air-segmented continuous flow analyzer.
Christopoulos, TK; Diamandis, EP; Koupparis, MA; Mitsana-Papazoglou, A, 1987
)
0.27
" Dosage adjustments of orally administered topotecan should not be necessary in patients who are pretreated with ranitidine, an H2 antagonist, or another agent that comparably raises gastric pH."( Pretreatment with ranitidine does not reduce the bioavailability of orally administered topotecan.
Akhtar, S; Beckman, RA; Doyle, E; Fields, SZ; Mould, DR; Wright, J, 2000
)
0.31
"Enrolled were 65 AR patients with sensitivity to a single allergen, the Parietaria, 36 of whom were randomly assigned to treatment with ranitidine at a dosage of 1 mg/kg per day intravenously for 20 days, and 29 to placebo treatment."( Changes in serum interferon-gamma, interleukin-4, and interleukin-12 cytokine levels in anti-histamine type 2-treated allergic rhinitis patients.
Mesolella, C; Mesolella, M; Mosti, MR; Motta, G; Testa, B; Testa, D, 2001
)
0.31
" This assay may be used for the determination of purity, identity and strength for the active ingredient and finished dosage forms."( Ranitidine hydrochloride: development of an isocratic stability--indicating high-performance liquid chromatographic separation.
Munro, JS; Walker, TA, 2001
)
0.31
"To determine the pharmacokinetics and pharmacodynamics of ranitidine in critically ill children and to design a dosage regimen that achieves a gastric pH > or =4."( Pharmacokinetics and pharmacodynamics of ranitidine in critically ill children.
Cash, J; Harrison, AM; Lugo, RA; Sweeley, J; Vernon, DD, 2001
)
0.31
" The description of ranitidine's pharmacokinetics and pharmacodynamics in this study may used to design an initial ranitidine dosage regimen that targets a gastric pH > or =4."( Pharmacokinetics and pharmacodynamics of ranitidine in critically ill children.
Cash, J; Harrison, AM; Lugo, RA; Sweeley, J; Vernon, DD, 2001
)
0.31
" Two weeks treatment of E2011 alone at an oral dosage of 150 mg/kg induced hepatocellular changes characterized by nuclear enlargement."( Protection from drug-induced hepatocellular changes by pretreatment with conjugating enzyme inhibitors in rats.
Aoki, T; Hosokawa, S; Sagami, F; Sato, G; Tsukidate, K, 2001
)
0.31
" Toxicity management consisted of dosage reduction or treatment delay; treatment often was discontinued."( Pegylated liposomal doxorubicin: tolerability and toxicity.
Goram, AL; Richmond, PL, 2001
)
0.31
"25 mg (1) alone, (2) on the third day of dosing ranitidine 75 mg twice daily for 4 days, and (3) on the third day of dosing ranitidine 150 mg twice daily for 4 days."( Effect of ranitidine on the pharmacokinetics of triazolam and alpha-hydroxytriazolam in both young (19-60 years) and older (61-78 years) people.
Kersey, K; Koch, KM; Lam, R; O'Connor-Semmes, RL; Williams, DH, 2001
)
0.31
" This newly developed capillary electrophoresis (CE) method was applied for the determination of analytes extracted from plasma taken from a volunteer dosing a cimetidine, ranitidine, and nizatidine tablet simultaneously."( Head-column field-amplified sample stacking in capillary electrophoresis for the determination of cimetidine, famotidine, nizatidine, and ranitidine-HCl in plasma.
Chen, SH; Ho, YH; Ko, HS; Wu, HL; Wu, SM, 2001
)
0.31
"Healthy subjects (12 male, 12 female) were dosed on three occasions with single oral doses of placebo, ranitidine, 75 mg, and famotidine, 10 mg, 1 h after lunch."( Control of intragastric acidity with over-the-counter doses of ranitidine or famotidine.
Hamilton, MI; Pounder, RE; Sercombe, J, 2001
)
0.31
"5-h period following dosing (4."( Control of intragastric acidity with over-the-counter doses of ranitidine or famotidine.
Hamilton, MI; Pounder, RE; Sercombe, J, 2001
)
0.31
"In at least 84% of all subjects, both formats were effective in the communication of label objectives for the contraindication against concurrent prescription stomach ulcer medication, maximum daily dose, and maximum duration of dosing at maximum daily doses."( A study of the nonprescription drug consumer's understanding of the ranitidine product label and actual product usage patterns in the treatment of episodic heartburn.
Ciociola, AA; Fung, K; McGuire, JA; Pappa, KA; Sirgo, MA,
)
0.13
"The study demonstrated that the vast majority of a large sample of unsupervised consumers understood the package label and fully complied with the package directions by not exceeding the maximum daily dosage and length of use."( A study of the nonprescription drug consumer's understanding of the ranitidine product label and actual product usage patterns in the treatment of episodic heartburn.
Ciociola, AA; Fung, K; McGuire, JA; Pappa, KA; Sirgo, MA,
)
0.13
" These results suggest a dissolution/Caco-2 system to be an experimentally based tool that may predict dissolution-absorption relationships from oral solid dosage forms, and hence the relative contributions of dissolution and permeation to oral drug absorption kinetics."( Prediction of dissolution-absorption relationships from a continuous dissolution/Caco-2 system.
Ginski, MJ; Polli, JE; Taneja, R, 1999
)
0.3
" When dosed with placebo, mean daytime intragastric acidity (0-10 hr after dose) was 37."( Decrease of intragastric acidity in healthy subjects dosed with ranitidine 75 mg, cimetidine 200 mg, or placebo.
Hamilton, MI; Pounder, RE; Sercombe, J, 2002
)
0.31
" pylori eradication (which was possible in 84% of the patients), at the end of the 1-year study period, on an intention to treat basis 62% of the patients could either stop or significantly reduce dosage of their H2RA."( Helicobacter pylori eradication in patients on long-term H2 receptor antagonists. Economic and symptomatic benefits. A large prospective study in primary care.
Giaffer, MH; Verma, S, 2002
)
0.31
" pylori eradication led to significant improvement in symptom scores and reduction in dosage of H2RA being consumed."( Helicobacter pylori eradication in patients on long-term H2 receptor antagonists. Economic and symptomatic benefits. A large prospective study in primary care.
Giaffer, MH; Verma, S, 2002
)
0.31
" Pharmacopeia (USP) apparatus 3 can be used as an alternative to USP apparatus 2 for dissolution testing of immediate-release (IR) dosage forms."( Evaluation of USP apparatus 3 for dissolution testing of immediate-release products.
Hussain, AS; Wang, JT; Yu, LX, 2002
)
0.31
" The large variability limited our ability to test for a difference in fat absorption and has significant implication for the use of this test, considered the gold standard, for determining enzyme dosage adequacy."( Ranitidine and omeprazole as adjuvant therapy to pancrelipase to improve fat absorption in patients with cystic fibrosis.
Bowser, E; Francisco, MP; Novak, DA; Sherman, JM; Theriaque, D; Wagner, MH, 2002
)
0.31
" The proposed method was used successfully for stability testing of the pure drugs in the presence of up to 90% of their degradates, in bulk powder and dosage forms."( Determination of cimetidine, famotidine, and ranitidine hydrochloride in the presence of their sulfoxide derivatives in pure and dosage forms by high-performance thin-layer chromatography and scanning densitometry.
Aziz, AM; Farrah, LA; Hegazy, MA; Kelani, KM,
)
0.13
"The ANN could be used for predicting the dissolution profiles of sustained release dosage form and for the design of optimal formulation."( [Application of an artificial neural network in the design of sustained-release dosage forms].
Liang, WQ; Wei, XH; Wu, JJ, 2001
)
0.31
"Three simple, accurate and sensitive colorimetric methods (A, B and C) for the determination of ranitidine HCl (RHCl) in bulk sample, in dosage forms and in the presence of its oxidative degradates are described."( Utility of oxidation-reduction reaction for the determination of ranitidine hydrochloride in pure form, in dosage forms and in the presence of its oxidative degradates.
Ahmed, IS; Amin, AS; Dessouki, HA; Gouda, EA, 2003
)
0.32
"Weekly dosing of paclitaxel has been demonstrated to be a well-tolerated, feasible and effective administration schedule."( Multicenter phase II trial of weekly paclitaxel for advanced or metastatic breast cancer: the Saitama Breast Cancer Clinical Study Group (SBCCSG-01).
Inoue, K; Kai, T; Koh, J; Mihara, H; Mochizuki, H; Okubo, K; Saito, T; Sato, K; Tabei, T, 2003
)
0.32
" Split dosing of rabeprazole was more effective than the single morning dose for inhibiting nocturnal gastric acid secretion."( Nocturnal gastric acid breakthrough during the administration of rabeprazole and ranitidine in Helicobacter pylori-negative subjects: effects of different regimens.
Adachi, K; Amano, Y; Fujishiro, H; Karim Rumi, MA; Kawamura, A; Kinoshita, Y; Komazawa, Y; Mihara, T; Ono, M; Yuki, M, 2003
)
0.32
" This method was successfully applied for ranitidine assay from pharmaceutical dosage forms."( [Visible spectrophotometric assay of ranitidine].
Apostu, M; Bibire, N; Dorneanu, V,
)
0.13
" Three decision trees for solid oral dosage forms or liquid suspensions are provided for evaluating when and how polymorphs of drug substances should be monitored and controlled in ANDA submissions."( Regulatory considerations of pharmaceutical solid polymorphism in Abbreviated New Drug Applications (ANDAs).
Adams, RC; Furness, MS; Gill, DS; Holcombe, FO; Raw, AS; Yu, LX, 2004
)
0.32
" In addition, L-OMP is advantageous in its once-a-day dosing and might be an alternative to S-H2RA, especially in Korean patients with MMRE."( [Therapeutic effect of low-dose omeprazole vs. standard-dose ranitidine in mild to moderate reflux esophagitis].
Baik, SK; Cho, MY; Kim, HS; Kim, JM; Kim, JW; Kwon, SO; Lee, DK; Suk, KT, 2004
)
0.32
"Gastric pH measurements, guaiac test results, appearance of gastric aspirates, and ranitidine and antacid dosing were recorded."( Evaluation of gastric pH and guaiac measurements in neonates receiving acid suppression therapy during extracorporeal membrane oxygenation.
Bugnitz, MC; Crill, CM; Hak, EB, 2004
)
0.32
" The percentage of time that serum concentrations remain above the MIC(90) during the dosing interval (T > MIC(90)) for Streptococcus pyogenes and Staphylococcus aureus associated with the pharmacokinetic profiles was calculated."( A randomized crossover study investigating the influence of ranitidine or omeprazole on the pharmacokinetics of cephalexin monohydrate.
Adejare, A; George, M; Madaras-Kelly, K; May, MP; Michas, P, 2004
)
0.32
"Literature and experimental data relevant to the decision to allow a waiver of in vivo bioequivalence testing for the approval of immediate release (IR) solid oral dosage forms containing ranitidine hydrochloride are reviewed."( Biowaiver monographs for immediate release solid oral dosage forms: ranitidine hydrochloride.
Barends, DM; Dressman, JB; Junginger, HE; Kortejärvi, H; Midha, KK; Shah, VP; Yliperttula, M, 2005
)
0.33
"The results of our study indicated that in patients over 50 years of age who are treated with ranitidine, the dosage of this agent should be appropriately adjusted in order to avoid adverse effects that may develop with prolonged use of the drug."( Effect of age on the pharmacokinetics of ranitidine in healthy Mexican volunteers.
Camacho-Vieyra, A; Carrasco-Portugal, M; Flores Pérez, C; Flores-Pŕez, J; Guillé-Pérez, A; Juárez-Olguín, H; Lares-Asseff, I; Pérez-Guillé, G; Toledo-López, A, 2005
)
0.33
" Because the design, dosage and duration of the treatments were different between the studies, it was not possible to conduct meta-analysis."( Additional bedtime H2-receptor antagonist for the control of nocturnal gastric acid breakthrough: a Cochrane systematic review.
Liu, FC; Pan, T; Wang, YP; Yang, JL, 2006
)
0.33
"Oral dosage of the H2 receptor antagonists, ranitidine and famotidine, has no significant effect on gastric emptying."( Influence of acid suppressants on gastric emptying: cross-over analysis in healthy volunteers.
Amano, Y; Ishihara, S; Kinoshita, Y; Kushiyama, Y; Miyake, T; Ose, T; Sato, S; Takahashi, Y; Yuki, T, 2006
)
0.33
" The enhanced bioavailability and elimination half-life observed in the present study may be due to the floating nature of the dosage form."( Controlled release calcium silicate based floating granular delivery system of ranitidine hydrochloride.
Agrawal, GP; Jain, AK; Jain, SK; Yadav, A, 2006
)
0.33
"Impurity profiling of pharmaceutical drug substances or dosage formulations require methods involving high sensitivity and resolution from LC and MS alike as well as an acceptable analysis time."( The application of sub-2-microm particle liquid chromatography-operated high mobile linear velocities coupled to orthogonal accelerated time-of-flight mass spectrometry for the analysis of ranitidine and its impurities.
Jones, MD; Plumb, RS, 2006
)
0.33
" She subsequently received maintenance dosing in the outpatient clinic weekly for 4 weeks and bimonthly for 8 weeks, and she continues monthly maintenance VIT."( Ultrarush venom desensitization after systemic reactions during conventional venom immunotherapy.
Chegini, S; Hamilos, DL; Oren, E, 2006
)
0.33
" The proposed method was successfully applied to the determination of the investigated drugs in pure and pharmaceutical dosage forms (recovery was 98."( Spectrophotometric determination of H(2)-receptor antagonists via their oxidation with cerium(IV).
Darwish, IA; Hassan, AI; Hussein, SA; Mahmoud, AM, 2008
)
0.35
" The aim of this study was to determine whether appropriate dosage adjustments were made for drugs that are nephrotoxic, excreted, or metabolized (TEM medications) by the kidney in patients with renal impairment."( Medication dosing errors in hospitalized patients with renal impairment: a study in Palestine.
Abu-Taha, AS; Al-Jabi, SW; Janem, SA; Jaradat, NA; Sabri, IA; Sawalha, AF; Sweileh, WM; Zaid, AA; Zyoud, SH, 2007
)
0.34
" Evaluation of appropriate dosing was based on Physician Disk Reference (PDR)."( Medication dosing errors in hospitalized patients with renal impairment: a study in Palestine.
Abu-Taha, AS; Al-Jabi, SW; Janem, SA; Jaradat, NA; Sabri, IA; Sawalha, AF; Sweileh, WM; Zaid, AA; Zyoud, SH, 2007
)
0.34
" Dosage adjustment was necessary for 193 TEM medications."( Medication dosing errors in hospitalized patients with renal impairment: a study in Palestine.
Abu-Taha, AS; Al-Jabi, SW; Janem, SA; Jaradat, NA; Sabri, IA; Sawalha, AF; Sweileh, WM; Zaid, AA; Zyoud, SH, 2007
)
0.34
"In our study, a wide range of dosing errors was common among patients with renal impairment that was common during hospitalization."( Medication dosing errors in hospitalized patients with renal impairment: a study in Palestine.
Abu-Taha, AS; Al-Jabi, SW; Janem, SA; Jaradat, NA; Sabri, IA; Sawalha, AF; Sweileh, WM; Zaid, AA; Zyoud, SH, 2007
)
0.34
" pylori treatment: effectiveness (>80%), simplicity (twice-daily dosing and excellent compliance) and safety (low incidence of adverse effects)."( First-line triple therapy with levofloxacin for Helicobacter pylori eradication.
Fernández-Bermejo, M; Gisbert, JP; González-García, G; Mateos-Rodríguez, JM; Molina-Infante, J; Pérez-Gallardo, B; Prieto-Bermejo, AB; Robledo-Andrés, P, 2007
)
0.34
" Concomitant administration of silymarin at this dosage did not alter ranitidine C(max) and AUC(0-infinity)."( Effect of silymarin on the oral bioavailability of ranitidine in healthy human volunteers.
Kumar, YS; Rao, BN; Rao, YM; Srinivas, M, 2007
)
0.34
"The real issue in the development of oral controlled release dosage forms is not just to prolong the delivery of drugs but also to prolong the presence of dosage forms in the stomach in order to improve the bioavailability of drugs with a 'narrow absorption window'."( In vitro and in vivo evaluation of ranitidine hydrochloride ethyl cellulose floating microparticles.
Dandagi, PM; Gadad, AP; Kulkarni, AR; Mastiholimath, VS; Mathews, R, 2008
)
0.35
" Pharmacological factors, in addition to the dosage regimen, favor development of a sustained-release system for ranitidine especially in the therapeutic condition of erosive esophagitis."( Bioadhesive ranitidine hydrochloride for gastroretention with controlled microenvironmental pH.
Adhikary, A; Vavia, PR, 2008
)
0.35
"The objective of this investigation was to develop the hollow microspheres as a new dosage form of floating drug delivery systems with prolonged stomach retention time."( In vitro and in vivo evaluation of ranitidine hydrochloride loaded hollow microspheres in rabbits.
Wei, YM; Zhao, L, 2008
)
0.35
" The dosage of the MMT-RT/Eudragit E-100 can be in the tablet form."( Controlled release formulation of ranitidine-containing montmorillonite and Eudragit E-100.
Bajaj, HC; Joshi, GV; Kevadiya, BD, 2010
)
0.36
"1 mol/l HCl-KCl buffer should be administered orally, 15 min before the dosage form."( Modification of gastric pH in the fasted dog.
Abrahamsson, B; Albery, T; Dressman, J; Polentarutti, B, 2010
)
0.36
" The prednisolone dosage was tapered over 3 - 8 weeks."( [Juvenile sterile granulomatous dermatitis and lymphadenitis in the dog].
Eule, C; Kohn, B; Weingart, C; Welle, M, 2011
)
0.37
" Doubling clopidogrel dosage to 150 mg restored the basal response."( Doubling the dose of clopidogrel restores the loss of antiplatelet effect induced by esomeprazole.
Cerboni, P; Doyen, D; Ferrari, E; Moceri, P, 2011
)
0.37
" For this reason, the dosage of [corrected] these drugs should be carefully evaluated [corrected] to minimize side effects."( Effects of some drugs on human cord blood erythrocyte carbonic anhydrases I and II: an in vitro study.
Aktas, M; Cankaya, M; Coban, TA; Gül, İ; Kuzucu, M, 2012
)
0.38
" The proposed method can be used for the determination of the three H(2) antagonists in raw materials, dosage forms and biological fluids."( Determination of ranitidine, nizatidine, and cimetidine by a sensitive fluorescent probe.
Chang, YX; Du, LM; Guo, M; Li, CF; Qiu, YQ, 2011
)
0.37
"The objective of this investigation was to develop the hollow microspheres as a new dosage form of floating drug delivery system with prolonged stomach retention time."( Preparation of Eudragit E100 microspheres by modified solvent evaporation method.
Chaudhary, AK; Singh, V,
)
0.13
" We have assessed in vivo the mortality-reducing efficacy of a group of known AChE inhibitors, when given in equitoxic dosage before exposure to the OPC paraoxon."( Usefulness of administration of non-organophosphate cholinesterase inhibitors before acute exposure to organophosphates: assessment using paraoxon.
Hasan, MY; Kuča, K; Lorke, DE; Nurulain, SM; Petroianu, GA; Shafiullah, M, 2013
)
0.39
" However, our findings suggest that a dosing scheme that takes into consideration both weight and cardiac failure/surgery would be more appropriate in order to avoid administration of higher or more frequent doses than necessary."( Prophylactic ranitidine treatment in critically ill children--a population pharmacokinetic study.
Collier, PS; Halliday, HL; Hawwa, AF; McElnay, JC; Millership, JS; Nunn, AJ; Shields, MD; Thurley, G; Westwood, PM; Yakkundi, S, 2013
)
0.39
" Greater potency of famotidine may offer clinical advantage due to lower drug exposure and less frequent dosing to achieve same pH lowering effect."( Pharmacokinetics and pharmacodynamics of famotidine and ranitidine in critically ill children.
Kauffman, R; Lai, ML; Lehr, VT; Madani, S; Sarniak, A; Simpson, P; Tolia, V, 2014
)
0.4
" The optimized FCS was combined with immediate release granules of rantidine HCl to get a bifunctional capsular dosage form."( Bifunctional capsular dosage form: novel fanicular cylindrical gastroretentive system of clarithromycin and immediate release granules of ranitidine HCl for simultaneous delivery.
Pathak, K; Rajput, P; Singh, D, 2014
)
0.4
"To review the product information (PI) for various brands of the same generic drugs and investigate the extent to which information is currently available on dosing in renal impairment and the concordance between the dosing recommendations for the same generic drug."( Renal drug dosing recommendations: evaluation of product information for brands of the same drug.
Castelino, RL; Jose, MD; Khanal, A; Peterson, GM, 2014
)
0.4
" For each generic drug all available brands listed as having solid oral dosage form were recorded."( Renal drug dosing recommendations: evaluation of product information for brands of the same drug.
Castelino, RL; Jose, MD; Khanal, A; Peterson, GM, 2014
)
0.4
" The majority of PI documents (88 of 155 PI; 57%) provided quantitative dosage recommendations, but this was often not detailed enough to help users to make an informed decision."( Renal drug dosing recommendations: evaluation of product information for brands of the same drug.
Castelino, RL; Jose, MD; Khanal, A; Peterson, GM, 2014
)
0.4
"The reporting of renal function quantification methods, and associated dosage recommendations, in PI requires standardisation to ensure optimal drug dosing."( Renal drug dosing recommendations: evaluation of product information for brands of the same drug.
Castelino, RL; Jose, MD; Khanal, A; Peterson, GM, 2014
)
0.4
" Protection was quantified using Cox analysis by determining the relative risk (RR) of death in rats that were administered these AChE inhibitors in equitoxic dosage (25% of LD01) 30 min before azinphos-methyl exposure."( Reversible cholinesterase inhibitors as pre-treatment for exposure to organophosphates: assessment using azinphos-methyl.
Hasan, MY; Kuča, K; Lorke, DE; Nurulain, SM; Petroianu, GA, 2015
)
0.42
"Conventional sustained dosage form of ranitidine hydrochloride (HCl) does not prevent frequent administration due to its degradation in colonic media and limited absorption in the upper part of GIT."( Formulation and evaluation of floating tablet of H2-receptor antagonist.
Kesarla, RS; Omri, A; Patel, G; Sridhar, BK; Vora, PA, 2015
)
0.42
" Moreover, the dosage form was found to be floating within a fraction of second independent of the pH of media ensuring a robust formulation."( Formulation and evaluation of floating tablet of H2-receptor antagonist.
Kesarla, RS; Omri, A; Patel, G; Sridhar, BK; Vora, PA, 2015
)
0.42
" In the ranitidine study, on day 13, participants were randomized to either concomitant dosing (treatment B) or staggered administration (treatment C) of erlotinib and ranitidine and crossed over to the other treatment starting on day 27."( Effect of gastric pH on erlotinib pharmacokinetics in healthy individuals: omeprazole and ranitidine.
Abt, M; Ducray, PS; Giraudon, M; Hamilton, M; Kletzl, H; Lum, BL, 2015
)
0.42
" Indeed, histamine elicited a sigmoid dose-response curve for IP3 production, shifted to the right by chlorpheniramine maleate, and elicited a double bell-shaped curve for cAMP production, partially suppressed by the selective H2R, H3R and H4R antagonists when each added alone, and completely ablated when combined together."( Histamine receptor expression in human renal tubules: a comparative pharmacological evaluation.
Camussi, G; Chazot, PL; Grange, C; Lanzi, C; Moggio, A; Pini, A; Rosa, AC; Veglia, E, 2015
)
0.42
"To examine the effects of PO administered ranitidine and omeprazole on intragastric pH in cats and to compare the efficacy of once-daily versus twice-daily dosage regimens for omeprazole."( The effect of orally administered ranitidine and once-daily or twice-daily orally administered omeprazole on intragastric pH in cats.
Hartnack, S; Kook, PH; Reusch, CE; Ruetten, M; Šutalo, S,
)
0.13
"To determine how many ambulatory older adults with chronic kidney disease receive medications that are contraindicated or dosed excessively given their level of renal function."( Use of Renally Inappropriate Medications in Older Veterans: A National Study.
Chang, F; Miao, Y; O'Hare, AM; Steinman, MA, 2015
)
0.42
" The proposed IPC method was successfully applied for the determination of pharmaceutical dosage forms without prior need for separation."( An Efficient Ion-Pair Liquid Chromatographic Method for the Determination of Some H2 Receptor Antagonists.
Ahmed, S; Elshaboury, SR; Farrag, S; Mohamed, NA, 2016
)
0.43
"BioGIT system could be useful for the evaluation of the impact of gastrointestinal transfer on concentrations in the upper intestinal lumen during the first hour, after oral administration of dispersing/solution dosage forms of lipophilic weak bases."( An in vitro biorelevant gastrointestinal transfer (BioGIT) system for forecasting concentrations in the fasted upper small intestine: Design, implementation, and evaluation.
Augustijns, P; Brouwers, J; Kourentas, A; Reppas, C; Stavrinoudakis, N; Symillides, M; Symillidis, A; Vertzoni, M, 2016
)
0.43
" No abnormal alterations were observed in normal rats treated with HAEPD at the dosage studied."( Effect of Pithecellobium dulce (Roxb.) Benth. fruit extract on cysteamine induced duodenal ulcer in rats.
Geetha, A; Megala, J, 2015
)
0.42
" Ranitidine (50mg/kg) was dissolved in water with different amounts of PEG 400-0 (control), 13, 26, 51, 77, 103, and 154mg/kg; these solutions were dosed orally by gavage to male and female Wistar rats."( Sex differences in excipient effects: Enhancement in ranitidine bioavailability in the presence of polyethylene glycol in male, but not female, rats.
Afonso-Pereira, F; Basit, AW; Murdan, S; Sousa, J; Veiga, F, 2016
)
0.43
"Fostamatinib is an orally dosed phosphate prodrug that is cleaved by intestinal alkaline phosphatase to the active metabolite R406."( Effects of ranitidine (antacid), food, and formulation on the pharmacokinetics of fostamatinib: results from five phase I clinical studies.
Flanagan, T; Gillen, M; Kruusmägi, M; Lisbon, E; Martin, P; Mathews, D, 2017
)
0.46
" The developed method was simple, rapid and reliable hence it could be applied for routine quality control analysis of the investigated H2-receptor antagonists in dosage forms."( Development of a Validated Comparative Stability-Indicating Assay Method for Some H2-Receptor Antagonists.
Ahmed, S; Elshaboury, SR; Farrag, S; Mohamed, NA, 2017
)
0.46
" This work intends to evaluate once-daily, 40 mg omeprazole and once-nightly, 300 mg ranitidine (QD/QHS) dosing as an alternative regimen, and use this study's cohort to evaluate empiric regimens prescribed for LPR as compared to up-front testing with pH impedance multichannel intraluminal impedance (MII) with dual pH probes and high-resolution manometry (HRM) for potential cost minimization."( Rethinking the laryngopharyngeal reflux treatment algorithm: Evaluating an alternate empiric dosing regimen and considering up-front, pH-impedance, and manometry testing to minimize cost in treating suspect laryngopharyngeal reflux disease.
Carroll, TL; Dezube, A; Nahikian, K; Roth, DF; Werner, A, 2017
)
0.46
" Initial QD/QHS dosing increased after 3 months to BID if no improvement and ultimately prescribed MII and HRM if they failed BID dosing."( Rethinking the laryngopharyngeal reflux treatment algorithm: Evaluating an alternate empiric dosing regimen and considering up-front, pH-impedance, and manometry testing to minimize cost in treating suspect laryngopharyngeal reflux disease.
Carroll, TL; Dezube, A; Nahikian, K; Roth, DF; Werner, A, 2017
)
0.46
" Furthermore, a drug interaction study with trospium chloride after intravenous (2 mg) and oral dosing (30 mg) plus ranitidine (300 mg) was performed in 12 healthy subjects and evaluated by noncompartmental analysis and population pharmacokinetic modeling."( Pharmacokinetic Drug-Drug Interactions Between Trospium Chloride and Ranitidine Substrates of Organic Cation Transporters in Healthy Human Subjects.
Abebe, BT; Meyer, MJ; Modess, C; Neumeister, C; Scheuch, E; Schulz, HU; Schwantes, U; Siegmund, W; Tadken, T; Tzvetkov, M; Wegner, D; Weiss, M, 2020
)
0.56
"A non-destructive discrimination method for crystals in solid dosage drug forms was first developed using a combination of Raman spectroscopy and X-ray micro-computed tomography (X-ray CT)."( Discrimination of ranitidine hydrochloride crystals using X-ray micro-computed tomography for the evaluation of three-dimensional spatial distribution in solid dosage forms.
Amano, Y; Ando, D; Goda, Y; Izutsu, KI; Kanazawa, H; Koide, T; Miyazaki, S; Miyazaki, T; Takeda, Y; Yamamoto, E, 2021
)
0.62
" This may provide a practical means to stabilize ranitidine DS and solid dosage formulations against NDMA formation."( Ranitidine: A Proposed Mechanistic Rationale for NDMA Formation and a Potential Control Strategy.
Harmon, P, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (5)

RoleDescription
anti-ulcer drugOne of various classes of drugs with different action mechanisms used to treat or ameliorate peptic ulcer or irritation of the gastrointestinal tract.
H2-receptor antagonistH2-receptor antagonists are the drugs that selectively bind to but do not activate histamine H2 receptors, thereby blocking the actions of endogenous histamine.
environmental contaminantAny minor or unwanted substance introduced into the environment that can have undesired effects.
xenobioticA xenobiotic (Greek, xenos "foreign"; bios "life") is a compound that is foreign to a living organism. Principal xenobiotics include: drugs, carcinogens and various compounds that have been introduced into the environment by artificial means.
drug allergenAny drug which causes the onset of an allergic reaction.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (5)

ClassDescription
aralkylamineAn alkylamine in which the alkyl group is substituted by an aromatic group.
furansCompounds containing at least one furan ring.
tertiary amino compoundA compound formally derived from ammonia by replacing three hydrogen atoms by organyl groups.
C-nitro compoundA nitro compound having the nitro group (-NO2) attached to a carbon atom.
organic sulfideCompounds having the structure RSR (R =/= H). Such compounds were once called thioethers.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (2)

PathwayProteinsCompounds
Ranitidine Action Pathway1012
Drug induction of bile acid pathway025

Protein Targets (44)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, HADH2 proteinHomo sapiens (human)Potency3.16230.025120.237639.8107AID886
Chain B, HADH2 proteinHomo sapiens (human)Potency3.16230.025120.237639.8107AID886
acetylcholinesteraseHomo sapiens (human)Potency19.65370.002541.796015,848.9004AID1347395; AID1347397; AID1347398
RAR-related orphan receptor gammaMus musculus (house mouse)Potency26.72060.006038.004119,952.5996AID1159521; AID1159523
USP1 protein, partialHomo sapiens (human)Potency17.78280.031637.5844354.8130AID504865
NFKB1 protein, partialHomo sapiens (human)Potency0.70790.02827.055915.8489AID895; AID928
GLS proteinHomo sapiens (human)Potency5.62340.35487.935539.8107AID624146
AR proteinHomo sapiens (human)Potency26.83250.000221.22318,912.5098AID743063
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)Homo sapiens (human)Potency3.98110.00137.762544.6684AID914; AID915
thyroid stimulating hormone receptorHomo sapiens (human)Potency7.94330.001318.074339.8107AID926; AID938
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency15.35530.000657.913322,387.1992AID1259377
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency10.96400.01237.983543.2770AID1645841
estrogen nuclear receptor alphaHomo sapiens (human)Potency33.80740.000229.305416,493.5996AID743069; AID743079
cytochrome P450 2D6Homo sapiens (human)Potency15.48710.00108.379861.1304AID1645840
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency11.22020.035520.977089.1251AID504332
cytochrome P450 2C19 precursorHomo sapiens (human)Potency39.81070.00255.840031.6228AID899
chromobox protein homolog 1Homo sapiens (human)Potency89.12510.006026.168889.1251AID488953
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency89.12510.050127.073689.1251AID588590
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency0.02030.005612.367736.1254AID624032
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency17.78280.251215.843239.8107AID504327
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency15.84890.00106.000935.4813AID943
lamin isoform A-delta10Homo sapiens (human)Potency0.07940.891312.067628.1838AID1487
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency37.93300.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Bile salt export pumpRattus norvegicus (Norway rat)IC50 (µMol)1,000.00000.40002.75008.6000AID1209456
Bile salt export pumpHomo sapiens (human)IC50 (µMol)566.50000.11007.190310.0000AID1209455; AID1473738
ATP-dependent translocase ABCB1Mus musculus (house mouse)IC50 (µMol)50.00000.06404.012610.0000AID150754; AID681128
ATP-dependent translocase ABCB1Homo sapiens (human)IC50 (µMol)50.00000.00022.318510.0000AID150752; AID150755; AID681122
Cytochrome P450 3A4Homo sapiens (human)IC50 (µMol)50.00000.00011.753610.0000AID54923
Cytochrome P450 2C9 Homo sapiens (human)IC50 (µMol)50.00000.00002.800510.0000AID1210069
Potassium-transporting ATPase alpha chain 1Homo sapiens (human)IC50 (µMol)0.04000.04001.09603.8000AID167652
ATP-dependent translocase ABCB1Mus musculus (house mouse)IC50 (µMol)50.00000.20004.713010.0000AID150753; AID681119
AcetylcholinesteraseHomo sapiens (human)IC50 (µMol)1.47500.00000.933210.0000AID31505; AID31967
Histamine H2 receptorCavia porcellus (domestic guinea pig)Ki0.05370.00071.02045.1250AID88327
Potassium-transporting ATPase subunit betaHomo sapiens (human)IC50 (µMol)0.04000.04001.09603.8000AID167652
Cytochrome P450 2J2Homo sapiens (human)IC50 (µMol)50.00000.01202.53129.4700AID1210069
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
Multidrug and toxin extrusion protein 1Homo sapiens (human)IC50 (µMol)8.30000.01002.765610.0000AID721754
Bile salt export pumpHomo sapiens (human)IC50 (µMol)567.50000.11007.190310.0000AID1443980; AID1449628
Carbonic anhydrase 1Homo sapiens (human)Ki42.20000.00001.372610.0000AID1803130
Carbonic anhydrase 2Homo sapiens (human)Ki42.20000.00000.72369.9200AID1803130
Histamine H4 receptorHomo sapiens (human)Ki10.00000.00060.478710.0000AID1798265
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Histamine H2 receptorCavia porcellus (domestic guinea pig)Kd0.06460.01170.15720.9550AID88152
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 22 member 1 Homo sapiens (human)Activity21.70000.71005.30179.7000AID681117
Solute carrier family 22 member 8Homo sapiens (human)Km234.00000.34501.32173.1000AID679305
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (155)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processSolute carrier family 22 member 1 Homo sapiens (human)
neurotransmitter transportSolute carrier family 22 member 1 Homo sapiens (human)
serotonin transportSolute carrier family 22 member 1 Homo sapiens (human)
establishment or maintenance of transmembrane electrochemical gradientSolute carrier family 22 member 1 Homo sapiens (human)
organic cation transportSolute carrier family 22 member 1 Homo sapiens (human)
quaternary ammonium group transportSolute carrier family 22 member 1 Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 1 Homo sapiens (human)
monoamine transportSolute carrier family 22 member 1 Homo sapiens (human)
putrescine transportSolute carrier family 22 member 1 Homo sapiens (human)
spermidine transportSolute carrier family 22 member 1 Homo sapiens (human)
acetylcholine transportSolute carrier family 22 member 1 Homo sapiens (human)
dopamine transportSolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine transportSolute carrier family 22 member 1 Homo sapiens (human)
thiamine transportSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 1 Homo sapiens (human)
epinephrine transportSolute carrier family 22 member 1 Homo sapiens (human)
serotonin uptakeSolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine uptakeSolute carrier family 22 member 1 Homo sapiens (human)
thiamine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
metanephric proximal tubule developmentSolute carrier family 22 member 1 Homo sapiens (human)
purine-containing compound transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
dopamine uptakeSolute carrier family 22 member 1 Homo sapiens (human)
monoatomic cation transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 22 member 1 Homo sapiens (human)
(R)-carnitine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
acyl carnitine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
spermidine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
cellular detoxificationSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transport across blood-brain barrierSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
G2/M transition of mitotic cell cycleATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic metabolic processATP-dependent translocase ABCB1Homo sapiens (human)
response to xenobiotic stimulusATP-dependent translocase ABCB1Homo sapiens (human)
phospholipid translocationATP-dependent translocase ABCB1Homo sapiens (human)
terpenoid transportATP-dependent translocase ABCB1Homo sapiens (human)
regulation of response to osmotic stressATP-dependent translocase ABCB1Homo sapiens (human)
transmembrane transportATP-dependent translocase ABCB1Homo sapiens (human)
transepithelial transportATP-dependent translocase ABCB1Homo sapiens (human)
stem cell proliferationATP-dependent translocase ABCB1Homo sapiens (human)
ceramide translocationATP-dependent translocase ABCB1Homo sapiens (human)
export across plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
transport across blood-brain barrierATP-dependent translocase ABCB1Homo sapiens (human)
positive regulation of anion channel activityATP-dependent translocase ABCB1Homo sapiens (human)
carboxylic acid transmembrane transportATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic transport across blood-brain barrierATP-dependent translocase ABCB1Homo sapiens (human)
regulation of chloride transportATP-dependent translocase ABCB1Homo sapiens (human)
lipid hydroxylationCytochrome P450 3A4Homo sapiens (human)
lipid metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid catabolic processCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid metabolic processCytochrome P450 3A4Homo sapiens (human)
cholesterol metabolic processCytochrome P450 3A4Homo sapiens (human)
androgen metabolic processCytochrome P450 3A4Homo sapiens (human)
estrogen metabolic processCytochrome P450 3A4Homo sapiens (human)
alkaloid catabolic processCytochrome P450 3A4Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 3A4Homo sapiens (human)
calcitriol biosynthetic process from calciolCytochrome P450 3A4Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D metabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D catabolic processCytochrome P450 3A4Homo sapiens (human)
retinol metabolic processCytochrome P450 3A4Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 3A4Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 3A4Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 3A4Homo sapiens (human)
oxidative demethylationCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C9 Homo sapiens (human)
steroid metabolic processCytochrome P450 2C9 Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2C9 Homo sapiens (human)
estrogen metabolic processCytochrome P450 2C9 Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C9 Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
urea metabolic processCytochrome P450 2C9 Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 2C9 Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C9 Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
amide metabolic processCytochrome P450 2C9 Homo sapiens (human)
icosanoid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
oxidative demethylationCytochrome P450 2C9 Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
response to xenobiotic stimulusPotassium-transporting ATPase alpha chain 1Homo sapiens (human)
regulation of proton transportPotassium-transporting ATPase alpha chain 1Homo sapiens (human)
establishment or maintenance of transmembrane electrochemical gradientPotassium-transporting ATPase alpha chain 1Homo sapiens (human)
monoatomic ion transmembrane transportPotassium-transporting ATPase alpha chain 1Homo sapiens (human)
pH reductionPotassium-transporting ATPase alpha chain 1Homo sapiens (human)
potassium ion transmembrane transportPotassium-transporting ATPase alpha chain 1Homo sapiens (human)
intracellular sodium ion homeostasisPotassium-transporting ATPase alpha chain 1Homo sapiens (human)
sodium ion export across plasma membranePotassium-transporting ATPase alpha chain 1Homo sapiens (human)
intracellular potassium ion homeostasisPotassium-transporting ATPase alpha chain 1Homo sapiens (human)
potassium ion import across plasma membranePotassium-transporting ATPase alpha chain 1Homo sapiens (human)
proton transmembrane transportPotassium-transporting ATPase alpha chain 1Homo sapiens (human)
acetylcholine catabolic process in synaptic cleftAcetylcholinesteraseHomo sapiens (human)
regulation of receptor recyclingAcetylcholinesteraseHomo sapiens (human)
osteoblast developmentAcetylcholinesteraseHomo sapiens (human)
acetylcholine catabolic processAcetylcholinesteraseHomo sapiens (human)
cell adhesionAcetylcholinesteraseHomo sapiens (human)
nervous system developmentAcetylcholinesteraseHomo sapiens (human)
synapse assemblyAcetylcholinesteraseHomo sapiens (human)
receptor internalizationAcetylcholinesteraseHomo sapiens (human)
negative regulation of synaptic transmission, cholinergicAcetylcholinesteraseHomo sapiens (human)
amyloid precursor protein metabolic processAcetylcholinesteraseHomo sapiens (human)
positive regulation of protein secretionAcetylcholinesteraseHomo sapiens (human)
retina development in camera-type eyeAcetylcholinesteraseHomo sapiens (human)
acetylcholine receptor signaling pathwayAcetylcholinesteraseHomo sapiens (human)
positive regulation of cold-induced thermogenesisAcetylcholinesteraseHomo sapiens (human)
cell adhesionPotassium-transporting ATPase subunit betaHomo sapiens (human)
response to organonitrogen compoundPotassium-transporting ATPase subunit betaHomo sapiens (human)
response to lipopolysaccharidePotassium-transporting ATPase subunit betaHomo sapiens (human)
pH reductionPotassium-transporting ATPase subunit betaHomo sapiens (human)
potassium ion transmembrane transportPotassium-transporting ATPase subunit betaHomo sapiens (human)
proton transmembrane transportPotassium-transporting ATPase subunit betaHomo sapiens (human)
potassium ion import across plasma membranePotassium-transporting ATPase subunit betaHomo sapiens (human)
intracellular potassium ion homeostasisPotassium-transporting ATPase subunit betaHomo sapiens (human)
sodium ion export across plasma membranePotassium-transporting ATPase subunit betaHomo sapiens (human)
intracellular sodium ion homeostasisPotassium-transporting ATPase subunit betaHomo sapiens (human)
fatty acid metabolic processCytochrome P450 2J2Homo sapiens (human)
icosanoid metabolic processCytochrome P450 2J2Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2J2Homo sapiens (human)
regulation of heart contractionCytochrome P450 2J2Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2J2Homo sapiens (human)
linoleic acid metabolic processCytochrome P450 2J2Homo sapiens (human)
organic acid metabolic processCytochrome P450 2J2Homo sapiens (human)
monoatomic ion transportSolute carrier family 22 member 8Homo sapiens (human)
response to toxic substanceSolute carrier family 22 member 8Homo sapiens (human)
inorganic anion transportSolute carrier family 22 member 8Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 8Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 8Homo sapiens (human)
transmembrane transportSolute carrier family 22 member 8Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 22 member 8Homo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
organic cation transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
putrescine transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
xenobiotic transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
transmembrane transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
thiamine transmembrane transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
amino acid import across plasma membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
L-arginine import across plasma membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
L-alpha-amino acid transmembrane transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
proton transmembrane transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
L-arginine transmembrane transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 1Homo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 2Homo sapiens (human)
positive regulation of synaptic transmission, GABAergicCarbonic anhydrase 2Homo sapiens (human)
positive regulation of cellular pH reductionCarbonic anhydrase 2Homo sapiens (human)
angiotensin-activated signaling pathwayCarbonic anhydrase 2Homo sapiens (human)
regulation of monoatomic anion transportCarbonic anhydrase 2Homo sapiens (human)
secretionCarbonic anhydrase 2Homo sapiens (human)
regulation of intracellular pHCarbonic anhydrase 2Homo sapiens (human)
neuron cellular homeostasisCarbonic anhydrase 2Homo sapiens (human)
positive regulation of dipeptide transmembrane transportCarbonic anhydrase 2Homo sapiens (human)
regulation of chloride transportCarbonic anhydrase 2Homo sapiens (human)
carbon dioxide transportCarbonic anhydrase 2Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 2Homo sapiens (human)
inflammatory responseHistamine H4 receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationHistamine H4 receptorHomo sapiens (human)
biological_processHistamine H4 receptorHomo sapiens (human)
regulation of MAPK cascadeHistamine H4 receptorHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayHistamine H4 receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayHistamine H4 receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerHistamine H4 receptorHomo sapiens (human)
chemical synaptic transmissionHistamine H4 receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (107)

Processvia Protein(s)Taxonomy
acetylcholine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
neurotransmitter transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
dopamine:sodium symporter activitySolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine:sodium symporter activitySolute carrier family 22 member 1 Homo sapiens (human)
protein bindingSolute carrier family 22 member 1 Homo sapiens (human)
monoamine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
secondary active organic cation transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
organic cation transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
pyrimidine nucleoside transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
thiamine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
putrescine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
spermidine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
quaternary ammonium group transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
toxin transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
identical protein bindingSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
(R)-carnitine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
protein bindingATP-dependent translocase ABCB1Homo sapiens (human)
ATP bindingATP-dependent translocase ABCB1Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
efflux transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
ATP hydrolysis activityATP-dependent translocase ABCB1Homo sapiens (human)
transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
ubiquitin protein ligase bindingATP-dependent translocase ABCB1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
carboxylic acid transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
phosphatidylcholine floppase activityATP-dependent translocase ABCB1Homo sapiens (human)
phosphatidylethanolamine flippase activityATP-dependent translocase ABCB1Homo sapiens (human)
ceramide floppase activityATP-dependent translocase ABCB1Homo sapiens (human)
floppase activityATP-dependent translocase ABCB1Homo sapiens (human)
monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
steroid bindingCytochrome P450 3A4Homo sapiens (human)
iron ion bindingCytochrome P450 3A4Homo sapiens (human)
protein bindingCytochrome P450 3A4Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
oxidoreductase activityCytochrome P450 3A4Homo sapiens (human)
oxygen bindingCytochrome P450 3A4Homo sapiens (human)
enzyme bindingCytochrome P450 3A4Homo sapiens (human)
heme bindingCytochrome P450 3A4Homo sapiens (human)
vitamin D3 25-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
caffeine oxidase activityCytochrome P450 3A4Homo sapiens (human)
quinine 3-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
aromatase activityCytochrome P450 3A4Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
iron ion bindingCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
caffeine oxidase activityCytochrome P450 2C9 Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
aromatase activityCytochrome P450 2C9 Homo sapiens (human)
heme bindingCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C9 Homo sapiens (human)
magnesium ion bindingPotassium-transporting ATPase alpha chain 1Homo sapiens (human)
ATP bindingPotassium-transporting ATPase alpha chain 1Homo sapiens (human)
P-type potassium:proton transporter activityPotassium-transporting ATPase alpha chain 1Homo sapiens (human)
ATP hydrolysis activityPotassium-transporting ATPase alpha chain 1Homo sapiens (human)
potassium ion bindingPotassium-transporting ATPase alpha chain 1Homo sapiens (human)
P-type sodium:potassium-exchanging transporter activityPotassium-transporting ATPase alpha chain 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-dependent translocase ABCB1Mus musculus (house mouse)
amyloid-beta bindingAcetylcholinesteraseHomo sapiens (human)
acetylcholinesterase activityAcetylcholinesteraseHomo sapiens (human)
cholinesterase activityAcetylcholinesteraseHomo sapiens (human)
protein bindingAcetylcholinesteraseHomo sapiens (human)
collagen bindingAcetylcholinesteraseHomo sapiens (human)
hydrolase activityAcetylcholinesteraseHomo sapiens (human)
serine hydrolase activityAcetylcholinesteraseHomo sapiens (human)
acetylcholine bindingAcetylcholinesteraseHomo sapiens (human)
protein homodimerization activityAcetylcholinesteraseHomo sapiens (human)
laminin bindingAcetylcholinesteraseHomo sapiens (human)
protein bindingPotassium-transporting ATPase subunit betaHomo sapiens (human)
P-type potassium:proton transporter activityPotassium-transporting ATPase subunit betaHomo sapiens (human)
heterocyclic compound bindingPotassium-transporting ATPase subunit betaHomo sapiens (human)
ATPase activator activityPotassium-transporting ATPase subunit betaHomo sapiens (human)
monooxygenase activityCytochrome P450 2J2Homo sapiens (human)
iron ion bindingCytochrome P450 2J2Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
isomerase activityCytochrome P450 2J2Homo sapiens (human)
linoleic acid epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
hydroperoxy icosatetraenoate isomerase activityCytochrome P450 2J2Homo sapiens (human)
arachidonic acid 5,6-epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
heme bindingCytochrome P450 2J2Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2J2Homo sapiens (human)
solute:inorganic anion antiporter activitySolute carrier family 22 member 8Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 8Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 8Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 22 member 8Homo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
protein bindingMultidrug and toxin extrusion protein 1Homo sapiens (human)
organic cation transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
L-amino acid transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
thiamine transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
antiporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
putrescine transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
L-arginine transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
polyspecific organic cation:proton antiporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
arylesterase activityCarbonic anhydrase 1Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 1Homo sapiens (human)
protein bindingCarbonic anhydrase 1Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 1Homo sapiens (human)
hydro-lyase activityCarbonic anhydrase 1Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 1Homo sapiens (human)
arylesterase activityCarbonic anhydrase 2Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 2Homo sapiens (human)
protein bindingCarbonic anhydrase 2Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 2Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 2Homo sapiens (human)
histamine receptor activityHistamine H4 receptorHomo sapiens (human)
G protein-coupled serotonin receptor activityHistamine H4 receptorHomo sapiens (human)
G protein-coupled acetylcholine receptor activityHistamine H4 receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (37)

Processvia Protein(s)Taxonomy
plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
basal plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
membraneSolute carrier family 22 member 1 Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
lateral plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
presynapseSolute carrier family 22 member 1 Homo sapiens (human)
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
cytoplasmATP-dependent translocase ABCB1Homo sapiens (human)
plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
cell surfaceATP-dependent translocase ABCB1Homo sapiens (human)
membraneATP-dependent translocase ABCB1Homo sapiens (human)
apical plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
extracellular exosomeATP-dependent translocase ABCB1Homo sapiens (human)
external side of apical plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
cytoplasmCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A4Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C9 Homo sapiens (human)
plasma membraneCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
cytoplasmCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
extracellular spacePotassium-transporting ATPase alpha chain 1Homo sapiens (human)
plasma membranePotassium-transporting ATPase alpha chain 1Homo sapiens (human)
potassium:proton exchanging ATPase complexPotassium-transporting ATPase alpha chain 1Homo sapiens (human)
apical plasma membranePotassium-transporting ATPase alpha chain 1Homo sapiens (human)
plasma membranePotassium-transporting ATPase alpha chain 1Homo sapiens (human)
plasma membraneATP-dependent translocase ABCB1Mus musculus (house mouse)
extracellular regionAcetylcholinesteraseHomo sapiens (human)
basement membraneAcetylcholinesteraseHomo sapiens (human)
extracellular spaceAcetylcholinesteraseHomo sapiens (human)
nucleusAcetylcholinesteraseHomo sapiens (human)
Golgi apparatusAcetylcholinesteraseHomo sapiens (human)
plasma membraneAcetylcholinesteraseHomo sapiens (human)
cell surfaceAcetylcholinesteraseHomo sapiens (human)
membraneAcetylcholinesteraseHomo sapiens (human)
neuromuscular junctionAcetylcholinesteraseHomo sapiens (human)
synaptic cleftAcetylcholinesteraseHomo sapiens (human)
synapseAcetylcholinesteraseHomo sapiens (human)
perinuclear region of cytoplasmAcetylcholinesteraseHomo sapiens (human)
side of membraneAcetylcholinesteraseHomo sapiens (human)
plasma membranePotassium-transporting ATPase subunit betaHomo sapiens (human)
potassium:proton exchanging ATPase complexPotassium-transporting ATPase subunit betaHomo sapiens (human)
apical plasma membranePotassium-transporting ATPase subunit betaHomo sapiens (human)
sodium:potassium-exchanging ATPase complexPotassium-transporting ATPase subunit betaHomo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2J2Homo sapiens (human)
extracellular exosomeCytochrome P450 2J2Homo sapiens (human)
cytoplasmCytochrome P450 2J2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2J2Homo sapiens (human)
plasma membraneSolute carrier family 22 member 8Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 8Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 8Homo sapiens (human)
extracellular exosomeSolute carrier family 22 member 8Homo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
plasma membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
basolateral plasma membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
apical plasma membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
cytosolCarbonic anhydrase 1Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 1Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
cytosolCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
myelin sheathCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 2Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
plasma membraneHistamine H4 receptorHomo sapiens (human)
plasma membraneHistamine H4 receptorHomo sapiens (human)
dendriteHistamine H4 receptorHomo sapiens (human)
synapseHistamine H4 receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (421)

Assay IDTitleYearJournalArticle
AID26362Ionization constant (pKa)2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID467613Volume of distribution at steady state in human2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID373867Hepatic clearance in human hepatocytes in absence of fetal calf serum2009European journal of medicinal chemistry, Apr, Volume: 44, Issue:4
First-principle, structure-based prediction of hepatic metabolic clearance values in human.
AID771317Cellular uptake in human HEK293 cells assessed as human OCT1-mediated drug transport at 2.5 uM after 4 mins by LC-MS/MS analysis2013Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18
Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2.
AID1091957Apparent permeability of the compound by PAMPA2011Journal of agricultural and food chemistry, Apr-13, Volume: 59, Issue:7
Importance of physicochemical properties for the design of new pesticides.
AID1195906Efflux ratio of apparent permeability across basolateral to apical side over apical to basolateral side in human Caco2 cells at 10 uM after 2 hrs2015Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3
Novel 2,4-disubstituted pyrimidines as potent, selective, and cell-permeable inhibitors of neuronal nitric oxide synthase.
AID236919Apparent permeability of the compound was determined inCaco-2 (human colon carcinoma) cells; Activity = Papp 10e-6 (ND =Not determined)2005Journal of medicinal chemistry, Feb-10, Volume: 48, Issue:3
In silico prediction of membrane permeability from calculated molecular parameters.
AID176401Evaluated for inhibition of basal gastric acid secretion on pyolus-ligated rats after intravenous administration1994Journal of medicinal chemistry, Jan-07, Volume: 37, Issue:1
Studies on antiulcer drugs. 7. 2-Guanidino-4-pyridylthiazoles as histamine H2-receptor antagonists with potent gastroprotective effects against nonsteroidal antiinflammatory drug-induced injury.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID714179Apparent permeability across human Caco2 cells at 20 uM2012European journal of medicinal chemistry, Mar, Volume: 49Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors.
AID496819Antimicrobial activity against Plasmodium falciparum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID678722Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1243940Apparent permeability from apical to basolateral side in human Caco2 cells2015European journal of medicinal chemistry, Aug-28, Volume: 101Discovery and characterization of aryl isonitriles as a new class of compounds versus methicillin- and vancomycin-resistant Staphylococcus aureus.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID183872In Vivo gastric Mucosal protective activity against gastric mucosal lesions induced by 0.6 N HCl in rats. (200 mg/kg, po)1992Journal of medicinal chemistry, Jun-26, Volume: 35, Issue:13
Synthesis and antiulcer activity of N-substituted N'-[3-[3-(piperidinomethyl)phenoxy]propyl]ureas: histamine H2-receptor antagonists with a potent mucosal protective activity.
AID28925Highest effective permeability across hexadecane membrane (pH 4-8)2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
AID86447Evaluated for antagonist activity against Histamine H3 receptor and represented as KB.1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Histamine H3 ligands: just pharmacological tools or potential therapeutic agents?
AID1539510Efflux ratio of apparent permeability across basolateral to apical side over apical to basolateral side in human Caco2 cells after 2 hrs by LC/MS/MS analysis
AID179022Effect on gastric mucosal blood flow 60 minutes after administration of HCl and aspirin after drug dosing at 100 mg/kg intragastrically1994Journal of medicinal chemistry, Jan-07, Volume: 37, Issue:1
Studies on antiulcer drugs. 7. 2-Guanidino-4-pyridylthiazoles as histamine H2-receptor antagonists with potent gastroprotective effects against nonsteroidal antiinflammatory drug-induced injury.
AID467611Dissociation constant, pKa of the compound2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID60988Inhibition of acid output in dogs (po)1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Inhibitors of gastric acid secretion: 3,4-diamino-1,2,5-thiadiazole 1-oxides and 1,1-dioxides as urea equivalents in a series of histamine H2-receptor antagonists.
AID681120TP_TRANSPORTER: inhibition of Rhodamine 123 efflux in Caco-2 cells2003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
AID444051Total clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID221624Inhibition of the positive chronotropic response (histamine H2 receptor antagonism) of guinea pig right atrium relative to cimetidine.1992Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12
Iodoaminopotentidine and related compounds: a new class of ligands with high affinity and selectivity for the histamine H2 receptor.
AID59827Efficacy against histamine stimulation was determined in dog1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
Syntheses and gastric acid antisecretory properties of the H2-receptor antagonist. N-[3-[3-(1-piperidinylmethyl)phenoxy]propyl]thieno[3,4-d]isot hiazol-3-amine 1,1-dioxide and related derivatives.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID678715Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID444058Volume of distribution at steady state in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1539509Apparent permeability across basolateral to apical side in human Caco2 cells after 2 hrs by LC/MS/MS analysis
AID624628Drug-stimulated Pgp ATPase activity ratio determined in MDR1-Sf9 cell membranes with test compound at a concentration of 20uM2001The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2
Rational use of in vitro P-glycoprotein assays in drug discovery.
AID168727Compound was evaluated for activity against ethanol-induced gastric lesions mg/kg;NS=No significant activity at 25 mg/kg1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
N-phenyl-2-pyridinecarbothioamides as gastric mucosal protectants.
AID1075511Efflux ratio of apparent permeability across apical to basolateral side over basolateral to apical side in human Caco2 cells at 10 uM for 2 hrs by LC-MS/MS analysis2014Journal of medicinal chemistry, Feb-27, Volume: 57, Issue:4
Simplified 2-aminoquinoline-based scaffold for potent and selective neuronal nitric oxide synthase inhibition.
AID237474Percentage of drug bound in bovine plasma albumin2004Journal of medicinal chemistry, Jul-29, Volume: 47, Issue:16
Contribution of ionization and lipophilicity to drug binding to albumin: a preliminary step toward biodistribution prediction.
AID236918Apparent permeability of the compound was determined in MDCK (madin darby canine kidney) strain I; Activity = Papp 10e-62005Journal of medicinal chemistry, Feb-10, Volume: 48, Issue:3
In silico prediction of membrane permeability from calculated molecular parameters.
AID551239Permeability from apical to basolateral side of human Caco2 cells after 2 hrs2011Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1
Arylsulfanyl pyrazolones block mutant SOD1-G93A aggregation. Potential application for the treatment of amyotrophic lateral sclerosis.
AID592681Apparent permeability across human Caco2 cell membrane after 2 hrs by LC-MS/MS analysis2011Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8
QSAR-based permeability model for drug-like compounds.
AID29811Oral bioavailability in human2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID496832Antimicrobial activity against Trypanosoma brucei rhodesiense2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID179016Effect on gastric mucosal blood flow 15 minutes before dosing of HCl and aspirin after drug dosing at 100 mg/kg intragastrically1994Journal of medicinal chemistry, Jan-07, Volume: 37, Issue:1
Studies on antiulcer drugs. 7. 2-Guanidino-4-pyridylthiazoles as histamine H2-receptor antagonists with potent gastroprotective effects against nonsteroidal antiinflammatory drug-induced injury.
AID88152Compound was evaluated in vitro inhibitory activity against histamine H2 receptor in isolated Guinea pig right atria.1992Journal of medicinal chemistry, Jun-26, Volume: 35, Issue:13
Synthesis and antiulcer activity of N-substituted N'-[3-[3-(piperidinomethyl)phenoxy]propyl]ureas: histamine H2-receptor antagonists with a potent mucosal protective activity.
AID1209456Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID681119TP_TRANSPORTER: inhibition of Calcein-AM efflux in Mdr1a-expressing LLC-PK1 cells2003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID288192Partition coefficient, log P of the compound2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
QSAR study on permeability of hydrophobic compounds with artificial membranes.
AID678717Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID677694Permeability of the compound at pH 7.4 by PAMPA2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Discovery of the first irreversible small molecule inhibitors of the interaction between the vitamin D receptor and coactivators.
AID19424Partition coefficient (logD7.4)2001Journal of medicinal chemistry, Jul-19, Volume: 44, Issue:15
ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds.
AID150751Inhibition of P-glycoprotein using ATPase in MDR1 membranes2003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
AID350784Permeability from basolateral to apical side in human Caco-2 cells2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Efficacy, pharmacokinetics, and metabolism of tetrahydroquinoline inhibitors of Plasmodium falciparum protein farnesyltransferase.
AID624629Inhibition of Pgp expressed in MDR1-MDCKII cells measured by calcein-AM assay2001The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2
Rational use of in vitro P-glycoprotein assays in drug discovery.
AID87944Determined the lowest drug concentration that inhibited macroscopic colonial growth against Helicobacter pylori.2000Journal of medicinal chemistry, Aug-24, Volume: 43, Issue:17
Anti-Helicobacter pylori agents. 4. 2-(Substituted guanidino)-4-phenylthiazoles and some structurally rigid derivatives.
AID1211870Total biliary clearance in iv dosed rat2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID496818Antimicrobial activity against Trypanosoma brucei brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID87878Compound was tested for H2 receptor antagonistic activity against histamine stimulated chronotropic response in isolated guinea pig right atrium1994Journal of medicinal chemistry, Jan-07, Volume: 37, Issue:1
Studies on antiulcer drugs. 7. 2-Guanidino-4-pyridylthiazoles as histamine H2-receptor antagonists with potent gastroprotective effects against nonsteroidal antiinflammatory drug-induced injury.
AID395325Lipophilicity, log P by microemulsion electrokinetic chromatography2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
AID183685Inhibition of aspirin induced gastric lesions in rats after peroral dose of 32 mg/kg1994Journal of medicinal chemistry, Jan-07, Volume: 37, Issue:1
Studies on antiulcer drugs. 7. 2-Guanidino-4-pyridylthiazoles as histamine H2-receptor antagonists with potent gastroprotective effects against nonsteroidal antiinflammatory drug-induced injury.
AID481446Effective permeability across human jejunum2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID31967Inhibition of guinea pig acetylcholinesterase1993Journal of medicinal chemistry, Mar-05, Volume: 36, Issue:5
Synthesis of 2-imidazolidinylidenepropanedinitrile derivatives as stimulators of gastrointestinal motility.
AID54923Inhibition of human cytochrome P450 3A42003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID78909Evaluated for the inhibition of H+/K+ ATPase enzyme from fundic mucosa of white rabbits at 100 uM1988Journal of medicinal chemistry, Sep, Volume: 31, Issue:9
Synthesis of (aryloxy)alkylamines. 1. Novel antisecretory agents with H+K+-ATPase inhibitory activity.
AID1211842Total biliary clearance in human at 50 mg, iv after 24 hrs by T-tube method2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement.
AID481444Octanol-water partition coefficient, log P of the compound2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID288184Permeability coefficient through artificial membrane in presence of unstirred water layer by PAMPA2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
QSAR study on permeability of hydrophobic compounds with artificial membranes.
AID496820Antimicrobial activity against Trypanosoma brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1210069Inhibition of human recombinant CYP2J2 assessed as reduction in astemizole O-demethylation by LC-MS/MS method2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
AID183248Inhibition of histamine stimulated gastric acid secretion in lumen perfused stomach of anesthetized rats2000Journal of medicinal chemistry, Aug-24, Volume: 43, Issue:17
Anti-Helicobacter pylori agents. 4. 2-(Substituted guanidino)-4-phenylthiazoles and some structurally rigid derivatives.
AID288185Permeability coefficient through artificial membrane in presence of stirred water layer2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
QSAR study on permeability of hydrophobic compounds with artificial membranes.
AID135327BBB penetration classification2000Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11
Predicting blood-brain barrier permeation from three-dimensional molecular structure.
AID455986Permeability across human Caco-2 cells2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.
AID678713Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID88156Histamine H2 receptor antagonistic activity on the isolated spontaneously beating guinea pig right atrium2003Bioorganic & medicinal chemistry letters, May-19, Volume: 13, Issue:10
Synthesis and pharmacological activity of fluorescent histamine H2 receptor antagonists related to potentidine.
AID496824Antimicrobial activity against Toxoplasma gondii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID681122TP_TRANSPORTER: inhibition of Calcein-AM efflux in MDR1-expressing LLC-PK1 cells2003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
AID1195904Apparent permeability across apical to basolateral side in human Caco2 cells at 10 uM after 2 hrs by LC/MS/MS analysis2015Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3
Novel 2,4-disubstituted pyrimidines as potent, selective, and cell-permeable inhibitors of neuronal nitric oxide synthase.
AID679078TP_TRANSPORTER: transepithelial transport of Ranitidine at a concentration of 100 uM in MDR1-expressing MDCK cells2003Pharmaceutical research, Aug, Volume: 20, Issue:8
Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium.
AID60223Evaluated against tetragastrin stimulated gastric acid secretion in conscious Hiedenhain-pouch dogs at a dose of 0.32 mg/Kg, po1994Journal of medicinal chemistry, Jan-07, Volume: 37, Issue:1
Studies on antiulcer drugs. 7. 2-Guanidino-4-pyridylthiazoles as histamine H2-receptor antagonists with potent gastroprotective effects against nonsteroidal antiinflammatory drug-induced injury.
AID771315Cellular uptake in human HEK293 cells assessed as human OCT1-mediated drug transport at 2.5 uM after 4 mins by LC-MS/MS analysis relative to passive uptake2013Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18
Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2.
AID444052Hepatic clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID567091Drug absorption in human assessed as human intestinal absorption rate2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
AID28235Unbound fraction (plasma)2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID88327Inhibition of [125I]APT binding to histamine H2 receptor in guinea pig cerebral membranes.1992Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12
Iodoaminopotentidine and related compounds: a new class of ligands with high affinity and selectivity for the histamine H2 receptor.
AID1129453Apparent permeability from apical to basolateral side in human Caco2 cells after 2 hrs2014European journal of medicinal chemistry, Apr-09, Volume: 76Development and characterization of 3-(benzylsulfonamido)benzamides as potent and selective SIRT2 inhibitors.
AID223215Inhibition of histamine-stimulated chronotropic response in isolated guinea pig right atrium2002Journal of medicinal chemistry, Jan-03, Volume: 45, Issue:1
Anti-Helicobacter pylori agents. 5. 2-(Substituted guanidino)-4-arylthiazoles and aryloxazole analogues.
AID444050Fraction unbound in human plasma2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID29925Volume of distribution in man (IV dose)2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID234825Slope value of the compound1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Inhibitors of gastric acid secretion: 3,4-diamino-1,2,5-thiadiazole 1-oxides and 1,1-dioxides as urea equivalents in a series of histamine H2-receptor antagonists.
AID28679Partition coefficient (logD6.8)2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
AID678718Metabolic stability in human liver microsomes assessed as high signal/noise ratio (S/N of >100) by measuring GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID7783Unbound fraction (plasma)2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID588966Substrates of transporters of clinical importance in the absorption and disposition of drugs, OCT22010Nature reviews. Drug discovery, Mar, Volume: 9, Issue:3
Membrane transporters in drug development.
AID168728Compound was evaluated for activity in stress-induced ulcers1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
N-phenyl-2-pyridinecarbothioamides as gastric mucosal protectants.
AID678714Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID496828Antimicrobial activity against Leishmania donovani2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID496827Antimicrobial activity against Leishmania amazonensis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID19260Logarithm of partition coefficient of the neutral form of compound given for octanol/water solvent system1988Journal of medicinal chemistry, Mar, Volume: 31, Issue:3
Development of a new physicochemical model for brain penetration and its application to the design of centrally acting H2 receptor histamine antagonists.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID491236Permeability in buffer of pH 7.4 by PAMPA2010Bioorganic & medicinal chemistry, Jul-01, Volume: 18, Issue:13
Amide conjugates of ketoprofen and indole as inhibitors of Gli1-mediated transcription in the Hedgehog pathway.
AID1211822Drug excretion in human assessed as compound excreted into bile at 50 mg, iv after 24 hrs by T-tube method2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement.
AID1539511Substrate activity at P-glycoprotein in human Caco2 cells after 2 hrs by LC-MS/MS analysis
AID1243941Apparent permeability from basolateral side to apical side in human Caco2 cells2015European journal of medicinal chemistry, Aug-28, Volume: 101Discovery and characterization of aryl isonitriles as a new class of compounds versus methicillin- and vancomycin-resistant Staphylococcus aureus.
AID168733Compound was evaluated for activity in acute lethality model1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
N-phenyl-2-pyridinecarbothioamides as gastric mucosal protectants.
AID1211861Unbound biliary clearance in human at 50 mg, iv after 24 hrs by T-tube method2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement.
AID404304Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
AID29359Ionization constant (pKa)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID679079TP_TRANSPORTER: transepithelial transport of Ranitidine at a concentration of 100 uM in Caco-2 cells2003Pharmaceutical research, Aug, Volume: 20, Issue:8
Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium.
AID1539508Apparent permeability across apical to basolateral side in human Caco2 cells after 2 hrs by LC/MS/MS analysis
AID59666Effective dose against tetragastrin stimulated gastric acid secretion in conscious Hiedenhain-pouch dogs after peroral administration1994Journal of medicinal chemistry, Jan-07, Volume: 37, Issue:1
Studies on antiulcer drugs. 7. 2-Guanidino-4-pyridylthiazoles as histamine H2-receptor antagonists with potent gastroprotective effects against nonsteroidal antiinflammatory drug-induced injury.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID444053Renal clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID28924Effective permeability (Pe) across a hexadecane membrane (pH 6.8)2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
AID197410Evaluated against histamine stimulated gastric acid secretion in lumen perfused anaesthetized rats after 1 mg/kg intravenous dose1994Journal of medicinal chemistry, Jan-07, Volume: 37, Issue:1
Studies on antiulcer drugs. 7. 2-Guanidino-4-pyridylthiazoles as histamine H2-receptor antagonists with potent gastroprotective effects against nonsteroidal antiinflammatory drug-induced injury.
AID496825Antimicrobial activity against Leishmania mexicana2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID361985Lipophilicity, log D of compound at pH 7.4 by microfluidic liquid-liquid extraction method2008Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16
Determination of log D via automated microfluidic liquid-liquid extraction.
AID481439Absolute bioavailability in human2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID29337Ionisation constant (pKa)2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID624626Ratio of apparent permeability from basolateral to apical side over apical to basolateral side determined in MDR1-MDCKII cells2001The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2
Rational use of in vitro P-glycoprotein assays in drug discovery.
AID1194717Solubility in pH 7.4 buffer after 18 hrs by UV spectroscopy based microSol assay2015Bioorganic & medicinal chemistry letters, May-01, Volume: 25, Issue:9
Improving both aqueous solubility and anti-cancer activity by assessing progressive lead optimization libraries.
AID496823Antimicrobial activity against Trichomonas vaginalis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1209455Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID150752Inhibition of P-glycoprotein, human L-MDR1 expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay2003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
AID15430Log (Cbrain/Cblood) in rats1988Journal of medicinal chemistry, Mar, Volume: 31, Issue:3
Development of a new physicochemical model for brain penetration and its application to the design of centrally acting H2 receptor histamine antagonists.
AID551241Ratio of permeability from basolateral to apical side to apical to basolateral side in human Caco2 cells2011Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1
Arylsulfanyl pyrazolones block mutant SOD1-G93A aggregation. Potential application for the treatment of amyotrophic lateral sclerosis.
AID409954Inhibition of mouse brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID496831Antimicrobial activity against Cryptosporidium parvum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID467612Fraction unbound in human plasma2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID168729Compound was evaluated for antisecretory action in the pylorus-ligated rat model (PLR)1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
N-phenyl-2-pyridinecarbothioamides as gastric mucosal protectants.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID31505The compound was evaluated for the inhibition of human Acetylcholinesterase1992Journal of medicinal chemistry, Mar-20, Volume: 35, Issue:6
Synthesis and cholinergic properties of bis[[(dimethylamino)methyl]furanyl] analogues of ranitidine.
AID781326pKa (acid-base dissociation constant) as determined by Avdeef ref: DOI: 10.1002/047145026X2014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID1195905Apparent permeability across basolateral to apical side in human Caco2 cells at 10 uM after 2 hrs by LC/MS/MS analysis2015Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3
Novel 2,4-disubstituted pyrimidines as potent, selective, and cell-permeable inhibitors of neuronal nitric oxide synthase.
AID223210Inhibition of histamine stimulated chronotropic response in isolated guinea pig right atrium2000Journal of medicinal chemistry, Aug-24, Volume: 43, Issue:17
Anti-Helicobacter pylori agents. 4. 2-(Substituted guanidino)-4-phenylthiazoles and some structurally rigid derivatives.
AID1129361Unbound fraction in HEK293 cell homogenate at 0.1 uM by equilibrium dialysis based UPLC-MS/MS analysis2014Journal of medicinal chemistry, Apr-10, Volume: 57, Issue:7
A high-throughput cell-based method to predict the unbound drug fraction in the brain.
AID26304Partition coefficient (logD6.5)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID8002Observed volume of distribution2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID568158Apparent permeability across human Caco2 cells2011Bioorganic & medicinal chemistry letters, Feb-15, Volume: 21, Issue:4
Structure and property based design, synthesis and biological evaluation of γ-lactam based HDAC inhibitors.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID88017Evaluated for antagonist activity against Histamine H2 receptor and represented as KB.1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Histamine H3 ligands: just pharmacological tools or potential therapeutic agents?
AID29423HPLC capacity factor (k')2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID87697In vitro Histamine H2 receptor antagonist activity in the histamine-stimulated guinea pig right atrium1988Journal of medicinal chemistry, Mar, Volume: 31, Issue:3
Development of a new physicochemical model for brain penetration and its application to the design of centrally acting H2 receptor histamine antagonists.
AID1209457Unbound Cmax in human plasma2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID681118TP_TRANSPORTER: transepithelial transport in Caco-2 cells2003International journal of pharmaceutics, Sep-16, Volume: 263, Issue:1-2
Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID228171Inhibition of histamine-stimulated gastric acid secretion in lumen-perfused stomach of anesthetized rats2002Journal of medicinal chemistry, Jan-03, Volume: 45, Issue:1
Anti-Helicobacter pylori agents. 5. 2-(Substituted guanidino)-4-arylthiazoles and aryloxazole analogues.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID87882H2 receptor antagonistic activity against histamine stimulated chronotropic response in isolated guinea pig right atrium at 1x10E-6 g/mL.1994Journal of medicinal chemistry, Jan-07, Volume: 37, Issue:1
Studies on antiulcer drugs. 7. 2-Guanidino-4-pyridylthiazoles as histamine H2-receptor antagonists with potent gastroprotective effects against nonsteroidal antiinflammatory drug-induced injury.
AID1073741Apparent permeability across apical to basolateral side in human Caco2 cells at 10 microM for 2 hrs by LC-MS/MS analysis2014Journal of medicinal chemistry, Feb-27, Volume: 57, Issue:4
Discovery and characterization of potent thiazoles versus methicillin- and vancomycin-resistant Staphylococcus aureus.
AID624623Apparent permeability (Papp) from basolateral to apical side determined in MDR1-MDCKII cells2001The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2
Rational use of in vitro P-glycoprotein assays in drug discovery.
AID497005Antimicrobial activity against Pneumocystis carinii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID679904TP_TRANSPORTER: inhibition of Vinblastine transepithelial transport (basal to apical) (Vinblastine: 0.004 uM, Ranitidipine: 3000 uM) in Caco-2 cells2000Pharmaceutical research, Dec, Volume: 17, Issue:12
Influence of passive permeability on apparent P-glycoprotein kinetics.
AID239884pKa value of the compound2004Journal of medicinal chemistry, Jul-29, Volume: 47, Issue:16
Contribution of ionization and lipophilicity to drug binding to albumin: a preliminary step toward biodistribution prediction.
AID721753Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells at 20 uM after 1.5 mins by fluorescence assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID496821Antimicrobial activity against Leishmania2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID60987Inhibition of acid output in dogs (iv)1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Inhibitors of gastric acid secretion: 3,4-diamino-1,2,5-thiadiazole 1-oxides and 1,1-dioxides as urea equivalents in a series of histamine H2-receptor antagonists.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID386623Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy2008Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
AID19468Partition coefficient (logP)2003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
AID28234% absorbed in human GI-tract2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
AID28236Unbound fraction (tissues)2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID1761236Permeability of compound at pH 7.4 measured after 6 hrs by PAMPA assay2021European journal of medicinal chemistry, Feb-05, Volume: 2112-Propargylamino-naphthoquinone derivatives as multipotent agents for the treatment of Alzheimer's disease.
AID771316Cellular uptake in human HEK293 cells assessed as human OCT2-mediated drug transport at 2.5 uM after 4 mins by LC-MS/MS analysis2013Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18
Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2.
AID1091956Apparent hydrophobicity, log D of the compound in Octanol-buffer2011Journal of agricultural and food chemistry, Apr-13, Volume: 59, Issue:7
Importance of physicochemical properties for the design of new pesticides.
AID551240Permeability from basolateral to apical side of human Caco2 cells after 2 hrs2011Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1
Arylsulfanyl pyrazolones block mutant SOD1-G93A aggregation. Potential application for the treatment of amyotrophic lateral sclerosis.
AID444055Fraction absorbed in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1073743Apparent permeability across basolateral to apical to side in human Caco2 cells at 10 microM for 2 hrs by LC-MS/MS analysis2014Journal of medicinal chemistry, Feb-27, Volume: 57, Issue:4
Discovery and characterization of potent thiazoles versus methicillin- and vancomycin-resistant Staphylococcus aureus.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID681128TP_TRANSPORTER: inhibition of Calcein-AM efflux in Mdr1b-expressing LLC-PK1 cells2003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
AID771314Cellular uptake in human HEK293 cells assessed as human OCT2-mediated drug transport at 2.5 uM after 4 mins by LC-MS/MS analysis relative to passive uptake2013Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18
Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2.
AID222109In vitro gastrointestinal motility enhancing activity was determined by potentiating action on electrically evoked contraction of the isolated guinea pig ileum1993Journal of medicinal chemistry, Mar-05, Volume: 36, Issue:5
Synthesis of 2-imidazolidinylidenepropanedinitrile derivatives as stimulators of gastrointestinal motility.
AID481440Dissociation constant, pKa of the compound2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID515780Intrinsic solubility of the compound in water2010Bioorganic & medicinal chemistry, Oct-01, Volume: 18, Issue:19
QSAR-based solubility model for drug-like compounds.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID177835Effective dose against aspirin induced gastric lesions in rats after peroral administration1994Journal of medicinal chemistry, Jan-07, Volume: 37, Issue:1
Studies on antiulcer drugs. 7. 2-Guanidino-4-pyridylthiazoles as histamine H2-receptor antagonists with potent gastroprotective effects against nonsteroidal antiinflammatory drug-induced injury.
AID150756Inhibition of P-gp was determined using rhodamine-assay in human CaCo-2 cells2003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID444057Fraction escaping hepatic elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID624622Apparent permeability (Papp) from apical to basolateral side determined in MDR1-MDCKII cells2001The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2
Rational use of in vitro P-glycoprotein assays in drug discovery.
AID1211802Drug excretion in iv dosed rat assessed as compound excreted into bile2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement.
AID150754Inhibition of P-glycoprotein, mouse L-mdr1b expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay2003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
AID625277FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of less concern for DILI2011Drug discovery today, Aug, Volume: 16, Issue:15-16
FDA-approved drug labeling for the study of drug-induced liver injury.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID179025Effect on gastric mucosal blood flow at basal value which is 15 minutes before dosing of drugs at 100 mg/kg intragastrically1994Journal of medicinal chemistry, Jan-07, Volume: 37, Issue:1
Studies on antiulcer drugs. 7. 2-Guanidino-4-pyridylthiazoles as histamine H2-receptor antagonists with potent gastroprotective effects against nonsteroidal antiinflammatory drug-induced injury.
AID87966Minimum inhibitory concentration required to inhibit macroscopic colonial growth of Helicobacter pylori2002Journal of medicinal chemistry, Jan-03, Volume: 45, Issue:1
Anti-Helicobacter pylori agents. 5. 2-(Substituted guanidino)-4-arylthiazoles and aryloxazole analogues.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID526527Apparent permeability across human Caco-2 cells2010Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
Property based optimization of δ-lactam HDAC inhibitors for metabolic stability.
AID150755Inhibition of P-glycoprotein using calcein-AM assay transfected in porcine PBCEC2003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
AID178936Effective dose required for the inhibition of total acid secretion in pylorus-ligated rats at 20 mg/kg1988Journal of medicinal chemistry, Sep, Volume: 31, Issue:9
Synthesis of (aryloxy)alkylamines. 1. Novel antisecretory agents with H+K+-ATPase inhibitory activity.
AID496826Antimicrobial activity against Entamoeba histolytica2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID167652Antisecretory activity evaluated by the inhibition of 14C -AP uptake in isolated rabbit parietal cells stimulated by exogenous histamine1988Journal of medicinal chemistry, Sep, Volume: 31, Issue:9
Synthesis of (aryloxy)alkylamines. 1. Novel antisecretory agents with H+K+-ATPase inhibitory activity.
AID87706In vitro inhibition of Histamine H2 receptor by measuring its ability to block dimaprit-stimulated chronotropic response of guinea pig atrium strips1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Inhibitors of gastric acid secretion: 3,4-diamino-1,2,5-thiadiazole 1-oxides and 1,1-dioxides as urea equivalents in a series of histamine H2-receptor antagonists.
AID91481Binding constant against human serum albumin (HSA)2001Journal of medicinal chemistry, Dec-06, Volume: 44, Issue:25
Cheminformatic models to predict binding affinities to human serum albumin.
AID721754Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1129455Efflux ratio of apparent permeability from basolateral to apical side over apical to basolateral side in human Caco2 cells after 2 hrs2014European journal of medicinal chemistry, Apr-09, Volume: 76Development and characterization of 3-(benzylsulfonamido)benzamides as potent and selective SIRT2 inhibitors.
AID496830Antimicrobial activity against Leishmania major2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID28233Fraction ionized (pH 7.4)2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID150753Inhibition of P-glycoprotein, mouse L-mdr1a expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay2003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
AID237416Distribution coeeficient for the compound at pH7.4 (Log D7.4) 2004Journal of medicinal chemistry, Jul-29, Volume: 47, Issue:16
Contribution of ionization and lipophilicity to drug binding to albumin: a preliminary step toward biodistribution prediction.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID15267Log of (Cbrain/Cblood) in rats1988Journal of medicinal chemistry, Mar, Volume: 31, Issue:3
Development of a new physicochemical model for brain penetration and its application to the design of centrally acting H2 receptor histamine antagonists.
AID678716Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1065213Permeability coefficient, log Pe of the compound at pH 7.4 by PAMPA2014ACS medicinal chemistry letters, Feb-13, Volume: 5, Issue:2
Development of novel Vitamin D Receptor-Coactivator Inhibitors.
AID481442Transcellular permeability at pH 6.5 calculated from in vitro P app values in Caco-2 and/or MDCK cells2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1091958Hydrophobicity, log P of the compound in octanol-water by shaking-flask method2011Journal of agricultural and food chemistry, Apr-13, Volume: 59, Issue:7
Importance of physicochemical properties for the design of new pesticides.
AID1161000Apparent permeability of the compound at pH 7.4 buffer by PAMPA2014Bioorganic & medicinal chemistry letters, Sep-15, Volume: 24, Issue:18
Novel Roflumilast analogs as soft PDE4 inhibitors.
AID496829Antimicrobial activity against Leishmania infantum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID444054Oral bioavailability in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID19259Partition coefficient (Log Pn, neutral form, cyclohexane/water)1988Journal of medicinal chemistry, Mar, Volume: 31, Issue:3
Development of a new physicochemical model for brain penetration and its application to the design of centrally acting H2 receptor histamine antagonists.
AID1091955Dissociation constant, pKa of the compound at pH 7.32011Journal of agricultural and food chemistry, Apr-13, Volume: 59, Issue:7
Importance of physicochemical properties for the design of new pesticides.
AID1075512Apparent permeability across basolateral to apical side in human Caco2 cells at 10 microM for 2 hrs by LC-MS/MS analysis2014Journal of medicinal chemistry, Feb-27, Volume: 57, Issue:4
Simplified 2-aminoquinoline-based scaffold for potent and selective neuronal nitric oxide synthase inhibition.
AID1075513Apparent permeability across apical to basolateral side in human Caco2 cells at 10 microM for 2 hrs by LC-MS/MS analysis2014Journal of medicinal chemistry, Feb-27, Volume: 57, Issue:4
Simplified 2-aminoquinoline-based scaffold for potent and selective neuronal nitric oxide synthase inhibition.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID350783Permeability from apical to basolateral side in human Caco-2 cells2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Efficacy, pharmacokinetics, and metabolism of tetrahydroquinoline inhibitors of Plasmodium falciparum protein farnesyltransferase.
AID1243942Efflux ratio in human Caco2 cells2015European journal of medicinal chemistry, Aug-28, Volume: 101Discovery and characterization of aryl isonitriles as a new class of compounds versus methicillin- and vancomycin-resistant Staphylococcus aureus.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID395328Lipophilicity, log P of the compound2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
AID88019Histamine H2 receptor antagonistic activity was evaluated in guinea pig atrium.1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Bioisosteric prototype design of biaryl imidazolyl and triazolyl competitive histamine H2-receptor antagonists.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID496817Antimicrobial activity against Trypanosoma cruzi2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID587818Apparent permeability across human Caco2 cells2011Journal of medicinal chemistry, Mar-10, Volume: 54, Issue:5
Potent farnesyltransferase inhibitors with 1,4-diazepane scaffolds as novel destabilizing microtubule agents in hormone-resistant prostate cancer.
AID22293Delta logD (logD6.5 - logD7.4)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID179019Effect on gastric mucosal blood flow 30 minutes after administration of HCl and aspirin after drug dosing at 100 mg/kg intragastrically1994Journal of medicinal chemistry, Jan-07, Volume: 37, Issue:1
Studies on antiulcer drugs. 7. 2-Guanidino-4-pyridylthiazoles as histamine H2-receptor antagonists with potent gastroprotective effects against nonsteroidal antiinflammatory drug-induced injury.
AID88318Histamine H2 receptor antagonism at a concentration of 1 umolar on the isolated guinea pig right atrium.1992Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12
Iodoaminopotentidine and related compounds: a new class of ligands with high affinity and selectivity for the histamine H2 receptor.
AID481441Aqueous diffusivity at 37C2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID87709In vitro inhibition of Histamine H2 receptor by measuring its ability to block the histamine-stimulated adenylate cyclase of guinea pig hippocampal homogenate1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Inhibitors of gastric acid secretion: 3,4-diamino-1,2,5-thiadiazole 1-oxides and 1,1-dioxides as urea equivalents in a series of histamine H2-receptor antagonists.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID361986Lipophilicity, log D of compound at pH 7.4 by shake flask method2008Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16
Determination of log D via automated microfluidic liquid-liquid extraction.
AID233937Ratio (po/iv) value of the compound1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Inhibitors of gastric acid secretion: 3,4-diamino-1,2,5-thiadiazole 1-oxides and 1,1-dioxides as urea equivalents in a series of histamine H2-receptor antagonists.
AID444056Fraction escaping gut-wall elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID679305TP_TRANSPORTER: cell accumulation in hOAT3 expressing HEK cells2006The Journal of pharmacology and experimental therapeutics, Mar, Volume: 316, Issue:3
Is the monkey an appropriate animal model to examine drug-drug interactions involving renal clearance? Effect of probenecid on the renal elimination of H2 receptor antagonists.
AID1129454Apparent permeability from basolateral to apical side in human Caco2 cells after 2 hrs2014European journal of medicinal chemistry, Apr-09, Volume: 76Development and characterization of 3-(benzylsulfonamido)benzamides as potent and selective SIRT2 inhibitors.
AID681117TP_TRANSPORTER: inhibition of TEA uptake in OCT1-expressing HeLa cells2003Molecular pharmacology, Mar, Volume: 63, Issue:3
Influence of molecular structure on substrate binding to the human organic cation transporter, hOCT1.
AID678712Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1211878Unbound biliary clearance in iv dosed rat2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1196791Apparent permeability across apical to basolateral side in human Caco2 cells at 10 uM after 2 hrs by LC/MS/MS analysis2015Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3
Novel 3-nitrotriazole-based amides and carbinols as bifunctional antichagasic agents.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1347112qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347122qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347123qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347128qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347127qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347125qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347117qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1576576Effective permeability of compound by PAMPA2019MedChemComm, Dec-01, Volume: 10, Issue:12
Synthesis of new lophine-carbohydrate hybrids as cholinesterase inhibitors: cytotoxicity evaluation and molecular modeling.
AID1890428Permeability of the compound across apical to basolateral side in human Caco-2 cells at pH 7.42022European journal of medicinal chemistry, Apr-05, Volume: 233Design, synthesis, and behavioral evaluation of dual-acting compounds as phosphodiesterase type 10A (PDE10A) inhibitors and serotonin ligands targeting neuropsychiatric symptoms in dementia.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1446780Apparent permeability across basolateral to apical side in human Caco2 cells at 10 uM after 2 hrs by LC-MS/MS method2017European journal of medicinal chemistry, Apr-21, Volume: 130Diphenylurea derivatives for combating methicillin- and vancomycin-resistant Staphylococcus aureus.
AID1404017Permeability of the compound at 500 uM after 8 hrs by PAMPA2018European journal of medicinal chemistry, Feb-10, Volume: 145Chameleon-like behavior of indolylpiperidines in complex with cholinesterases targets: Potent butyrylcholinesterase inhibitors.
AID1482938Efflux ratio of apparent permeability across basolateral to apical side to apical to basolateral side in human Caco2 cells at 10 uM measured up to 2 hrs by ESI-LC/MS/MS analysis2017Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
Nitrile in the Hole: Discovery of a Small Auxiliary Pocket in Neuronal Nitric Oxide Synthase Leading to the Development of Potent and Selective 2-Aminoquinoline Inhibitors.
AID1676993Apparent permeability across basolateral to apical side in human Caco-2 cells
AID1831854Effective permeability of compound in PBS at pH 7.4 incubated upto 6 hrs by HPLC-MS analysis2021Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8
Sustainable Drug Discovery of Multi-Target-Directed Ligands for Alzheimer's Disease.
AID1482929Apparent permeability across apical to basolateral side in human Caco2 cells at 10 uM measured up to 2 hrs by ESI-LC/MS/MS analysis2017Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
Nitrile in the Hole: Discovery of a Small Auxiliary Pocket in Neuronal Nitric Oxide Synthase Leading to the Development of Potent and Selective 2-Aminoquinoline Inhibitors.
AID1446779Apparent permeability across apical to basolateral side in human Caco2 cells at 10 uM after 2 hrs by LC-MS/MS method2017European journal of medicinal chemistry, Apr-21, Volume: 130Diphenylurea derivatives for combating methicillin- and vancomycin-resistant Staphylococcus aureus.
AID1636429Drug activation in human Hep3B cells assessed as human CYP2D6-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 78.6 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of N2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID1261675Efflux ratio of apparent permeability across apical to basolateral side over basolateral to apical side in human Caco2 cells after 2 hrs2015Journal of medicinal chemistry, Nov-12, Volume: 58, Issue:21
Phenyl Ether- and Aniline-Containing 2-Aminoquinolines as Potent and Selective Inhibitors of Neuronal Nitric Oxide Synthase.
AID1623668Permeability of compound at pH 7.4 by PAMPA2019European journal of medicinal chemistry, Feb-15, Volume: 164Identification of substituted 5-membered heterocyclic compounds as potential anti-leukemic agents.
AID1446781Efflux ratio of apparent permeability across basolateral to apical over apical to basolateral side in human Caco2 cells at 10 uM after 2 hrs by LC-MS/MS method2017European journal of medicinal chemistry, Apr-21, Volume: 130Diphenylurea derivatives for combating methicillin- and vancomycin-resistant Staphylococcus aureus.
AID1458740Efflux ratio of apparent permeability across basolateral to apical over apical to basolateral side in human Caco2 cells at 10 uM after 2 hrs by LC/MS/MS analysis2017Journal of medicinal chemistry, 08-24, Volume: 60, Issue:16
Hydrophilic, Potent, and Selective 7-Substituted 2-Aminoquinolines as Improved Human Neuronal Nitric Oxide Synthase Inhibitors.
AID1374479Apparent intrinsic permeability in human Caco2 cells from apical to basolateral side after 120 mins by mass spectrometry2018Bioorganic & medicinal chemistry letters, 03-01, Volume: 28, Issue:5
Pharmacology and in vivo efficacy of pyridine-pyrimidine amides that inhibit microtubule polymerization.
AID1623690Permeability of compound at pH 7.4 assessed as drug retention by PAMPA2019European journal of medicinal chemistry, Feb-15, Volume: 164Identification of substituted 5-membered heterocyclic compounds as potential anti-leukemic agents.
AID1636373Drug activation in human Hep3B cells assessed as human CYP3A4-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 90.1 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of N2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID1482937Apparent permeability across basolateral to apical side in human Caco2 cells at 10 uM measured up to 2 hrs by ESI-LC/MS/MS analysis2017Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
Nitrile in the Hole: Discovery of a Small Auxiliary Pocket in Neuronal Nitric Oxide Synthase Leading to the Development of Potent and Selective 2-Aminoquinoline Inhibitors.
AID1312959Apparent permeability across apical to basolateral side in human Caco2 cells at pH 6.5 after 2 hrs by LC/MS/MS analysis2016Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10
Second-Generation Phenylthiazole Antibiotics with Enhanced Pharmacokinetic Properties.
AID1371165Apparent permeability of the compound across apical side to basolateral side in human Caco2 cells by LC-MS/MS analysis2017Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
Investigating the Antibacterial Activity of Biphenylthiazoles against Methicillin- and Vancomycin-Resistant Staphylococcus aureus (MRSA and VRSA).
AID1305707Permeability across apical side at pH 6.5 to basolateral side at pH 7.4 in human Caco2 cells assessed as compound recovery at 10 uM2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Coumarin carboxylic acids as monocarboxylate transporter 1 inhibitors: In vitro and in vivo studies as potential anticancer agents.
AID1415061Half life in human liver microsomes in presence of NADPH by LC-MS/MS analysis2018Journal of medicinal chemistry, 12-13, Volume: 61, Issue:23
Application of Sequential Palladium Catalysis for the Discovery of Janus Kinase Inhibitors in the Benzo[ c]pyrrolo[2,3- h][1,6]naphthyridin-5-one (BPN) Series.
AID1703908Permeability of the compound by PAMPA-TGI assay2020European journal of medicinal chemistry, Oct-15, Volume: 204Discovery of sulfonyl hydrazone derivative as a new selective PDE4A and PDE4D inhibitor by lead-optimization approach on the prototype LASSBio-448: In vitro and in vivo preclinical studies.
AID1584806Permeability of the compound at pH 7.4 by PAMPA2018Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20
Discovery and Optimization of Novel Hydrogen Peroxide Activated Aromatic Nitrogen Mustard Derivatives as Highly Potent Anticancer Agents.
AID1305708Permeability across basolateral side at pH 6.5 to apical side at pH 7.4 in human Caco2 cells assessed as compound recovery at 10 uM2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Coumarin carboxylic acids as monocarboxylate transporter 1 inhibitors: In vitro and in vivo studies as potential anticancer agents.
AID1371167Efflux ratio of permeability from basolateral to apical side over apical to basolateral side of human Caco2 cells by LC-MS/MS analysis2017Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
Investigating the Antibacterial Activity of Biphenylthiazoles against Methicillin- and Vancomycin-Resistant Staphylococcus aureus (MRSA and VRSA).
AID1400068Efflux ratio of apparent permeability in human Caco2 cells at 10 uM after 2 hrs by LC-MS/MS analysis2018Bioorganic & medicinal chemistry, 09-15, Volume: 26, Issue:17
An antimycobacterial pleuromutilin analogue effective against dormant bacilli.
AID1400067Apparent permeability from basolateral to apical side in human Caco2 cells at 10 uM after 2 hrs by LC-MS/MS analysis2018Bioorganic & medicinal chemistry, 09-15, Volume: 26, Issue:17
An antimycobacterial pleuromutilin analogue effective against dormant bacilli.
AID1458738Apparent permeability from apical to basolateral side in human Caco2 cells at 10 uM after 2 hrs by LC/MS/MS analysis2017Journal of medicinal chemistry, 08-24, Volume: 60, Issue:16
Hydrophilic, Potent, and Selective 7-Substituted 2-Aminoquinolines as Improved Human Neuronal Nitric Oxide Synthase Inhibitors.
AID1576577Effective permeability of compound incubated for 8 hrs by PAMPA2019MedChemComm, Dec-01, Volume: 10, Issue:12
Synthesis of new lophine-carbohydrate hybrids as cholinesterase inhibitors: cytotoxicity evaluation and molecular modeling.
AID1703889Permeability of the compound incubated for 8 hrs by PAMPA-TGI assay2020European journal of medicinal chemistry, Oct-15, Volume: 204Discovery of sulfonyl hydrazone derivative as a new selective PDE4A and PDE4D inhibitor by lead-optimization approach on the prototype LASSBio-448: In vitro and in vivo preclinical studies.
AID1374481Efflux ratio of apparent intrinsic permeability in human Caco2 cells after 120 mins by mass spectrometry2018Bioorganic & medicinal chemistry letters, 03-01, Volume: 28, Issue:5
Pharmacology and in vivo efficacy of pyridine-pyrimidine amides that inhibit microtubule polymerization.
AID1415059Apparent permeability across apical to basolateral side in human Caco2 cells at pH 6.5 to 7.5 after 2 hrs by LC/MS/MS analysis2018Journal of medicinal chemistry, 12-13, Volume: 61, Issue:23
Application of Sequential Palladium Catalysis for the Discovery of Janus Kinase Inhibitors in the Benzo[ c]pyrrolo[2,3- h][1,6]naphthyridin-5-one (BPN) Series.
AID1542240Permeability of the compound at 30 to 50 uM at pH 7.4 measured up to 6 hrs by PAMPA-BBB assay method2019European journal of medicinal chemistry, Apr-01, Volume: 167Tackling neuroinflammation and cholinergic deficit in Alzheimer's disease: Multi-target inhibitors of cholinesterases, cyclooxygenase-2 and 15-lipoxygenase.
AID1860217Apparent permeability across apical to basolateral side in human Caco-2 cells assessed as drug recovery at pH 6.5 to 7.42022European journal of medicinal chemistry, Aug-05, Volume: 238Design and synthesis of new quinoline derivatives as selective C-RAF kinase inhibitors with potent anticancer activity.
AID1451287Apparent permeability across basolateral to apical side in human Caco2 cells after 2 hrs by LC-MS/MS method2017Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
Blockade of Asparagine Endopeptidase Inhibits Cancer Metastasis.
AID1382493Efflux ratio of apparent permeability in human Caco2 cells at 10 uM after 60 mins by LC-MS/MS analysis2018European journal of medicinal chemistry, Mar-25, Volume: 148Alkynyl-containing phenylthiazoles: Systemically active antibacterial agents effective against methicillin-resistant Staphylococcus aureus (MRSA).
AID1451288Efflux ratio of apparent permeability in human Caco2 cells after 2 hrs by LC-MS/MS method2017Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
Blockade of Asparagine Endopeptidase Inhibits Cancer Metastasis.
AID1415060Apparent permeability across basolateral to apical side in human Caco2 cells at pH 6.5 to 7.5 after 2 hrs by LC/MS/MS analysis2018Journal of medicinal chemistry, 12-13, Volume: 61, Issue:23
Application of Sequential Palladium Catalysis for the Discovery of Janus Kinase Inhibitors in the Benzo[ c]pyrrolo[2,3- h][1,6]naphthyridin-5-one (BPN) Series.
AID1476987Apparent permeability across apical to basolateral side in human Caco2 cells at 10 uM measured over 2 hrs by LC-MS/MS analysis2017Journal of medicinal chemistry, 11-22, Volume: 60, Issue:22
Improvement of Cell Permeability of Human Neuronal Nitric Oxide Synthase Inhibitors Using Potent and Selective 2-Aminopyridine-Based Scaffolds with a Fluorobenzene Linker.
AID1371166Apparent permeability of the compound across basolateral side to apical side in human Caco2 cells by LC-MS/MS analysis2017Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
Investigating the Antibacterial Activity of Biphenylthiazoles against Methicillin- and Vancomycin-Resistant Staphylococcus aureus (MRSA and VRSA).
AID1305706Permeability across basolateral side at pH 6.5 to apical side at pH 7.4 in human Caco2 cells at 10 uM2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Coumarin carboxylic acids as monocarboxylate transporter 1 inhibitors: In vitro and in vivo studies as potential anticancer agents.
AID1312961Efflux ratio of apparent permeability from basolateral to apical side over apical to basolateral side in human Caco2 cells after 2 hrs by LC/MS/MS analysis2016Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10
Second-Generation Phenylthiazole Antibiotics with Enhanced Pharmacokinetic Properties.
AID1333574Permeability of the compound at pH 5 after 2 hrs by PAMPA2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Polyfluorinated salicylic acid derivatives as analogs of known drugs: Synthesis, molecular docking and biological evaluation.
AID1458739Apparent permeability from basolateral to apical side in human Caco2 cells at 10 uM after 2 hrs by LC/MS/MS analysis2017Journal of medicinal chemistry, 08-24, Volume: 60, Issue:16
Hydrophilic, Potent, and Selective 7-Substituted 2-Aminoquinolines as Improved Human Neuronal Nitric Oxide Synthase Inhibitors.
AID1400066Apparent permeability from apical to basolateral side in human Caco2 cells at 10 uM after 2 hrs by LC-MS/MS analysis2018Bioorganic & medicinal chemistry, 09-15, Volume: 26, Issue:17
An antimycobacterial pleuromutilin analogue effective against dormant bacilli.
AID1382492Apparent permeability from basolateral to apical side in human Caco2 cells at 10 uM after 60 mins by LC-MS/MS analysis2018European journal of medicinal chemistry, Mar-25, Volume: 148Alkynyl-containing phenylthiazoles: Systemically active antibacterial agents effective against methicillin-resistant Staphylococcus aureus (MRSA).
AID1443980Inhibition of human BSEP expressed in fall armyworm sf9 cell plasma membrane vesicles assessed as reduction in vesicle-associated [3H]-taurocholate transport preincubated for 10 mins prior to ATP addition measured after 15 mins in presence of [3H]-tauroch2010Toxicological sciences : an official journal of the Society of Toxicology, Dec, Volume: 118, Issue:2
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
AID1676992Apparent permeability across apical to basolateral side in in human Caco-2 cells
AID1889700Permeability of compound at pH 7.4 by PAMPA assay2022European journal of medicinal chemistry, Mar-15, Volume: 232Novel D
AID1860216Apparent permeability of the compound from apical to basolateral side in human Caco-2 cells at pH 6.5 to 7.42022European journal of medicinal chemistry, Aug-05, Volume: 238Design and synthesis of new quinoline derivatives as selective C-RAF kinase inhibitors with potent anticancer activity.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID1703888Drug absorption of the compound incubated for 8 hrs by PAMPA-TGI assay2020European journal of medicinal chemistry, Oct-15, Volume: 204Discovery of sulfonyl hydrazone derivative as a new selective PDE4A and PDE4D inhibitor by lead-optimization approach on the prototype LASSBio-448: In vitro and in vivo preclinical studies.
AID1333575Permeability of the compound at pH 6.2 after 2 hrs by PAMPA2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Polyfluorinated salicylic acid derivatives as analogs of known drugs: Synthesis, molecular docking and biological evaluation.
AID1769837Permeability of the compound at pH 5.5 incubated for 4 hrs by PAMPA-based UV spectrophotometry2021Journal of medicinal chemistry, 08-12, Volume: 64, Issue:15
Discovery, Structure-Activity Relationships, and In Vivo Evaluation of Novel Aryl Amides as Brain Penetrant Adaptor Protein 2-Associated Kinase 1 (AAK1) Inhibitors for the Treatment of Neuropathic Pain.
AID1261677Apparent permeability in human Caco2 cells across basolateral to apical side at 10 uM after 2 hrs2015Journal of medicinal chemistry, Nov-12, Volume: 58, Issue:21
Phenyl Ether- and Aniline-Containing 2-Aminoquinolines as Potent and Selective Inhibitors of Neuronal Nitric Oxide Synthase.
AID1879914Permeability of compound incubated for 3 hrs by UV plate reader based PAMPA assay2022European journal of medicinal chemistry, May-05, Volume: 235Design, synthesis and biological evaluations of niclosamide analogues against SARS-CoV-2.
AID1890426Permeability of the compound across apical to basolateral side in human Caco-2 cells at pH 6.52022European journal of medicinal chemistry, Apr-05, Volume: 233Design, synthesis, and behavioral evaluation of dual-acting compounds as phosphodiesterase type 10A (PDE10A) inhibitors and serotonin ligands targeting neuropsychiatric symptoms in dementia.
AID1305705Permeability across apical side at pH 6.5 to basolateral side at pH 7.4 in human Caco2 cells at 10 uM2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Coumarin carboxylic acids as monocarboxylate transporter 1 inhibitors: In vitro and in vivo studies as potential anticancer agents.
AID1476989Efflux ratio of apparent permeability from basolateral to apical side over apparent permeability from apical to basolateral side in human Caco2 cells at 10 uM measured over 2 hrs by LC-MS/MS analysis2017Journal of medicinal chemistry, 11-22, Volume: 60, Issue:22
Improvement of Cell Permeability of Human Neuronal Nitric Oxide Synthase Inhibitors Using Potent and Selective 2-Aminopyridine-Based Scaffolds with a Fluorobenzene Linker.
AID1312960Apparent permeability across basolateral to apical side in human Caco2 cells at pH 7.2 after 2 hrs by LC/MS/MS analysis2016Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10
Second-Generation Phenylthiazole Antibiotics with Enhanced Pharmacokinetic Properties.
AID1404016Permeability of the compound by PAMPA2018European journal of medicinal chemistry, Feb-10, Volume: 145Chameleon-like behavior of indolylpiperidines in complex with cholinesterases targets: Potent butyrylcholinesterase inhibitors.
AID1382491Apparent permeability from apical to basolateral side in human Caco2 cells at 10 uM after 60 mins by LC-MS/MS analysis2018European journal of medicinal chemistry, Mar-25, Volume: 148Alkynyl-containing phenylthiazoles: Systemically active antibacterial agents effective against methicillin-resistant Staphylococcus aureus (MRSA).
AID1476988Apparent permeability across basolateral to apical side in human Caco2 cells at 10 uM measured over 2 hrs by LC-MS/MS analysis2017Journal of medicinal chemistry, 11-22, Volume: 60, Issue:22
Improvement of Cell Permeability of Human Neuronal Nitric Oxide Synthase Inhibitors Using Potent and Selective 2-Aminopyridine-Based Scaffolds with a Fluorobenzene Linker.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1415058Aqueous solubility of the compound in simulated gastric fluid2018Journal of medicinal chemistry, 12-13, Volume: 61, Issue:23
Application of Sequential Palladium Catalysis for the Discovery of Janus Kinase Inhibitors in the Benzo[ c]pyrrolo[2,3- h][1,6]naphthyridin-5-one (BPN) Series.
AID1415056Aqueous solubility of the compound in PBS buffer at pH 7.4 after 2 hrs2018Journal of medicinal chemistry, 12-13, Volume: 61, Issue:23
Application of Sequential Palladium Catalysis for the Discovery of Janus Kinase Inhibitors in the Benzo[ c]pyrrolo[2,3- h][1,6]naphthyridin-5-one (BPN) Series.
AID1764875Permeability of the compound at 50 uM measured after 4 hrs by PAMPA assay2021European journal of medicinal chemistry, Jun-05, Volume: 218Discovery of novel potent migrastatic Thiazolo[5,4-b]pyridines targeting Lysyl-tRNA synthetase (KRS) for treatment of Cancer metastasis.
AID1261678Apparent permeability in human Caco2 cells across apical to basolateral side at 10 uM after 2 hrs2015Journal of medicinal chemistry, Nov-12, Volume: 58, Issue:21
Phenyl Ether- and Aniline-Containing 2-Aminoquinolines as Potent and Selective Inhibitors of Neuronal Nitric Oxide Synthase.
AID1451286Apparent permeability across apical to basolateral side in human Caco2 cells after 2 hrs by LC-MS/MS method2017Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
Blockade of Asparagine Endopeptidase Inhibits Cancer Metastasis.
AID1576578Fraction absorbed of the compound by PAMPA2019MedChemComm, Dec-01, Volume: 10, Issue:12
Synthesis of new lophine-carbohydrate hybrids as cholinesterase inhibitors: cytotoxicity evaluation and molecular modeling.
AID1769838Permeability of the compound at pH 7.4 incubated for 4 hrs by PAMPA-based UV spectrophotometry2021Journal of medicinal chemistry, 08-12, Volume: 64, Issue:15
Discovery, Structure-Activity Relationships, and In Vivo Evaluation of Novel Aryl Amides as Brain Penetrant Adaptor Protein 2-Associated Kinase 1 (AAK1) Inhibitors for the Treatment of Neuropathic Pain.
AID1415057Aqueous solubility of the compound in simulated intestinal fluid2018Journal of medicinal chemistry, 12-13, Volume: 61, Issue:23
Application of Sequential Palladium Catalysis for the Discovery of Janus Kinase Inhibitors in the Benzo[ c]pyrrolo[2,3- h][1,6]naphthyridin-5-one (BPN) Series.
AID1333576Permeability of the compound at pH 7.4 after 2 hrs by PAMPA2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Polyfluorinated salicylic acid derivatives as analogs of known drugs: Synthesis, molecular docking and biological evaluation.
AID1636356Drug activation in human Hep3B cells assessed as human CYP2C9-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID1374480Apparent intrinsic permeability in human Caco2 cells from basolateral to apical side after 120 mins by mass spectrometry2018Bioorganic & medicinal chemistry letters, 03-01, Volume: 28, Issue:5
Pharmacology and in vivo efficacy of pyridine-pyrimidine amides that inhibit microtubule polymerization.
AID1678497Permeability of the compound on PBS buffer pH 7.4 at 100 uM by PAMPA-BBB assay2020ACS medicinal chemistry letters, Dec-10, Volume: 11, Issue:12
α-Linolenic Acid-Valproic Acid Conjugates: Toward Single-Molecule Polypharmacology for Multiple Sclerosis.
AID1798265H4R Radioligand Binding Assay from Article 10.1124/jpet.105.087965: \\Evaluation of histamine H1-, H2-, and H3-receptor ligands at the human histamine H4 receptor: identification of 4-methylhistamine as the first potent and selective H4 receptor agonist.\\2005The Journal of pharmacology and experimental therapeutics, Sep, Volume: 314, Issue:3
Evaluation of histamine H1-, H2-, and H3-receptor ligands at the human histamine H4 receptor: identification of 4-methylhistamine as the first potent and selective H4 receptor agonist.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1346133Rat H2 receptor (Histamine receptors)1997British journal of pharmacology, Nov, Volume: 122, Issue:5
Heterologous expression of rat epitope-tagged histamine H2 receptors in insect Sf9 cells.
AID1346095Human H2 receptor (Histamine receptors)1994British journal of pharmacology, Jul, Volume: 112, Issue:3
Pharmacological characterization of the human histamine H2 receptor stably expressed in Chinese hamster ovary cells.
AID1803130Esterase Activity Assay from Article 10.3109/14756366.2011.604852: \\Effects of some drugs on human cord blood erythrocyte carbonic anhydrases I and II: an in vitro study.\\2012Journal of enzyme inhibition and medicinal chemistry, Oct, Volume: 27, Issue:5
Effects of some drugs on human cord blood erythrocyte carbonic anhydrases I and II: an in vitro study.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (4,946)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901745 (35.28)18.7374
1990's1812 (36.64)18.2507
2000's856 (17.31)29.6817
2010's406 (8.21)24.3611
2020's127 (2.57)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 111.62

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index111.62 (24.57)
Research Supply Index4.45 (2.92)
Research Growth Index4.96 (4.65)
Search Engine Demand Index203.92 (26.88)
Search Engine Supply Index2.02 (0.95)

This Compound (111.62)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials1,788 (33.75%)5.53%
Reviews3 (3.53%)6.00%
Reviews355 (6.70%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies484 (9.14%)4.05%
Observational0 (0.00%)0.25%
Observational4 (0.08%)0.25%
Other82 (96.47%)84.16%
Other2,667 (50.34%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (63)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Randomized,2-way Crossover, Bioequivalence Study of Ranitidine 300 mg Tablets Zantac 300 mg Tablets Administered as 1 x 300 mg Tablet in Healthy Subjects Under Fasting Conditions [NCT01131702]Phase 124 participants (Actual)Interventional2003-01-31Completed
Clinical Study to Investigate the Urinary Excretion of N-nitrosodimethylamine (NDMA) After Ranitidine Administration [NCT04397445]Phase 118 participants (Actual)Interventional2020-06-08Completed
The Study of the Diagnosis of Eustachian Tube Dysfunction (ETD): Identifying the Relationship of Ear Fullness to Laryngopharyngeal Reflux (LPR) [NCT02123498]Phase 40 participants (Actual)InterventionalWithdrawn(stopped due to IRB not approved)
The Effect of Concomitant Cimetidine p.o. 400 mg t.i.d. and p.o. Ranitidine 300 mg Once Daily on Single Dose Pharmacokinetics of Tiotropium (14.4 µg) Given Intravenously Over 15 Minutes in Healthy Male and Female Subjects of 50-65 Years (Randomized, Open [NCT02172417]Phase 118 participants (Actual)Interventional2000-07-31Completed
A Comparison of Efficacy of Intravenous Esomeprazole and Ranitidine Treatment of Dyspeptic Pain: A Double-Blind, Randomized, Controlled Trial [NCT02197143]Phase 4286 participants (Actual)Interventional2013-03-31Completed
Single Arm Study To Assess Comprehensive Infusion Guidance For The Management Of The Infusion- Associated Reactions (IARs) In Relapsing-Remitting Multiple Sclerosis (RRMS) Patients Treated With LEMTRADA [NCT02205489]Phase 458 participants (Actual)Interventional2014-10-31Completed
Cabazitaxel in Combination With Prednisolone With Primary Prophylaxis With PEG-G-CSF for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer [NCT02441894]Phase 421 participants (Actual)Interventional2015-04-30Completed
A Phase 1, Open-label, Randomized, Crossover Study to Assess the Drug-drug Interaction of Acid Reducing Agent(s) on the Pharmacokinetics of a Single Oral Dose of Lumicitabine (JNJ-64041575) in Healthy Adult Subjects [NCT03468777]Phase 118 participants (Actual)Interventional2018-03-06Terminated(stopped due to The study has been terminated due to pending data analysis)
A Phase I Open-label, Randomised, Single Dose, Three-way Crossover Relative Bioavailability Study of Ranitidine Hydrochloride (Maximum Strength ZANTAC 150®) Compared to Two Different 150 mg Ranitidine Hydrochloride Oral Disintegrating Tablet (ODT) Formula [NCT02195804]Phase 142 participants (Actual)Interventional2009-05-31Completed
Bioavailability of BIBR 953 ZW After Single Oral Doses of 12.5, 50 or 200 mg BIBR 1048 MS Film-coated Tablet Over 2 Days With and Without Coadministration of Ranitidine to Healthy Subjects. Three Groups, 2-way Crossover, Randomised, Open Trial. [NCT02170792]Phase 130 participants (Actual)Interventional2001-02-28Completed
Mechanisms of N-acetylcysteine Mediated Vascular Adverse Effects [NCT01209455]24 participants (Anticipated)Interventional2011-01-31Recruiting
An 8 Week Non-selected Cohort Study to Investigate Whether the Treatment of Reflux Induced Cough Alters Associated Bronchial Hyper-responsiveness [NCT00668317]Phase 35 participants (Actual)Interventional2006-09-30Terminated(stopped due to Primary care physicians began prescribing antacid therapy for chronic cough)
A Comparative Efficacy and Safety Study of Nexium Delayed-Release Capsules (40mg qd and 20mg qd) Versus Ranitidine 150mg Bid for the Healing of NSAID-Associated Gastric Ulcers When Daily NSAID Use is Continued [NCT00633672]Phase 3400 participants (Anticipated)Interventional2001-02-28Completed
Nefopam vs Tramadol in the Prevention of Post Anaesthetic Shivering Following Subarachnoid Block [NCT02441673]Phase 2130 participants (Anticipated)Interventional2018-10-12Not yet recruiting
A Multicenter, Randomized, Double-blind, Double-dummy, Parallel-group, 8 Week Comparative Efficacy and Safety Study of Esomeprazole 20 mg Every Day (qd) Versus Ranitidine 150 mg Twice a Day (Bid) in Patients With an NSAID-associated Gastric Ulcer When Dai [NCT00401752]Phase 3397 participants (Actual)Interventional2006-03-31Completed
"Effect of Orally Administered Two Successive Doses of PPIs and/ or H2RAs Without or With a Prokinetic Drug, on the Intragastric pH and Volume and Bile Refluxate in Adults Patients Undergoing Elective Surgery." [NCT02703896]Phase 41,920 participants (Actual)Interventional2012-01-31Completed
Extending Acute Stroke Trials to the Aerial Inter-hospital Transfer Setting (AIRDOC) [NCT00585351]100 participants (Actual)Interventional2007-01-31Completed
A Randomized Double-Blind Parallel Study of Rabeprazole Extended Release 50 mg Versus Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD) [NCT00839306]Phase 3240 participants (Actual)Interventional2008-08-31Completed
Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg vs. Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD) [NCT00838526]Phase 3240 participants (Actual)Interventional2008-08-31Completed
An Open-Label, 3-Period, Fixed Sequence Study to Evaluate the Effect of an H2 Antagonist and a Proton Pump Inhibitor on the Single Dose Pharmacokinetics of LOXO-292 in Healthy Adult Subjects [NCT05338502]Phase 120 participants (Actual)Interventional2019-07-08Completed
Evaluation of the Influence of Statins and Proton Pump Inhibitors on Clopidogrel Antiplatelet Effects [NCT00930670]Phase 4320 participants (Actual)Interventional2009-06-30Completed
In Infants With Symptoms of Tracheomalacia or Laryngomalacia, Does Acid-Blocking Medication Improve Respiratory Symptoms? A Randomized, Controlled Trial [NCT02700087]0 participants (Actual)Interventional2016-02-29Withdrawn
Proton Pump Inhibitors and the Risk of Hospitalization for Community-acquired Pneumonia: Replicated Cohort Studies With Meta-analysis [NCT02555852]4,238,504 participants (Actual)Observational2011-09-30Completed
Cross-over Trial of Medical Treatment for GERD in Preterm Infants [NCT00131248]Phase 318 participants (Actual)Interventional2004-04-30Completed
[NCT02733640]42 participants (Actual)Interventional2012-10-31Completed
A Phase 1, Open-Label, Drug-Drug Interaction Study to Evaluate the Potential Effects of Ranitidine on the Pharmacokinetics of Lesinurad in Healthy Adult Male Subjects [NCT01908257]Phase 116 participants (Actual)Interventional2013-07-31Completed
Ontogeny of Voriconazole Pharmacokinetics and Metabolism in Children and Adolescents [NCT01976078]45 participants (Actual)Observational2012-09-30Completed
Evaluation and Treatment of Autonomic Failure. [NCT00223691]Phase 1389 participants (Actual)Interventional2002-03-31Completed
Phytomedicine-based and Quadruple Therapies in Helicobacter Pylori Infection. A Comparative Randomized Trial [NCT02004197]Phase 2/Phase 3176 participants (Actual)Interventional2010-01-31Completed
Effect of Intravenous Esomeprazole Versus Ranitidine on Gastric pH in Critically Ill Patients - a Prospective, Randomized, Double-Blind Study. [NCT00590928]Phase 475 participants (Actual)Interventional2004-07-31Completed
A Multi-center, Open-label, Single-arm, Before and After Switch Study to Evaluate the Efficacy, Safety and Tolerability of Alemtuzumab in Paediatric Patients With Relapsing Remitting Multiple Sclerosis (RRMS) With Disease Activity on Prior Disease Modifyi [NCT03368664]Phase 316 participants (Actual)Interventional2017-10-24Active, not recruiting
An Open-label, Single-center, 2-Part, Randomized Study to Assess the Pharmacokinetics of R406 in Healthy Subjects When Fostamatinib 150 mg is Administered Alone in Fed and Fasted State and in Combination With Ranitidine in Fasted State, and to Assess the [NCT01682408]Phase 128 participants (Actual)Interventional2012-09-30Completed
A Phase 2 Open-Label Study of TPI 287 in Patients With Breast Cancer Metastatic to the Brain [NCT01332630]Phase 224 participants (Actual)Interventional2011-08-16Completed
Peanut Allergy Oral Immunotherapy Desensitization [NCT01601522]Phase 243 participants (Actual)Interventional2012-02-29Completed
A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor [NCT05298683]Phase 2108 participants (Anticipated)Interventional2022-05-31Not yet recruiting
[NCT00633412]Phase 3400 participants (Anticipated)Interventional2001-02-28Completed
A Clinico-Bacteriological Study and Effect of Stress Ulcer Prophylaxis on Occurrence of Ventilator Associated Pneumonia: a Randomized Prospective Study [NCT00702871]Phase 450 participants (Actual)Interventional2005-03-31Completed
A Study to Evaluate the Effects of Two Different Meal Types, Omeprazole and Ranitidine on Danoprevir Pharmacokinetics When Coadministered With Ritonavir in Healthy Subjects [NCT01392755]Phase 132 participants (Actual)Interventional2011-07-31Completed
A Randomized, Double-blind, Four Period Cross-over Comparison of the Effect of Two Doses Lavoltidine, Esomeprazole, and Placebo on 24 Hour Gastric pH and Frequency of Heartburn in Symptomatic GERD Subjects Without Esophageal Erosions [NCT00405119]Phase 292 participants (Actual)Interventional2006-05-31Completed
Comparative Randomized Controlled Trial Study of General Balanced Anesthesia Based on Opioid and Opioid Sparing Balanced Anesthesia for Cholecystectomy Surgery Via Laparoscopy: Intraoperative and Postoperative Outcomes [NCT02953210]Phase 440 participants (Anticipated)Interventional2016-11-30Enrolling by invitation
A Pilot Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Multicenter Trial to Evaluate the Effect of Ranitidine on Immunologic Indicators in Asymptomatic HIV-1 Infected Subjects With a CD4 Cell Count Between 400-700 Cells/mm3 [NCT00002106]Phase 2104 participants InterventionalCompleted
Effects of Esomeprazole Magnesium on Gastric Free Radical Production and Total Antioxidant Capacity in Dyspeptic Patients Receiving Non-steroidal Anti-inflammatory Drugs [NCT00443963]Phase 40 participants (Actual)Interventional2006-12-31Withdrawn(stopped due to The study was not approved by the Human Studies Subcommittee.)
Phase 1 Dose Escalation Study of LY2090314 in Patients With Advanced or Metastatic Cancer in Combination With Pemetrexed and Carboplatin [NCT01287520]Phase 141 participants (Actual)Interventional2007-11-30Completed
Vascular Function in Health & Disease: Rehabilitation for Hypertension; Exercise and Skeletal Muscle Afferent Feedback [NCT02966665]Phase 1420 participants (Anticipated)Interventional2008-09-30Recruiting
A Phase 1 Trial to Evaluate the Safety of Single Agent Flotetuzumab in Advanced CD123-Positive Hematological Malignancies [NCT04681105]Phase 113 participants (Actual)Interventional2020-11-18Active, not recruiting
Pharmacokinetic Interaction Between Trospium Chloride After Intravenous (2 mg) and Oral Administration (30 mg) With Ranitidine (300 mg p.o.) as an Inhibitor of OCT1 and With Clarithromycin (500 mg p.o.) as an Inhibitor of P-glycoprotein in 24 Healthy Subj [NCT03011463]Phase 124 participants (Actual)Interventional2016-11-30Completed
YF476: Effects of a Single Dose at 3 Dose Levels on 24-hour Ambulatory Gastric pH Compared With Placebo and Ranitidine in Healthy Volunteers [NCT01538797]Phase 122 participants (Actual)Interventional1996-07-31Completed
A Phase I, Randomized, Open-label, Single-center Study to Assess the Pharmacokinetics of Vandetanib (CAPRELSA) in Healthy Subjects When a Single Oral Dose of Vandetanib 300 mg is Administered Alone and in Combination With Omeprazole or Ranitidine [NCT01539655]Phase 134 participants (Actual)Interventional2012-02-29Completed
Studies of Esophageal Metaplasia Using a Novel Antibody: Reversibility of Columnar Metaplasia by Proton Pump Inhibitor [NCT00161200]Phase 360 participants Interventional2002-12-31Terminated(stopped due to slow accrual)
Phase 2, Safety and Efficacy Study of Isatuximab, an Anti-CD38 Monoclonal Antibody, Administered by Intravenous (IV) Infusion in Patients With Relapsed or Refractory T-acute Lymphoblastic Leukemia (T-ALL) or T-lymphoblastic Lymphoma (T-LBL) [NCT02999633]Phase 214 participants (Actual)Interventional2017-03-08Terminated(stopped due to Due to an unsatisfactory benefit/risk ratio, as specified in & 14.8.1 of the protocol, Sanofi decided to stop enrollment and terminate ACT14596 prematurely)
A Prospective, Randomized Trial Comparing the Effect of Intravenous Omeprazole to That of Intravenous Ranitidine on the Maintenance of Hemostasis After Successful Endoscopic Treatment of Bleeding Peptic Ulcer [NCT00247130]Phase 40 participants (Actual)Interventional2005-10-31Withdrawn(stopped due to Superiority of iv omeprazole to ranitidine has already been proven by others.)
Comparison of an Antacid/H2-Receptor Antagonist/Proton Pump Inhibitor Versus a Proton Pump Inhibitor/H2-Receptor Antagonist/Antacid Treatment Strategy for Patients With New Onset Dyspepsia in General Practice (The DIAMOND-Study) [NCT00247715]664 participants (Actual)Interventional2003-10-31Completed
Intravenous Pantoprazole vs Ranitidine in Dyspepsia in Emergency Department: A Randomized Controlled Trial. [NCT01737840]Phase 466 participants (Actual)Interventional2012-10-31Completed
Safely Stopping Pre-Medications in Patients Receiving Paclitaxel: A Randomized Trial [NCT04862585]Phase 2/Phase 3100 participants (Anticipated)Interventional2021-10-07Recruiting
The Effect of Increasing Gastric pH Upon the Bioavailability of Orally Administered Phosphonoformic Acid (Foscarnet) [NCT00000964]Phase 16 participants InterventionalCompleted
A Phase II Clinical Trial of BMS-247550 (NSC 710428), an Epothilone B Analog, in Renal Cell Carcinoma [NCT00030992]Phase 2102 participants (Actual)Interventional2002-02-28Completed
Effect of Histamine 2 Receptor Antagonist (H2RA) and Proton Pump Inhibitor (PPI) on the Positivity Rates and Clinical Outcomes of Coronavirus Disease-19 (COVID-19). [NCT04834752]400,000 participants (Anticipated)Observational2021-05-01Not yet recruiting
A Phase 1b/2 Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of Isatuximab (SAR650984) in Patients Awaiting Kidney Transplantation [NCT04294459]Phase 1/Phase 223 participants (Actual)Interventional2020-06-18Terminated(stopped due to Terminated due to non-safety reasons)
Sublingual Misoprostol Versus Placebo to Reduce Blood Loss During Elective Cesarean Delivery : A Randomized Controlled Study [NCT03140033]Phase 2158 participants (Anticipated)Interventional2016-07-31Recruiting
A Double-Blind, Randomized, Placebo-Controlled Cross-Over Study Assessing the Role of Pathogen-Specific IgE and Histamine Release in the Hyper-IgE Syndrome and the Effect of Ranitidine on Laboratory and Clinical Manifestations [NCT00527878]Phase 216 participants (Actual)Interventional2007-09-30Terminated(stopped due to Failure to enroll adequate patient numbers due to small number of eligible patients)
Possible Drug Interaction Between Clopidogrel and Ranitidin or Omeprazole in Patients With Stable Coronary Heart Disease: a Comparative Study [NCT01896557]Phase 492 participants (Actual)Interventional2011-10-31Completed
A Randomized Controlled Study Comparing the Prophylactic Effect of histamine1 and Histamine 2 Receptor Blocker in Prevention Systolic Hypotension After Protamine Administration in Cardiac Patient Having Cardiopulmonary Bypass [NCT03583567]Phase 440 participants (Actual)Interventional2018-09-05Completed
Histamine Receptor 2 Antagonists as Enhancers of Anti-Tumour Immunity [NCT03145012]Phase 430 participants (Actual)Interventional2018-05-01Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00030992 (2) [back to overview]Response Rate
NCT00030992 (2) [back to overview]Number of Participants With Adverse Events
NCT00131248 (1) [back to overview]Bradycardia Episodes/Day
NCT00401752 (6) [back to overview]The Percentage of Participants Whose Duodenal Ulcer(s) (DUs) Was (Were) Healed at Week 4 and Week 8 After Treatment With Esomeprazole 20 mg qd and Ranitidine 150 mg Bid in Patients Receiving Daily NSAID Therapy.
NCT00401752 (6) [back to overview]Percentage of Participants With the Occurance of Any Adverse Event.
NCT00401752 (6) [back to overview]The Percentage of Participants Whose GU(s) and DU(s) in Combination Were Healed at Week 4 and Week 8 After Treatment With Esomeprazole 20 mg qd and Ranitidine 150 mg Bid in Patients Receiving Daily NSAID Therapy
NCT00401752 (6) [back to overview]The Percentage of Subjects Whose Gastric Ulcer(s) (GUs) Was (Were) Healed at Week 4 After Treatment With Esomeprazole 20 mg qd and Ranitidine 150 mg Bid in Patients Receiving Daily Non-steroidal Anti-inflammatory Drug (NSAID)Therapy.
NCT00401752 (6) [back to overview]The Percentage of Subjects Whose Gastric Ulcer(s) Was (Were) Healed at Week 8 After Treatment With Esomeprazole 20 mg qd and Ranitidine 150 mg Bid in Patients Receiving Daily NSAID Therapy.
NCT00401752 (6) [back to overview]The Resolution of Heartburn Symptoms at Week 4 and Week 8 After Treatment With Esomeprazole 20 mg qd and Ranitidine 150 mg Bid in Patients Receiving Daily NSAID Therapy.
NCT00527878 (4) [back to overview]Number of Infections in Subjects With HIES.
NCT00527878 (4) [back to overview]New Skin Infections
NCT00527878 (4) [back to overview]New Lung Infections
NCT00527878 (4) [back to overview]Clinical Severity Score
NCT00585351 (2) [back to overview]Prevention of Chemical Pneumonitis
NCT00585351 (2) [back to overview]The Benefit of Advanced Notification in Promoting Informed Consent
NCT00668317 (1) [back to overview]Change in Methacholine Sensitivity
NCT00838526 (3) [back to overview]Percentage of Participants With Investigator-recorded Sustained Resolution of Heartburn at Week 26
NCT00838526 (3) [back to overview]Percentage of Participants With Maintenance of Complete Healing of eGERD at Week 26
NCT00838526 (3) [back to overview]Percentage of Participants With Adverse Events by Category
NCT00839306 (2) [back to overview]Percentage of Participants With Maintenance of Complete Healing of eGERD at Week 26
NCT00839306 (2) [back to overview]Percentage of Participants With Investigator-recorded Sustained Resolution of Heartburn at Week 26
NCT01287520 (10) [back to overview]Pharmacokinetic (PK) Parameter: Area Under the Concentration-Time Curve From Time 0 Hour to Infinity (AUC0-∞) of LY2090314
NCT01287520 (10) [back to overview]Pharmacokinetic (PK) Parameter: Area Under the Concentration-Time Curve From Time 0 Hour to Infinity (AUC0-∞) of Pemetrexed (Pem)
NCT01287520 (10) [back to overview]PK Parameter: AUC0-∞ of Free Carboplatin (Carb)
NCT01287520 (10) [back to overview]PK Parameter: AUC0-∞ of LY2090314 Coadministered With Pemetrexed (Pem) and Carboplatin (Carb)
NCT01287520 (10) [back to overview]PK Parameter: Cmax of Free Carboplatin
NCT01287520 (10) [back to overview]PK Parameter: Maximum Plasma Concentration (Cmax) of LY2090314
NCT01287520 (10) [back to overview]PK Parameter: Maximum Plasma Concentration (Cmax) of LY2090314 Coadministered With Pemetrexed (Pem) and Carboplatin (Carb)
NCT01287520 (10) [back to overview]PK Parameter: Maximum Plasma Concentration (Cmax) of Pemetrexed (Pem)
NCT01287520 (10) [back to overview]Recommended LY2090314 Dose for Phase 2 Studies (Maximum Tolerated Dose [MTD])
NCT01287520 (10) [back to overview]Number of Participants With Best Overall Tumor Response
NCT01332630 (1) [back to overview]Overall Response Rate (ORR)
NCT01737840 (2) [back to overview]Visual Analogue Scale Score
NCT01737840 (2) [back to overview]Need for Additional Drug
NCT01896557 (4) [back to overview]Comparison of the Primary Outcome With PFA-100 (Collagen/ADP Cartridge)
NCT01896557 (4) [back to overview]Comparing Platelet Function of Patients on Dual Antiplatelet Therapy With ASA + Clopidogrel, Between the Groups Ranitidin and Omeprazole, After One Week of Randomized Treatment
NCT01896557 (4) [back to overview]Comparing Platelet Function of Patients on Dual Antiplatelet Therapy With ASA + Clopidogrel, Between the Groups Ranitidin and Omeprazole, Using VerifyNow Method.
NCT01896557 (4) [back to overview]Comparison of the Primary Outcome With Bioimpedance Aggregometry
NCT02999633 (1) [back to overview]Percentage of Participants With Objective Response
NCT03368664 (3) [back to overview]Change From Baseline in Expanded Disability Status Scale (EDSS) Score at Months 4 and 8
NCT03368664 (3) [back to overview]Brain Magnetic Resonance Imaging (MRI) Assessment: Number of Participants With New or Enlarged T2 Lesions Per MRI Scan
NCT03368664 (3) [back to overview]Brain Magnetic Resonance Imaging (MRI) Assessment: Number of New or Enlarged T2 Lesions Per MRI Scan
NCT04294459 (23) [back to overview]Duration for Achieving Target cPRA
NCT04294459 (23) [back to overview]Duration of Response (DOR)
NCT04294459 (23) [back to overview]Number of Kidney Transplant Offers
NCT04294459 (23) [back to overview]Number of Participants Achieving Target cPRA
NCT04294459 (23) [back to overview]Number of Participants With Graft Survival at 6 Months Post-Transplant
NCT04294459 (23) [back to overview]Percentage of Participants With Response
NCT04294459 (23) [back to overview]Pharmacokinetics (PK) Parameters: Concentration Observed at the End of First Intravenous Infusion (Ceoi) of Isatuximab
NCT04294459 (23) [back to overview]PK Parameters: Area Under the Plasma Concentration Versus Time Curve From Time 0 to 168 Hours Over the Dosing Interval (AUC0-168 Hours) After First Infusion of Isatuximab
NCT04294459 (23) [back to overview]PK Parameters: Last Concentration Observed Above the Lower Limit of Quantification (Clast) After the First Infusion of Isatuximab
NCT04294459 (23) [back to overview]PK Parameters: Maximum Concentration Observed (Cmax) After the First Infusion of Isatuximab
NCT04294459 (23) [back to overview]PK Parameters: Time of Clast (Tlast) After First Infusion of Isatuximab
NCT04294459 (23) [back to overview]PK Parameters: Time Taken to Reach Cmax (Tmax) After the First Infusion of Isatuximab
NCT04294459 (23) [back to overview]PK Parameters: Trough Plasma Concentrations (Ctrough) of Isatuximab
NCT04294459 (23) [back to overview]Time to First Transplant Offer
NCT04294459 (23) [back to overview]Number of Participants With Abnormal Electrolytes Parameters
NCT04294459 (23) [back to overview]Number of Participants With Abnormal Metabolism Parameters
NCT04294459 (23) [back to overview]Number of Participants With Anti-drug Antibodies (ADA) Against Isatuximab
NCT04294459 (23) [back to overview]Number of Participants With Anti-Human Leukocyte Antigen (HLA)-Antibody Reduction
NCT04294459 (23) [back to overview]Number of Participants With Hematological Abnormalities
NCT04294459 (23) [back to overview]Number of Participants With Liver Function Abnormalities
NCT04294459 (23) [back to overview]Number of Participants With Renal Function Abnormalities
NCT04294459 (23) [back to overview]Time to Transplant
NCT04294459 (23) [back to overview]Number of Participants With Treatment-Emergent Adverse Events (TEAEs), and Treatment-Emergent Serious Adverse Events (TESAEs)
NCT04397445 (6) [back to overview]AUC(0-t) of Plasma DMA
NCT04397445 (6) [back to overview]Cumulative Ranitidine Amount Excreted in Urine Over 24 Hours After Drug Administration
NCT04397445 (6) [back to overview]Cumulative NDMA Amount Excreted in Urine Over 24 Hours After Drug Administration (Comparison Between Ranitidine and Placebo)
NCT04397445 (6) [back to overview]Cumulative NDMA Amount Excreted in Urine Over 24 Hours After Drug Administration (Comparison Between Diets)
NCT04397445 (6) [back to overview]Cumulative Dimethylamine (DMA) Amount Excreted in Urine Over 24 Hours After Drug Administration
NCT04397445 (6) [back to overview]AUC(0-t) of Plasma Ranitidine

Response Rate

Response rate is the percentage of participants with a response assessed by the Response Evaluation Criteria in Solid Tumors (RECIST). Complete response (CR) is disappearance of all target lesions, Partial response (PR) is at least a 30% decrease in the sum of the longest diameter (LD) of target lesions,progressive disease (PD) is at least a 20% increase in the sum of the LD of target lesions or the appearance of one or more new lesions, stable disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. (NCT00030992)
Timeframe: 6 weeks

InterventionPercentage of participants (Number)
Complete responsePartial ResponseProgressive diseaseStable disease
BMS-24755019.412.676.8

[back to top]

Number of Participants With Adverse Events

Here is the number of participants with adverse events. For the detailed list of adverse events see the adverse event module. (NCT00030992)
Timeframe: 10 years

InterventionParticipants (Number)
BMS-24755099

[back to top]

Bradycardia Episodes/Day

(NCT00131248)
Timeframe: 7 days

Interventionepisodes per day (Mean)
Medications4.6
Placebo3.6

[back to top]

The Percentage of Participants Whose Duodenal Ulcer(s) (DUs) Was (Were) Healed at Week 4 and Week 8 After Treatment With Esomeprazole 20 mg qd and Ranitidine 150 mg Bid in Patients Receiving Daily NSAID Therapy.

Healed was defined as the absence of ulcers (Ulcers were on S stage or absent). It was calculated as the proportion of subjects whose duodenal ulcer healed after 4 and 8 weeks treatment. (NCT00401752)
Timeframe: 4 and 8 week

InterventionPercentage of participants (Number)
Esomeprazole93.3
Ranitidine81.8

[back to top]

Percentage of Participants With the Occurance of Any Adverse Event.

Safety evaluation including vital signs, physical examination, ECG, adverse events and clinical laboratory evaluations during 8 weeks treatment. (NCT00401752)
Timeframe: 8 weeks

InterventionPercentage of participants (Number)
Esomeprazole16.8
Ranitidine22.7

[back to top]

The Percentage of Participants Whose GU(s) and DU(s) in Combination Were Healed at Week 4 and Week 8 After Treatment With Esomeprazole 20 mg qd and Ranitidine 150 mg Bid in Patients Receiving Daily NSAID Therapy

Healed was defined as the absence of ulcers (Ulcers were on S stage or absent). It was calculated as the proportion of subjects whose gastric and duodenal ulcer healed after 4 and 8 weeks treatment. (NCT00401752)
Timeframe: 4 & 8 weeks

InterventionPercentage of participants (Number)
Esomeprazole80.2
Ranitidine69.4

[back to top]

The Percentage of Subjects Whose Gastric Ulcer(s) (GUs) Was (Were) Healed at Week 4 After Treatment With Esomeprazole 20 mg qd and Ranitidine 150 mg Bid in Patients Receiving Daily Non-steroidal Anti-inflammatory Drug (NSAID)Therapy.

"Healed was defined as the absence of gastric ulcers. It was calculated as the proportion of subjects whose gastric ulcer(s) healed after 4 weeks treatment.~(Ulcers were on S stage, stage 1 = Nonblanchable erythema of intact skin, stage 2 = Partial thickness skin loss involving epidermis, dermis, or both, stage 3 = Full thickness skin loss involving damage to or necrosis of subcutaneous tissue, stage 4 = Full thickness skin loss with extensive destruction, tissue necrosis, or damage to muscle, bone, or supporting structures or absent)." (NCT00401752)
Timeframe: 4 weeks

InterventionPercentage of participants (Number)
Esomeprazole59.4
Ranitidine59.5

[back to top]

The Percentage of Subjects Whose Gastric Ulcer(s) Was (Were) Healed at Week 8 After Treatment With Esomeprazole 20 mg qd and Ranitidine 150 mg Bid in Patients Receiving Daily NSAID Therapy.

Healed was defined as the absence of gastric ulcers (Ulcers were on S stage or absent). It was calculated as the proportion of subjects whose gastric ulcer(s) healed after 8 weeks treatment. (NCT00401752)
Timeframe: 8 weeks

InterventionPercentage of participants (Number)
Esomeprazole81.1
Ranitidine73.9

[back to top]

The Resolution of Heartburn Symptoms at Week 4 and Week 8 After Treatment With Esomeprazole 20 mg qd and Ranitidine 150 mg Bid in Patients Receiving Daily NSAID Therapy.

Resolution rate of investigator-assessed GI symptoms, including heartburn, acid regurgitation, nausea, abdominal fullness and sleep disorder. It was calculated as the percentage of subjects whose heartburn symptoms were resolved at Week 8. (NCT00401752)
Timeframe: week 4 and week 8

InterventionPercentage of participants (Number)
Esomeprazole100
Ranitidine97.7

[back to top]

Number of Infections in Subjects With HIES.

Patients received one year of treatment medication and one year of placebo. New infections (bacterial, fungal, viral or parasitic) were defined as those requiring an addition or change of an antimicrobial (including topical, oral or intravenous therapies) or those requiring a medical procedure (i.e., incision and drainage of a skin abscess, warm soaks to aid abscess drainage or sinus drainage). (NCT00527878)
Timeframe: 1 year on intervention

Interventioninfections (Median)
Placebo4
Ranitidine4

[back to top]

New Skin Infections

Patients reported the number of new skin infections (NCT00527878)
Timeframe: 12 months placebo/12 months ranitidine

Interventionskin infections (Median)
Placebo1
Ranitidine0

[back to top]

New Lung Infections

Number of new infection while on placebo or study drug (NCT00527878)
Timeframe: 12 months placebo and 12 months ranitidine

Interventionnew lung infections (Median)
Placebo1
Ranitidine0

[back to top]

Clinical Severity Score

Scoring that was completed every 3 months. Clinical severity scored had outcomes that could range from 0 to 121 with 0 being the least severe and 121 being the most severe. (NCT00527878)
Timeframe: one year on ranitidine and one year on placebo

Interventionscore on a scale (Mean)
Placebo9.8
Ranitidine8.5

[back to top]

Prevention of Chemical Pneumonitis

Number of subjects that did not develop aspiration pneumonia in the intervention group (Ranitidine vs. placebo). (NCT00585351)
Timeframe: Assessed on the day of discharge (average length of stay is approximately 3-7 days)

InterventionParticipants (Number)
Advanced Notification + Ranitidine5
No Advanced Notification + Ranitidine7
Advanced Notification + Placebo6
No Advanced Notification + Placebo3

[back to top] [back to top]

Change in Methacholine Sensitivity

"Concentration of methacholine (mg/ml) at which participants forced expired volume in 1 sec (FEV1) is reduced by 20% (the provocation concentration of methacholine causing a 20% fall in FEV1-PC20).~To measure if there is a significant difference in PC20 recorded at baseline to that recorded following 8 weeks treatment with omeprazole and ranitidine" (NCT00668317)
Timeframe: baseline and 8 weeks

Interventionmg/ml (Mean)
Omeprazole and Ranitidine0.598

[back to top]

Percentage of Participants With Investigator-recorded Sustained Resolution of Heartburn at Week 26

Heartburn or other GERD-associated symptoms (regurgitation, epigastric or chest pain, dysphagia, belching, bloating, early satiety, other) was based on a 4-point Likert scale that included the following: None (No symptoms); Mild (Awareness of symptoms but easily tolerated); Moderate (Discomforting symptom sufficient to cause interference with normal activities including sleep); Severe (Incapacitating symptom, inability to perform normal activities). (NCT00838526)
Timeframe: Baseline to Week 26

,
InterventionPercentage of Participants (Number)
YesNoMissing
RAB ER 50mg QD57.418.823.9
RAN 150mg BID8.525.466.1

[back to top]

Percentage of Participants With Maintenance of Complete Healing of eGERD at Week 26

eGERD (erosive gastroesophageal reflux disease) healing measured by the Time-to-Relapse of Oesophageal Erosions using an Esophagogastroduodenoscopy (EGD). Lesions were identified and graded using the following Los Angeles (LA) classification of Oesophagitis: Not Present: No breaks (erosions) in the esophageal mucosa (however, edema, erythema, or friability may be present). Grade A: One or more mucosal breaks not more than 5mm in maximum length. Grade B: One or more mucosal breaks more than 5mm in maximum length, but not continuous between the tops of 2 mucosal folds. Grade C: Mucosal breaks continuous between the tops of 2 or more mucosal folds, but involving less than 75% of the esophageal circumference. Grade D: Mucosal breaks involving at least 75% of the esophageal circumference. (NCT00838526)
Timeframe: Baseline to Week 26

InterventionPercentage of Participants (Number)
RAN 150mg BID32.9
RAB ER 50mg QD84.9

[back to top]

Percentage of Participants With Adverse Events by Category

An adverse event (AE) was any untoward medical occurrence in a participant administered an investigational product. A treatment emergent AE (TEAE) was any AE beginning on or after the confirmed date of first dose of study medication, up to and including 7 days after the last dose of study medication. A TEAE was considered related to study treatment if a causal relationship between the study treatment and the AE was a reasonable possibility. AEs were graded as severe if they were incapacitating, with inability to work or to perform normal daily activity. Serious AEs (SAEs) were events that resulted in death, were life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, or were a congenital anomaly/birth defect. (NCT00838526)
Timeframe: From the time of administration of the first dose of study drug up to a maximum of approximately 30 weeks.

,
InterventionPercentage of participants (Number)
Any TEAETreatment-related TEAESevere TEAESevere, treatment-related TEAEDeathOther SAETreatment-related SAETEAEs leading to discontinuation of treatment
RAB ER 50mg QD64.214.58.10.606.406.9
RAN 150mg BID47.58.53.41.701.706.8

[back to top]

Percentage of Participants With Maintenance of Complete Healing of eGERD at Week 26

"eGERD (erosive gastroesophageal reflux disease) healing measured by the Time-to-Relapse of Oesophageal Erosions using an Esophagogastroduodenoscopy (EGD). Lesions were identified and graded using the following Los Angeles (LA) classification of Oesophagitis: Not Present: No breaks (erosions) in the oesophageal mucosa (however, edema, erythema, or friability may be present).~Grade A: One or more mucosal breaks not more than 5mm in maximum length. Grade B: One or more mucosal breaks more than 5mm in maximum length, but not continuous between the tops of 2 mucosal folds.~Grade C: Mucosal breaks continuous between the tops of 2 or more mucosal folds, but involving less than 75% of the esophageal circumference.~Grade D: Mucosal breaks involving at least 75% of the esophageal circumference." (NCT00839306)
Timeframe: Baseline to Week 26

InterventionPercentage of Participants (Number)
RAN 150mg BID31.7
RAB ER 50mg QD88.4

[back to top]

Percentage of Participants With Investigator-recorded Sustained Resolution of Heartburn at Week 26

Heartburn or other GERD-associated symptoms (regurgitation, epigastric or chest pain, dysphagia, belching, bloating, early satiety, other) was based on a 4-point Likert scale that included the following: None (No symptoms); Mild (Awareness of symptoms but easily tolerated); Moderate (Discomforting symptom sufficient to cause interference with normal activities including sleep); Severe (Incapacitating symptom, inability to perform normal activities). (NCT00839306)
Timeframe: Baseline to Week 26

,
InterventionPercentage of Participants (Number)
YesNoMissing
RAB ER 50mg QD53.717.528.8
RAN 150mg BID8.316.775

[back to top]

Pharmacokinetic (PK) Parameter: Area Under the Concentration-Time Curve From Time 0 Hour to Infinity (AUC0-∞) of LY2090314

AUC0-∞ was calculated from the area under the concentration versus time curve from time 0 to infinity of LY2090314 when administered alone. (NCT01287520)
Timeframe: Cycle 1 Day 1 of a 28 day cycle

Interventionnanograms*hour per milliliter (Geometric Mean)
LY 10/Carb 5 or Carb 6/Pem 500 (Cohorts 1 and 2)216
LY 20/Carb 6/Pem 500 (Cohort 3)427
LY 40/Carb 6/Pem 500 (Cohorts 4 and 9)976
LY 80/Carb 6/Pem 500 (Cohorts 5 and 7)1870
LY 120/Carb 6/Pem 500 (Cohort 6)3310
LY 60/Carb 6/Pem 500 + R50 (Cohort 8)1600

[back to top]

Pharmacokinetic (PK) Parameter: Area Under the Concentration-Time Curve From Time 0 Hour to Infinity (AUC0-∞) of Pemetrexed (Pem)

AUC0-∞ was calculated from the area under the concentration versus time curves of Pem given as a single dose with Carb (doublet therapy) and when co-administered with Carb and LY2090314 (triplet therapy). (NCT01287520)
Timeframe: Cycle 1 Day 8 of 28-day cycle and Cycle 2 up to Cycle 10 Day 1 of 21-day cycle

Interventionhours*nanograms/milliliter/ milligram (Geometric Mean)
Pemetrexed (Doublet Therapy)212
Pemetrexed (Triplet Therapy)202

[back to top]

PK Parameter: AUC0-∞ of Free Carboplatin (Carb)

AUC0-∞ of free Carb was calculated from the area under the concentration versus time curves of Carb given as a single dose with Pem (doublet therapy) and when co-administered with Pem and LY2090314 (triplet therapy). (NCT01287520)
Timeframe: Cycle 1 Day 8 of 28-day cycle and Cycle 2 up to Cycle 9: Day 1 of 21-day cycle

Interventionhours*nanograms per milliliter per mg (Geometric Mean)
Carboplatin (Doublet Therapy)81.6
Carboplatin (Triplet Therapy)88.1

[back to top]

PK Parameter: AUC0-∞ of LY2090314 Coadministered With Pemetrexed (Pem) and Carboplatin (Carb)

AUC0-∞ was calculated from the area under the concentration versus time curves of LY2090314 from time zero to infinity when coadministered with Pem and Carb. (NCT01287520)
Timeframe: Cycle 1 Day 8 of a 28-day cycle or Cycle 2 Day 1 of a 21-day cycle

Interventionnanograms*hour per milliliter (Geometric Mean)
LY 10/Carb 5 or Carb 6/Pem 500 (Cohorts 1 and 2)192
LY 20/Carb 6/Pem 500 (Cohort 3)404
LY 40/Carb 6/Pem 500 (Cohorts 4 and 9)938
LY 80/Carb 6/Pem 500 (Cohorts 5 and 7)1830
LY 120/Carb 6/Pem 500 (Cohort 6)2190
LY 60/Carb 6/Pem 500 + R50 (Cohort 8)1570

[back to top]

PK Parameter: Cmax of Free Carboplatin

Cmax of free Carb given as a single dose with Pem (doublet therapy) and when co-administered with Pem and LY2090314 (triplet therapy). (NCT01287520)
Timeframe: Cycle 1, Day 8 of 28-day cycle and Cycle 2 up to Cycle 9: Day 1 of 21-day cycle

Interventionnanograms/milliliter/milligram (Geometric Mean)
Carboplatin (Doublet Therapy)24.0
Carboplatin (Triplet Therapy)25.5

[back to top]

PK Parameter: Maximum Plasma Concentration (Cmax) of LY2090314

(NCT01287520)
Timeframe: Cycle 1 Day 1 of a 28-day cycle

Interventionnanograms per milliliter (Geometric Mean)
LY 10/Carb 5 or Carb 6/Pem 500 (Cohorts 1 and 2)122
LY 20/Carb 6/Pem 500 (Cohort 3)246
LY 40/Carb 6/Pem 500 (Cohorts 4 and 9 )603
LY 80/Carb 6/Pem 500 (Cohorts 5 and 7898
LY 120/Carb 6/Pem 500 (Cohort 6)1700
LY 60/Carb 6/Pem 500 + R50 (Cohort 8)881

[back to top]

PK Parameter: Maximum Plasma Concentration (Cmax) of LY2090314 Coadministered With Pemetrexed (Pem) and Carboplatin (Carb)

(NCT01287520)
Timeframe: Cycle 1 Day 8 of a 28-day cycle or Cycle 2 Day 1 of a 21-day cycle

Interventionnanograms per milliliter (Geometric Mean)
LY 10/Carb 5 or Carb 6/Pem 500 (Cohorts 1 and 2)106
LY 20/Carb 6/Pem 500 (Cohort 3)271
LY 40/Carb 6/Pem 500 (Cohorts 4 and 9)657
LY 80/Carb 6/Pem 500 (Cohorts 5 and 7)1150
LY 120/Carb 6/Pem 500 (Cohort 6)768
LY 60/Carb 6/Pem 500 + R50 (Cohort 8)1040

[back to top]

PK Parameter: Maximum Plasma Concentration (Cmax) of Pemetrexed (Pem)

Cmax of Pem given as a single dose with Carb (doublet therapy) and when coadministered with Carb and LY2090314 (triplet therapy). (NCT01287520)
Timeframe: Cycle 1 Day 8 of 28-day cycle and Cycle 2 up to Cycle 10 Day 1 of 21-day cycle

Interventionnanogram per milliliter per milligram (Geometric Mean)
Pemetrexed (Doublet Therapy)109
Pemetrexed (Triplet Therapy)108

[back to top] [back to top]

Number of Participants With Best Overall Tumor Response

Best overall observed tumor response at any point during the study until disease progression/recurrence defined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response (CR) was defined as the disappearance of all target and non-target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 millimeter (mm) and normalization of tumor marker level of non-target lesions; Partial Response (PR) was defined as at least 30% decrease in sum of longest diameter of target lesions; Progressive Disease (PD) was defined as at least 20% increase in sum of longest diameter of target lesions and minimum 5 mm increase over nadir; Stable Disease (SD) was defined as small changes that did not meet above criteria. (NCT01287520)
Timeframe: Baseline up to Cycle 9 (Cycle 1 was 28 days, Cycles 2 to 9 were 21 days)

,,,,,,,,
Interventionparticipants (Number)
CRPRSDPDUnknown (discontinued before response assessment)
LY 10/Carb 5/Pem 500 (Cohort 1)00201
LY 10/Carb 6/Pem 500 (Cohort 2)00421
LY 120/Carb 6/Pem 500 (Cohort 6)00000
LY 20/Carb 6/Pem 500 (Cohort 3)01211
LY 40/Carb 6/Pem 500 (Cohort 4)01230
LY 40/Carb 6/Pem 500 + R50 (Cohort 9)00221
LY 60/Carb 6/Pem 500 + R50 (Cohort 8)01120
LY 80/Carb 6/Pem 500 (Cohort 5)00012
LY 80/Carb 6/Pem 500 + R50 (Cohort 7)01100

[back to top]

Overall Response Rate (ORR)

"Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR." (NCT01332630)
Timeframe: 8-24 weeks

InterventionParticipants (Count of Participants)
TPI 28721

[back to top]

Visual Analogue Scale Score

The investigators are measuring the change of pain from the baseline to the 30th and 60th minutes by visual anologue scale (VAS). Visual Analogue Scale measurement is between 0 (no pain) and 100 (worst pain). A decrease of 13 or 16 mm in VAS score is accepted as a minimum clinically significant change in pain. (NCT01737840)
Timeframe: 30th and 60th minutes

,
InterventionVisual Analogue Scale (Mean)
VAS score changes at 60 minutesVAS scores changes at 30 minutes
Pantoprazole39.627.6
Ranitidine42.328.3

[back to top]

Need for Additional Drug

The investigators are measuring the need for additional drug at the end of 60 minutes. (NCT01737840)
Timeframe: 60 th minute

Interventionparticipants (Number)
Pantoprazole13
Ranitidine8

[back to top]

Comparison of the Primary Outcome With PFA-100 (Collagen/ADP Cartridge)

After 1 week of randomization to ranitidin or omeprazole, the platelet function will also be analysed by other method: PFA-100(Collagen/ADP cartridge). (NCT01896557)
Timeframe: 1 week after drug exposure

Interventionseconds (Mean)
Omeprazole95.1
Ranitidine97.2

[back to top]

Comparing Platelet Function of Patients on Dual Antiplatelet Therapy With ASA + Clopidogrel, Between the Groups Ranitidin and Omeprazole, After One Week of Randomized Treatment

One week after starting double-blind, double-dummy, randomized therapy with ranitidin or omeprazole on patients treated with DAPT, platelet function will be compared with the method VerifyNow, in P2Y12 Reactivity Units. (NCT01896557)
Timeframe: One week after randomized treatment exposure (omeprazole or ranitidine)

InterventionP2Y12 Reactivity Units (Mean)
Omeprazole173.54
Ranitidine153.61

[back to top]

Comparing Platelet Function of Patients on Dual Antiplatelet Therapy With ASA + Clopidogrel, Between the Groups Ranitidin and Omeprazole, Using VerifyNow Method.

One week after starting double-blind, double-dummy, randomized therapy with ranitidin or omeprazole on patients treated with DAPT, platelet function will be compared with the method VerifyNow, in percent Inhibition of Platelet Aggregation (IPA) from baseline. IPA was calculated as the percent change in aggregability from baseline, with the formula IPA = (on-treatment aggregability minus baseline aggregability)/baseline aggregability. Since baseline aggregation is always, per definition, equal or more than on-treatment aggregation, there is no possibility that this number might be negative. (NCT01896557)
Timeframe: One week after drug exposure (omeprazole/ranitidine); 2 weeks after baseline

InterventionPercentage (Mean)
Omeprazole17.4
Ranitidine30.1

[back to top]

Comparison of the Primary Outcome With Bioimpedance Aggregometry

After 1 week of randomization to ranitidin or omeprazole, the platelet function will also be analysed by other method: bioimpedance aggregometry with ADP 10 mcM as reagent (NCT01896557)
Timeframe: 1 week after drug exposure

InterventionOhms (Mean)
Omeprazole2
Ranitidine2.77

[back to top]

Percentage of Participants With Objective Response

Objective response was defined as percentage of participants with complete response (CR) or with complete response with incomplete peripheral recovery (CRi) as per National Comprehensive Cancer Network (NCCN) guidelines. CR was defined as no circulating blasts or extramedullary disease, no lymphadenopathy, splenomegaly, skin/gum infiltration/testicular mass/central nervous system involvement, trilineage hematopoiesis and less than 5 percentage blasts, absolute neutrophil count (ANC) greater than 1000 per micro liter, platelets less than 100 000 per micro liter, no recurrence for 4 weeks. CRi meet all criteria for complete response except platelet count and/or ANC. (NCT02999633)
Timeframe: Baseline until disease progression or death (maximum duration: 12.1 weeks)

Interventionpercentage of participants (Number)
Isatuximab0

[back to top]

Change From Baseline in Expanded Disability Status Scale (EDSS) Score at Months 4 and 8

EDSS is an ordinal scale in half-point increments that qualifies disability in participants with MS. It consists of 8 ordinal rating scales assessing seven functional systems (pyramidal, cerebellar, brainstem, sensory, bowel and bladder, visual, cerebral, and other). EDSS total score ranges from 0 (normal neurological examination) to 10 (death due to MS), where higher scores indicated worst outcomes. (NCT03368664)
Timeframe: Baseline, Months 4 and 8

Interventionscores on scale (Mean)
Month 4Month 8
Alemtuzumab0.050.00

[back to top]

Brain Magnetic Resonance Imaging (MRI) Assessment: Number of Participants With New or Enlarged T2 Lesions Per MRI Scan

Number of participants with at least one new or enlarged T2 lesions per MRI scan was reported in this outcome measure. Number of new or enlarged T2 lesions per scan was defined as the total number of new or enlarged T2 lesion that occurred during treatment period divided by the total number of scans performed during treatment period. (NCT03368664)
Timeframe: Period 1: Month -4 up to Month 0, Period 2: Month 4 to Month 8

InterventionParticipants (Count of Participants)
Period 110
Period 23

[back to top]

Brain Magnetic Resonance Imaging (MRI) Assessment: Number of New or Enlarged T2 Lesions Per MRI Scan

Number of new or enlarged T2 lesions per scan was defined as the total number of new or enlarged T2 lesion that occurred during a specified period divided by the total number of scans performed during that specified period. (NCT03368664)
Timeframe: Period 1: Month -4 up to Month 0, Period 2: Month 4 to Month 8

Interventionlesions per scan (Number)
Period 13.53
Period 20.13

[back to top]

Duration for Achieving Target cPRA

Duration of achieving target cPRA was defined as the time (in weeks) from laboratory sample collection date of achieving target cPRA (defined as the reduction of cPRA required to achieve at least 100% increase of LCD) the first time up to the laboratory sample collection date when no longer achieving target cPRA calculated using OPTN calculator or the date of death due to any cause, whichever occurs first. The duration of achieving target cPRA was assessed using the Kaplan-Meier method. (NCT04294459)
Timeframe: From first dose of study drug until study cut-off date (maximum duration: up to 97.7 weeks)

Interventionweeks (Median)
Cohort A: Participants With cPRA >=99.90%NA
Cohort B: Participants With cPRA 80.00% to 99.89%7.29

[back to top]

Duration of Response (DOR)

Duration of response (DOR) was defined as time (in weeks) from laboratory sample collection date used in determining a participant to be a responder (defined as participants meeting at least one of the predefined desensitization efficacy criteria: reduction in cPRA resulting in at least 100% increase of likelihood of finding a compatible donor; reduction in antibody titer [>=75% reduction from Baseline] to achieve target cPRA; elimination of >=1 anti-HLA antibody i.e. MFI reduced to <2000 as measured by a SAB assay, for antibodies with Baseline MFI >=3000) up to the laboratory sample collection date when participant was confirmed as no longer meeting any response criterion (i.e., non-responder) or the date of death due to any cause, whichever occurs first. DOR was analyzed using Kaplan-Meier method. (NCT04294459)
Timeframe: From first dose of study drug until end of follow-up period (maximum duration: up to 39.1 weeks)

Interventionweeks (Median)
Cohort A: Participants With cPRA >=99.90%NA
Cohort B: Participants With cPRA 80.00% to 99.89%NA

[back to top]

Number of Kidney Transplant Offers

Number of kidney transplants offers received for each participant was reported in the outcome measure. Data on transplant offers were collected and followed up until study cut-off date. (NCT04294459)
Timeframe: From first dose of study drug until study cut-off date (maximum duration: up to 97.7 weeks)

Interventiontransplant offers (Number)
Cohort A: Participants With cPRA >=99.90%3
Cohort B: Participants With cPRA 80.00% to 99.89%3

[back to top]

Number of Participants Achieving Target cPRA

Target calculated panel reactive antibodies (cPRA) was defined as the reduction of cPRA required to achieve at least 100% increase of likelihood of compatible donor (LCD). Number of participants who achieved target cPRA was assessed using the Organ Procurement and Transplantation Network (OPTN) calculator during the specified timepoint were reported in this outcome measure. Participants who retained their target cPRA values were censored at the date of the last available laboratory assessment achieving their target cPRA. (NCT04294459)
Timeframe: From first dose of study drug until study cut-off date (maximum duration: up to 97.7 weeks)

InterventionParticipants (Count of Participants)
Cohort A: Participants With cPRA >=99.90%4
Cohort B: Participants With cPRA 80.00% to 99.89%2

[back to top]

Number of Participants With Graft Survival at 6 Months Post-Transplant

Number of participants with graft survival status as functioning at 6-months post-transplant was reported in this outcome measure. (NCT04294459)
Timeframe: At 6 Months post-transplant

InterventionParticipants (Count of Participants)
Cohort A: Participants With cPRA >=99.90%1
Cohort B: Participants With Calculated Panel Reactive Antibodies (cPRA) 80.00% to 99.89%0

[back to top]

Percentage of Participants With Response

Response was defined as the percentage of participants meeting at least one of the predefined desensitization efficacy criteria as measured by single antigen bead (SAB) assay as follows: reduction in cPRA resulting in at least 100% increase of likelihood of finding a compatible donor; reduction in antibody titer (>=75% reduction from Baseline) to achieve target cPRA; elimination of >=1 human leukocyte antigen (HLA) antibody (i.e., mean fluorescence intensity [MFI] reduced to <2000) as measured by a SAB assay, for antibodies with Baseline MFI >=3000. (NCT04294459)
Timeframe: From first dose of study drug until end of follow-up period (maximum duration: up to 39.1 weeks)

Interventionpercentage of participants (Number)
Cohort A: Participants With cPRA >=99.90%83.3
Cohort B: Participants With cPRA 80.00% to 99.89%81.8

[back to top]

Pharmacokinetics (PK) Parameters: Concentration Observed at the End of First Intravenous Infusion (Ceoi) of Isatuximab

Ceoi is the plasma concentration observed at the end of intravenous infusion of isatuximab. (NCT04294459)
Timeframe: At End of infusion on Cycle 1 Day 1

Interventionmicrograms per milliliter (mcg/mL) (Mean)
Cohort A: Participants With cPRA >=99.90%290
Cohort B: Participants With cPRA 80.00% to 99.89%270

[back to top]

PK Parameters: Area Under the Plasma Concentration Versus Time Curve From Time 0 to 168 Hours Over the Dosing Interval (AUC0-168 Hours) After First Infusion of Isatuximab

AUC0-168 hours was defined as the area under the plasma concentration versus time curve from time 0 to 168 hours post dose calculated using trapezoidal method after first infusion of isatuximab. (NCT04294459)
Timeframe: At Start of infusion (SOI), End of infusion (EOI), EOI+4H (initial protocol) EOI+1H (amended protocol), 72H and 168H on Day 1 of Cycle 1

Interventionmicrograms*hours/milliliter (mcg*h/mL) (Mean)
Cohort A: Participants With cPRA >=99.90%29400
Cohort B: Participants With cPRA 80.00% to 99.89%20000

[back to top]

PK Parameters: Last Concentration Observed Above the Lower Limit of Quantification (Clast) After the First Infusion of Isatuximab

Clast was defined as the last concentration of isatuximab observed above the lower limit of quantification calculated using non-compartmental analysis after the first infusion of isatuximab. (NCT04294459)
Timeframe: At Start of infusion (SOI), End of infusion (EOI), EOI+4H (initial protocol) EOI+1H (amended protocol), 72H and 168H on Day 1 of Cycle 1

Interventionmcg/mL (Mean)
Cohort A: Participants With cPRA >=99.90%104
Cohort B: Participants With cPRA 80.00% to 99.89%76.3

[back to top]

PK Parameters: Maximum Concentration Observed (Cmax) After the First Infusion of Isatuximab

Cmax was defined as the maximum concentration observed after the first administration calculated using the noncompartmental analysis after the intravenous infusion of isatuximab. (NCT04294459)
Timeframe: At Start of infusion (SOI), End of infusion (EOI), EOI+4H (initial protocol) EOI+1H (amended protocol), 72H and 168H on Day 1 of Cycle 1

Interventionmcg/mL (Mean)
Cohort A: Participants With cPRA >=99.90%295
Cohort B: Participants With cPRA 80.00% to 99.89%285

[back to top]

PK Parameters: Time of Clast (Tlast) After First Infusion of Isatuximab

Tlast was defined as the time of last concentration observed above the lower limit of quantification, calculated using the non-compartmental analysis after the intravenous infusion of isatuximab. (NCT04294459)
Timeframe: At Start of infusion (SOI), End of infusion (EOI), EOI+4H (initial protocol) EOI+1H (amended protocol), 72H and 168H on Day 1 of Cycle 1

Interventionhours (Median)
Cohort A: Participants With cPRA >=99.90%166.00
Cohort B: Participants With cPRA 80.00% to 99.89%167.00

[back to top]

PK Parameters: Time Taken to Reach Cmax (Tmax) After the First Infusion of Isatuximab

Tmax was defined as the time to reach Cmax, calculated using the non-compartmental analysis after the intravenous infusion of isatuximab. (NCT04294459)
Timeframe: At Start of infusion (SOI), End of infusion (EOI), EOI+4H (initial protocol) EOI+1H (amended protocol), 72H and 168H on Day 1 of Cycle 1

Interventionhours (Median)
Cohort A: Participants With cPRA >=99.90%3.67
Cohort B: Participants With cPRA 80.00% to 99.89%3.40

[back to top]

PK Parameters: Trough Plasma Concentrations (Ctrough) of Isatuximab

Ctrough was the plasma concentration of isatuximab observed just before (pre-dose) treatment administration. (NCT04294459)
Timeframe: Cycle 2 Day 1

Interventionmcg/mL (Mean)
Cohort A: Participants With cPRA >=99.90%308
Cohort B: Participants With cPRA 80.00% to 99.89%246

[back to top]

Time to First Transplant Offer

Time to first transplant offer was defined as time (in days) from date of first study treatment dose up to date of first kidney transplant offer. Data on transplant status were collected and followed up until study cut-off date. (NCT04294459)
Timeframe: From first dose of study drug until study cut-off date (maximum duration: up to 97.7 weeks)

Interventiondays (Median)
Cohort A: Participants With cPRA >=99.90%373
Cohort B: Participants With cPRA 80.00% to 99.89%156

[back to top]

Number of Participants With Abnormal Electrolytes Parameters

Abnormal electrolyte parameters assessed were hypernatremia, hyponatremia, hyperkalemia, hypokalemia, hypercalcemia, hypocalcemia, blood bicarbonate decreased, hypermagnesemia, hypomagnesemia and chloride. The abnormal grades were based on NCI-CTCAE, Version 5.0, where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially Life Threatening. Grade refers to the severity of the AEs. Chloride was estimated as per PCSA criteria: <80 millimoles per liter (mmol/L) and >115 mmol/L. (NCT04294459)
Timeframe: From first dose of study drug until study cut-off date (maximum duration: up to 97.7 weeks)

,
InterventionParticipants (Count of Participants)
Hypernatremia: Grade 1Hypernatremia: Grade 2Hypernatremia: Grade 3Hypernatremia: Grade 4Hyponatremia: Grade 1Hyponatremia: Grade 2Hyponatremia: Grade 3Hyponatremia: Grade 4Hyperkalemia: Grade 1Hyperkalemia: Grade 2Hyperkalemia: Grade 3Hyperkalemia: Grade 4Hypokalemia: Grade 1Hypokalemia: Grade 2Hypokalemia: Grade 3Hypokalemia: Grade 4Hypercalcemia: Grade 1Hypercalcemia: Grade 2Hypercalcemia: Grade 3Hypercalcemia: Grade 4Hypocalcemia: Grade 1Hypocalcemia: Grade 2Hypocalcemia: Grade 3Hypocalcemia: Grade 4Hypermagnesemia: Grade 1Hypermagnesemia: Grade 2Hypermagnesemia: Grade 3Hypermagnesemia: Grade 4Hypomagnesemia: Grade 1Hypomagnesemia: Grade 2Hypomagnesemia: Grade 3Hypomagnesemia: Grade 4Chloride (PCSA): <80 mmol/LChloride (PCSA): >115 mmol/L
Cohort A: Participants With cPRA >=99.90%0000400023100001010060002000300000
Cohort B: Participants With cPRA 80.00% to 99.89%0000100061200000100052000000300000

[back to top]

Number of Participants With Abnormal Metabolism Parameters

Abnormal metabolism parameters assessed were hypoglycemia, hypoalbuminemia and glycated Hemoglobin (HbA1c). The abnormal grades were based on NCI-CTCAE, Version 5.0, where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially Life Threatening. Grade refers to the severity of the AEs. HbA1c was estimated as per PCSA criteria: >8%. (NCT04294459)
Timeframe: From first dose of study drug until study cut-off date (maximum duration: up to 97.7 weeks)

,
InterventionParticipants (Count of Participants)
Hypoglycemia: Grade 1Hypoglycemia: Grade 2Hypoglycemia: Grade 3Hypoglycemia: Grade 4Hypoalbuminemia: Grade 1Hypoalbuminemia: Grade 2Hypoalbuminemia: Grade 3Hypoalbuminemia: Grade 4
Cohort A: Participants With cPRA >=99.90%11003200
Cohort B: Participants With cPRA 80.00% to 99.89%20000200

[back to top]

Number of Participants With Anti-drug Antibodies (ADA) Against Isatuximab

ADA responses were categorized as treatment boosted ADA and treatment-induced ADA. Treatment boosted ADA was defined as pre-existing ADAs with a significant increase in the ADA titer during the study compared to the Baseline titer. Treatment-induced ADA was defined as ADA that developed at any time during the ADA on-study observation period in participants without pre-existing ADA. (NCT04294459)
Timeframe: From first dose of study drug until study cut-off date (maximum duration: up to 97.7 weeks)

,
InterventionParticipants (Count of Participants)
Treatment-induced ADATreatment boosted ADA
Cohort A: Participants With cPRA >=99.90%00
Cohort B: Participants With cPRA 80.00% to 99.89%00

[back to top]

Number of Participants With Anti-Human Leukocyte Antigen (HLA)-Antibody Reduction

Number of participants with anti-HLA-antibody (Baseline MFI >=3000) reduced to <2000 as measured using a SAB assay per central laboratory assessment was reported in this outcome measure. Participants were categorized in various categories of number of antibodies which were reduced as: none, 1-5, >5-10, >10-15, and >15. If multiple visits had the same number of total anti-HLA antibody reduction, the last visit data was summarized. (NCT04294459)
Timeframe: From first dose of study drug until end of follow-up period (maximum duration: up to 39.1 weeks)

,
InterventionParticipants (Count of Participants)
None1-5 antibodies>5-10 antibodies>10-15 antibodies>15 antibodies
Cohort A: Participants With cPRA >=99.90%24411
Cohort B: Participants With cPRA 80.00% to 99.89%24401

[back to top]

Number of Participants With Hematological Abnormalities

Abnormal hematological parameters assessed were anemia, platelet count decreased, neutrophil count decreased, lymphocyte count decreased and monocytes. The hematological abnormality grades were based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0, where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially Life Threatening. Grade refers to the severity of the AEs. Monocytes were assessed as per potentially clinically significant abnormality (PCSA) criteria defined as: greater than (>) 0.7*10^9/L. (NCT04294459)
Timeframe: From first dose of study drug until study cut-off date (maximum duration: up to 97.7 weeks)

,
InterventionParticipants (Count of Participants)
Anemia: Grade 1Anemia: Grade 2Anemia: Grade 3Anemia: Grade 4Platelet count decreased: Grade 1Platelet count decreased: Grade 2Platelet count decreased: Grade 3Platelet count decreased: Grade 4Neutrophil count decreased: Grade 1Neutrophil count decreased: Grade 2Neutrophil count decreased: Grade 3Neutrophil count decreased: Grade 4Lymphocyte count decreased: Grade 1Lymphocyte count decreased: Grade 2Lymphocyte count decreased: Grade 3Lymphocyte count decreased: Grade 4Monocytes (PCSA) > 0.7*10^9/L
Cohort A: Participants With cPRA >=99.90%63002000000041103
Cohort B: Participants With cPRA 80.00% to 99.89%82006000000021003

[back to top]

Number of Participants With Liver Function Abnormalities

Abnormal liver function parameters assessed were Alanine aminotransferase (ALT) increased, Aspartate aminotransferase (AST) increased, Alkaline phosphatase (ALP) increased, and Total bilirubin (TB) increased. The abnormal grades were based on NCI-CTCAE, Version 5.0, where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially Life Threatening. Grade refers to the severity of the AEs. (NCT04294459)
Timeframe: From first dose of study drug until study cut-off date (maximum duration: up to 97.7 weeks)

,
InterventionParticipants (Count of Participants)
ALT increased: Grade 1ALT increased: Grade 2ALT increased: Grade 3ALT increased: Grade 4AST increased: Grade 1AST increased: Grade 2AST increased: Grade 3AST increased: Grade 4ALP increased: Grade 1ALP increased: Grade 2ALP increased: Grade 3ALP increased: Grade 4TB increased: Grade 1TB increased: Grade 2TB increased: Grade 3TB increased: Grade 4
Cohort A: Participants With cPRA >=99.90%1000100030000000
Cohort B: Participants With cPRA 80.00% to 99.89%1000000020000000

[back to top]

Number of Participants With Renal Function Abnormalities

Abnormal renal parameters assessed were creatinine increased and estimated Glomerular Filtration Rate (eGFR). The renal function abnormality grades were based on NCI-CTCAE, Version 5.0, where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially Life Threatening. Grade refers to the severity of the AEs. eGFR was assessed as per PCSA criteria: 60 (less than equal to) <= to less than (<) 90 milliliter/minute/1.73 meter square (mL/min/1.73m^2) (Mild), 30<= to <60 mL/min/1.73m^2 (Moderate), 15<=to <30 mL/min/1.73m^2 (Severe), <15 mL/min/1.73m^2 (End Stage Renal Disease). (NCT04294459)
Timeframe: From first dose of study drug until study cut-off date (maximum duration: up to 97.7 weeks)

,
InterventionParticipants (Count of Participants)
Creatinine increased: Grade 1Creatinine increased: Grade 2Creatinine increased: Grade 3Creatinine increased: Grade 4eGFR: 60<= - <90 mL/min/1.73m^2eGFR: 30<= - <60 mL/min/1.73m^2eGFR: 15<= - <30 mL/min/1.73m^2eGFR: <15 mL/min/1.73m^2
Cohort A: Participants With cPRA >=99.90%0011100012
Cohort B: Participants With cPRA 80.00% to 99.89%003800011

[back to top]

Time to Transplant

Time to transplant was defined as time (in days) from date of first study treatment dose up to date of kidney transplant. Data on transplant status were collected and followed up until study cut-off date. (NCT04294459)
Timeframe: From first dose of study drug until study cut-off date (maximum duration: up to 97.7 weeks)

Interventiondays (Median)
Cohort A: Participants With cPRA >=99.90%445
Cohort B: Participants With cPRA 80.00% to 99.89%259.5

[back to top]

Number of Participants With Treatment-Emergent Adverse Events (TEAEs), and Treatment-Emergent Serious Adverse Events (TESAEs)

An AE was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily had to have a causal relationship with the treatment. Serious adverse events (SAEs) were any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event. TEAEs were defined as AEs that developed, worsened or became serious during the TEAE period (defined as the time from the first dose of study drug until study cut-off date). (NCT04294459)
Timeframe: From first dose of study drug until study cut-off date (maximum duration: up to 97.7 weeks)

,
InterventionParticipants (Count of Participants)
TEAEsTESAEs
Cohort A: Participants With cPRA >=99.90%30
Cohort B: Participants With cPRA 80.00% to 99.89%40

[back to top]

AUC(0-t) of Plasma DMA

Determined for each subject using non-compartmental methods. All parameters will be reported with standard descriptive statistics including the geometric mean and coefficient of variation. Calculation of pharmacokinetic parameters will be performed using actual sampling times over a 24-h period. (NCT04397445)
Timeframe: 24-hours post-dose with planned samples at 0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 9, 11, 14, and 24 h post-dose

Interventionmicrograms*hour/milliliter (Geometric Mean)
Ranitidine and Noncured Meats Diet26.3
Placebo and Noncured Meats Diet26.2
Ranitidine and Cured Meats Diet20.9
Placebo and Cured Meats Diet20.9

[back to top]

Cumulative Ranitidine Amount Excreted in Urine Over 24 Hours After Drug Administration

The cumulative amount of ranitidine excreted over 24 hours is determined by calculating the amount excreted during specified intervals (includes all planned collections and unscheduled voids) and summarizing totals over a 24-h period. (NCT04397445)
Timeframe: 24-hours post-dose including planned collections (at 3, 6, 9, 12, 15, and 24 hours post-dose) and unscheduled voids. All subjects voided at approximately 0 hours (pre-dose), which was not included in the assessment.

Interventionmilligrams (Geometric Mean)
Ranitidine and Cured Meats Diet91.7
Ranitidine and Noncured Meats Diet74.1

[back to top]

Cumulative NDMA Amount Excreted in Urine Over 24 Hours After Drug Administration (Comparison Between Ranitidine and Placebo)

The cumulative amount of NDMA excreted over 24 hours is determined by calculating the amount excreted during specified intervals (includes all planned collections and unscheduled voids) and summarizing totals over a 24-h period. (NCT04397445)
Timeframe: 24-hours post-dose including planned collections (at 3, 6, 9, 12, 15, and 24 hours post-dose) and unscheduled voids. All subjects voided at approximately 0 hours (pre-dose), which was not included in the assessment.

Interventionnanograms (Median)
Ranitidine and Noncured Meats Diet0.6
Placebo and Noncured Meats Diet10.5
Ranitidine and Cured Meats Diet11.9
Placebo and Cured Meats Diet23.4

[back to top]

Cumulative NDMA Amount Excreted in Urine Over 24 Hours After Drug Administration (Comparison Between Diets)

The cumulative amount of NDMA excreted over 24 hours is determined by calculating the amount excreted during specified intervals (includes all planned collections and unscheduled voids) and summarizing totals over a 24-h period. (NCT04397445)
Timeframe: 24-hours post-dose including planned collections (at 3, 6, 9, 12, 15, and 24 hours post-dose) and unscheduled voids. All subjects voided at approximately 0 hours (pre-dose), which was not included in the assessment.

Interventionnanograms (Median)
Ranitidine and Cured Meats Diet11.9
Ranitidine and Noncured Meats Diet0.6
Placebo and Cured Meats Diet23.4
Placebo and Noncured Meats Diet10.5

[back to top]

Cumulative Dimethylamine (DMA) Amount Excreted in Urine Over 24 Hours After Drug Administration

The cumulative amount of DMA excreted over 24 hours is determined by calculating the amount excreted during specified intervals (includes all planned collections and unscheduled voids) and summarizing totals over a 24-h period. (NCT04397445)
Timeframe: 24-hours post-dose including planned collections (at 3, 6, 9, 12, 15, and 24 hours post-dose) and unscheduled voids. All subjects voided at approximately 0 hours (pre-dose), which was not included in the assessment.

Interventionmilligrams (Geometric Mean)
Ranitidine and Noncured Meats Diet38.8
Placebo and Noncured Meats Diet41.1
Ranitidine and Cured Meats Diet40.7
Placebo and Cured Meats Diet43.1

[back to top]

AUC(0-t) of Plasma Ranitidine

Determined for each subject using non-compartmental methods. All parameters will be reported with standard descriptive statistics including the geometric mean and coefficient of variation. Calculation of pharmacokinetic parameters will be performed using actual sampling times over a 24-h period. (NCT04397445)
Timeframe: 24-hours post-dose with planned samples at 0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 9, 11, 14, and 24 h post-dose

Interventionnanograms*hour/milliliter (Geometric Mean)
Ranitidine and Cured Meats Diet3736
Ranitidine and Noncured Meats Diet4857

[back to top]